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Abstract 
 
The Wnt/β-catenin signalling pathway is involved in regulating cellular transcription of 
numerous target genes in chronic myeloid leukaemia (CML). A previous report using 
granulocyte-macrophage progenitors (GMPs) showed that elevated levels of 
unphosphorylated (active) β-catenin, alongside mis-splicing of glycogen synthase 
kinase 3β (GSK3β), correlated with disease progression. It was of interest to determine 
if using the more readily available peripheral blood mononuclear cells (MNCs) also 
showed any correlation with patient outcome when β-catenin and GSK3β were 
measured in this source material. Further investigation in these cells addressed GSK3β 
activity regulation, possible regulation of c-Myc degradation by GSK3β, and 
investigation of Wnt transcription factors in CML.  
 
Results indicated that levels of β-catenin (and its phosphorylated variants) could not be 
used to distinguish patient treatment outcomes using CML MNCs. However the levels of 
BCR-ABL1 induced β-catenin-Tyr654 phosphorylation showed a significant decrease in 
patients in blast crisis compared to chronic phase (P=0.012), as did the levels of GSK3β 
– which demonstrated significantly decreased activity in blast crisis patients via a 
significant increase in Ser9 phosphorylation and a significant decrease in Tyr216 
phosphorylation in blast crisis compared to chronic phase (P=0.026 and <0.001 
respectively). 
 
This decrease in GSK3β activity was not reflected by changes in the levels of β-catenin 
and, as such, this led to the question of whether alternative mechanisms were 
influencing regulation of GSK3β activity other than Wnt/β-catenin signalling. Results 
showed that protein phosphatase 2A (PP2A) was regulating the inhibition of GSK3β in 
CML. This is a dual mechanism with GSK3β also affecting PP2A inhibition. 
 
GSK3β is known to have numerous substrates, which include c-Myc. Due to the role of c-
Myc as an oncogene in CML and the role of GSK3β in c-Myc degradation, it was of 
interest to determine if the changes in GSK3β activity were reflected in the degradation 
of c-Myc. Results showed that neither GSK3β nor PP2A (also involved in the 
mechanism) were the rate limiting components of c-Myc degradation.  
 
Analysis of the Wnt signalling pathway revealed up regulation of WNT1, WNT8A, 
WNT9A and FZD7 mRNAs in chronic phase MNCs (P=0.011, 0.045, 0.037 and 0.037 
respectively) - which was inconsistent with β-catenin findings. These unexpected 
results can be explained by internal regulation of the pathway by the negative regulator 
NKD1, which is also significantly higher in samples from chronic phase patients 
(P=0.013).  
 
Finally, investigation into Wnt transcription factors showed that factors TCF1, TCF4 and 
LEF1 mRNA levels were significantly higher in blast crisis samples compared to chronic 
phase (P=0.001, 0.016, and 0.003 respectively). This suggests a possible mechanism for 
Wnt-independent activation of these transcription factors in the blast crisis phase of the 
disease. 
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In conclusion, it was determined that β-catenin levels cannot be used to either; 
distinguish between patient response cohorts, or be a factor of disease progression in 
CML MNCs. The activity of GSK3β is significantly down-regulated in blast crisis. PP2A is 
involved in this regulation. However when investigating c-Myc degradation, neither 
GSK3β nor PP2A act as the regulating factors in CML. There may be an internal 
regulation of the pathway by which NKD1 prevents an upregulation of pathway activity 
via WNT1, WNT8A, WNT9A and FZD7 reaching β-catenin (CTNNB1). Finally, the 
transcription factors mRNA expression is significantly upregulated in blast crisis, but 
they could be acting independently of the Wnt pathway.  
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Chapter 1 - General Introduction 
 
1.1 The history of CML 
 
The first recognition of a disease entity consistent with what we now call ‘Chronic 
Myeloid Leukaemia (CML)’ took place in 1845 by John Hughes Bennett (Edinburgh) [1]. 
This was accompanied by a similar description five weeks later by Rudolf Virchow 
(Berlin), whereby both observed an enlargement of the spleen, liver and lymph nodes, 
along with a ‘pus-like’ substance in the veins [2, 3]. Both independently devised the 
phrases ‘leucocythaemia’ (Bennett) and ‘Weisses Blut’ (Virchow), which translate to 
‘white cell blood’ and ‘white blood’ respectively [1, 3, 4]. Previous to Bennett’s findings 
his colleague David Craigie (Glasgow) had two patients (in 1841, and 1844) whose 
symptoms were fever, splenomegaly and leukocytosis, which when Bennett performed 
an autopsy on the latter patient enabled him to submit his findings to the Edinburgh 
Medical and Surgical Journal.  
 
In 1852 Bennett published a major review, which reported 37 cases [5]. Virchow also 
reported, in 1847, accounts of nine cases where an association was noted between the 
appearance of the blood and the occurrence of an abnormally enlarged spleen. He also 
observed that granular blood cells with irregular or divided nuclei were linked with 
splenomegaly [2, 6].  This was an astonishing feat when considering the limited 
resources available to him, in terms of both the efficiency of the microscopes of the day, 
and the lack of developed staining techniques. 
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In 1856, Virchow described the pathophysiology of the disease by noting the 
characteristics of leukaemia included elevated levels of ‘colourless’ cells alongside a 
decrease in red cells and alterations in the liver and spleen. Additionally he made the 
influential suggestion that there are two forms of chronic leukaemia; splenic and 
lymphatic [2]. Bennett and Virchow disagreed on the cause of death of the patients; 
Bennett concluded an infection was the cause, whereas Virchow believed it was a 
neoplastic disorder. The nomenclature of the disease was debated for many years [4]. 
 
In 1872, Ernst Neumann discovered the next important characteristic of CML; that it 
originates in the bone marrow. He identified that there was an additional form of 
leukaemia which he referred to as a ‘myelogenous’ leukaemia [4, 7]. Following this in 
1878, Neumann additionally recognised that the anaemia which was observed in 
patients was due to disturbance in the marrow which he previously linked with 
leukaemia. This was acknowledged by Gowers in 1879 [2]. 
 
In 1879 Paul Ehrlich established methods for staining blood cells, making it easier to 
distinguish between the different forms of leukaemia [8]. This led to the observation 
that Virchow’s ‘splenic leukaemia’ and Neumann’s ‘myelogenous leukaemia’ were in fact 
observations of the same type, with both consisting of granular cells. This led to the 
‘splenic’ nomenclature being dropped and the acknowledgement of two forms of 
chronic leukaemia; myelogenous and lymphatic [2].  
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1.1.1 Discovery of the Philadelphia Chromosome 
 
A critical leap in the understanding of CML took place in Philadelphia in 1960. Nowell 
and Hungerford examined the blood of seven CML patients and identified a minute 
chromosome in the cells. Their findings were recognised worldwide, and the 
chromosome was entitled the ‘Philadelphia chromosome’ (Ph1) [4, 9]. 
 
In 1973, after improvements in cytogenetic techniques, Janet Rowley reported in nine 
CML patients that Ph1 was part of a reciprocal translocation between chromosome 9 and 
chromosome 22 [10] (Figure 1.1). Following this, in the 1980s, it was recognised that a 
gene typically located on chromosome 9, known as ABL1, was translocated to the Ph1 
chromosome [11]. Studies were undertaken to determine the region on the ABL1 gene 
at which the breakpoint was located. It was found to be in the first intron of the ABL1 
gene [12]. The breakpoint was more difficult to categorise on chromosome 22. In 1984, 
Groffen et al., [13] discovered there were multiple breakpoints clustered into a region of 
5.8-kb which they termed as the ‘breakpoint cluster region (BCR)’. This region was later 
found to be part of a gene named accordingly as the BCR gene. Witte et al., [14] found via 
the K562 cell line (the first cell line representative of myelogenous leukaemia that was 
derived from a 53 year old female patient in blast crisis) that the ABL1 protein was 
abnormally sized with increased enzymatic activity, implying that this abnormal ABL1 
activity may be involved in the pathogenesis of CML. Using the idea that somehow BCR 
may influence the activity of ABL1, Eli Canaani [15] led a team of investigators who 
identified a BCR-ABL1 fusion transcript in CML patient cells [4].  The discovery of this 
BCR-ABL1 fusion protein, which is formed by the coiled-coil domain located on the BCR 
protein fusing to the N-terminus of the ABL protein [16], was shown to generate a 
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constitutively active protein kinase involved in the activation of numerous signalling 
pathways [17, 18], and was a crucial breakthrough in understanding the pathogenesis of 
CML [2]. 
 
Figure 1.1 A diagram to show the reciprocal translocation which produces the 
Philadelphia Chromosome 
 
 
  
Philadelphia 
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Chromosome 9
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1.2 Molecular Pathogenesis 
 
1.2.1 ABL1 
 
ABL1 is a 145kDa modular protein with tyrosine kinase activity, which is ubiquitously 
expressed in the cell [19, 20]. At the N-terminus are three SRC-homology domains (SH1-
SH3), which are integral to the function of the protein (Figure 1.2). The tyrosine kinase 
function is situated in the SH1 domain. The SH2 and SH3 domains act by binding other 
proteins via the recognition of different sequences. The SH2 domain identifies 
phosphotyrosine residues, while the SH3 domain identifies proline-rich sequences [20]. 
Located on the last exon region of ABL1, three nuclear localisation signals (NLS) [19, 
21], alongside one nuclear export signal (NES) [22] enable ABL1 to localise in both the 
nucleus and the cytoplasm.  
 
Regulation of the function of ABL1 is important as without restraint multiple cellular 
functions are uncontrolled leading to adverse effects [19]. Abl1 null mice show elevated 
perinatal mortality, skeletal abnormalities and inferior immune function, signifying the 
importance of normal Abl1 function in the cell and in development [23]. In normal 
physiological conditions, a myristoyl group bound to the N-terminus of ABL1 is capable 
of binding several regions across the molecule, including a hydrophobic region on the 
SH1 domain, which leads to autoinhibition of the protein [20, 24]. This inhibition is 
reversed when Tyr412 is phosphorylated [19] which then allows access to the 
regulatory activation loop and phosphorylation of Tyr393 which was previously 
prevented by the conformation of the autoinhibited protein [20]. 
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ABL1 is involved in many signalling pathways, and its subcellular localisation influences 
its impact on the cell. When located in the cytoplasm, it is connected to proliferation and 
cell survival. In contrast, ABL1 is  located in the nucleus subsequent to cell cycle arrest 
and apoptosis via DNA damage. These functions prove that ABL1 is a fundamental 
protein involved in the maintenance of cell homeostasis [20].  
 
 1.2.2 BCR 
 
The 160kDa BCR protein is ubiquitously expressed in the cell [25]and has various roles, 
however its true function still remains elusive. It is involved in cytoskeleton remodelling 
[20] via its regulatory effect on the Rho family GTPases [26]. Additionally, it may act as a 
tumour suppressor via its negative regulation of the RAS-ERK pathway [27], along with 
the Wnt/β-catenin pathway [28]. It is a multi-domain protein consisting of a coiled-coil 
domain on the N-terminus, allowing oligomerisation with other proteins. Adjacent to 
this is a serine/threonine kinase domain [20], followed by a dbl homology domain in the 
middle of the protein, which has homology with the guanine nucleotide dissociation-
stimulating domain of  the DBL oncogene product. Alongside the dbl homology domain 
is a pleckstrin homology domain. Both of these stimulate the exchange of guanidine 
diphosphate (GDP) on small GTPases of the Rho family [26]. Finally the C-terminus 
enables the GTPase activity of Rac to be switched on [20]. 
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1.2.3 What is BCR-ABL1? 
 
BCR-ABL1 is regarded as a crucial driving factor in the development of CML (Section 
1.1.1) however the formation of BCR-ABL1 is not limited to one transcript type (Figure 
1.2). ABL1 has a breakpoint region mainly between exons 1a and 1b, however it can 
also occur downstream of exon 1a or upstream of exon 1b [17, 29]. BCR has three 
common breakpoint regions that give rise to different transcript types. The most 
prevalent isoform found in CML is the p210BCR-ABL1 transcript, which has its breakpoint 
within a region known as the ‘major breakpoint cluster region’ (M-bcr) which covers 
the introns between exons e12-e16. Additionally in Ph+ acute lymphoblastic leukaemia 
and rare cases of CML, there is another region within BCR where a breakpoint can occur, 
known as the ‘minor breakpoint cluster region’ (m-bcr) found in the long intron 
between the exons e2’ and e2. This produces a p190 BCR-ABL1 transcript [17, 29].  Finally 
the third transcript type, which is associated with chronic neutrophilic leukaemia 
(CNL), has a breakpoint located downstream of exon 19 (μ-bcr) which produces the 
p230BCR-ABL1 transcript type [29-31].  
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Figure 1.2 Schematic of the most common BCR-ABL1 transcript types 
 
[32] 
 
Although the BCR-ABL1 transcript types described above are the most commonly found 
in CML, some patients who have the characteristics of the disease lack both the Ph1 
chromosome and the BCR-ABL1 fusion protein. These cases have been assigned as 
atypical CML [33], which is actually a different disease to true CML with a worse 
prognosis, and does not respond to tyrosine kinase inhibitors (TKIs). Additionally, 5% 
of true CML cases are BCR-ABL1 positive but Ph1 negative.  Expression of the p210BCR-
ABL1 transcript is found in these patients, and the disease characteristics are 
indistinguishable from Ph1 positive CML. As a result these cases are currently believed 
to have cytogenetically invisible rearrangements of the chromosome [34].  
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1.3 CML in the Clinic 
 
CML can be defined as a clonal myeloproliferative disease, affecting haematopoietic 
stem cells (HSCs). It is characterised by the amplification of myeloid proliferation 
leading to increased neutrophils and their immediate precursors in the peripheral 
blood, and by the increased cellularity of bone marrow resulting from expansion of the 
myeloid mass [35].  
 
1.3.1 Epidemiology 
 
The annual incidence of CML is 1.34 cases per 100,000 individuals [36], with a 
predominance of males over females in most series (1.69:1) [37]. The median age of 
disease onset is 60 years old [36]. However, the median age of patients recruited for 
trial studies is typically up to a decade younger [38]. The prevalence of CML in the 
population is currently rising due to the development of improved therapies TKIs , 
which are increasing survival rates [39]. 
 
1.3.2 Pathogenesis 
 
There are limited contributing factors known to the pathogenesis of CML. Heyssel et al. 
[40] investigated the effect ionising radiation has on leukaemia development through 
analysing the disease prevalence in Hiroshima atomic bomb survivors. Results showed 
that the victims closest to the hypocentre of the explosion had massively increased 
incidence of leukaemia development compared to those further from the explosion site. 
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Those closest to the hypocentre at 0-999 meters had an annual incidence of 1,460 cases 
per million, while those furthest from the hypocentre at 2,000-10,000 meters had an 
annual incidence of 29 cases per million.  
 
1.3.3 Diagnosis 
 
At diagnosis, all patients should be analysed by both G-banded chromosome analysis of 
marrow cell metaphases to identify the presence of the Ph1 chromosome, and 
qualitative polymerase chain reaction (PCR) to identify the BCR-ABL1 transcript types. 
In addition, fluorescence in situ hybridisation (FISH) analysis can be undertaken in 
patients that are Ph1 negative to identify variant and cryptic translocations [41]. From 
these tests a diagnosis can be made, and a treatment schedule put in place. 
 
1.3.4 Clinical Features 
 
Text book descriptions of CML often describe its course as a triphasic disease which 
develops through three clinical phases; chronic phase, accelerated phase, and blast 
crisis. However, in the era of the TKIs this may no longer be true, as few patients remain 
in accelerated phase for any length of time, with some bypassing it altogether. Patients 
who do progress can transform directly into blast crisis thus giving the appearance of a 
biphasic disorder of chronic phase and blast crisis. However, the vast majority of 
present day patients may remain in chronic phase indefinitely [42]. Table 1.1 gives the 
European LeukaemiaNet (ELN) and World Health Organisation (WHO) definitions of the 
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clinical phases. Those patients in chronic phase do not meet any of the criteria stated for 
accelerated phase and blast crisis [41]. 
 
Table 1.1 Definitions of the clinical CML phases 
CML Phase 
ELN Definition – Any of the 
following; 
WHO Definition – Any of the 
following; 
Accelerated 
Phase 
 15-29% of blasts in the 
blood or bone marrow, or 
>30% of blasts plus 
promyelocytes in the blood 
or bone marrow with 
<30% blasts. 
 ≥20% basophils in the 
blood. 
 Persistent 
thrombocytopenia 
unrelated to treatment 
(<100x109/L). 
 Clonal chromosome 
abnormalities in Ph+ cells 
on treatment. 
 10-19% of blasts in the blood or bone 
marrow. 
 ≥20% basophils in the blood. 
 Persistent thrombocytopaenia 
unrelated to treatment (<100x109/L), 
or thrombocytosis (>1000x109/L) 
unresponsive to therapy. 
 Increase in white blood cell count and 
spleen size which is unresponsive to 
therapy. 
 Clonal chromosome abnormalities in 
Ph+ cells on treatment. 
Blast Crisis 
 ≥30% of blasts in the blood 
or bone marrow. 
 Blast proliferation 
occurring outside the bone 
marrow, except for the 
spleen. 
 ≥20% of blasts in the blood or bone 
marrow. 
 Blast proliferation occurring outside 
the bone marrow. 
 Clusters of blasts on bone marrow 
biopsy. 
[41] 
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1.4 Response Definitions 
 
1.4.1 Monitoring response to treatment 
 
Monitoring a patient’s response to treatment is important in determining subsequent 
treatment requirements. The hierarchy of treatment response is shown in Table 1.2. 
Complete haematological response (CHR) is the first target of treatment, while complete 
cytogenetic response (CCyR) reflects a deeper response. Major molecular response 
(MMR) indicates an even deeper response with a progression rate to blast crisis of <1% 
at 5 years. 
 
Table 1.2 CML response definitions 
Response Definition 
Haematological Complete (CHR) 
All of the following: 
White blood cell (WBC) < 10x109/L 
<5% Basophils 
No myelocytes, promyelocytes, or myeloblasts 
within the WBCs 
A platelet count < 450x109/L 
A spleen that is nonpalpable 
Cytogenetic 
 
Complete (CCyR): 
Partial:  
Minor:  
Minimal:  
None: 
No Ph+ metaphases (at least 20 examined) 
1-35% Ph+ metaphases 
36-65% Ph+ metaphases 
66-95% Ph+ metaphases 
> 95% Ph+ metaphases 
Molecular Major(MMR): 
MR1 
MR2 
MR3 
MR4 
 
 
MR4.5 
 
 
MR5 
Ratio of BCR-ABL1 : ABL of ≤0.1% 
Ratio of BCR-ABL1 : ABL of ≤10% 
Ratio of BCR-ABL1 : ABL of ≤1% 
As MMR 
Ratio of BCR-ABL1 : ABL of ≤0.01% 
or undetectable BCR-ABL1 transcripts with 
>10,000 ABL1 transcripts 
Ratio of BCR-ABL1 : ABL of ≤0.0032% 
or undetectable BCR-ABL1 transcripts with 
>32,000 ABL1 transcripts 
Ratio of BCR-ABL1 : ABL of ≤0.001% 
[41, 43] 
37 |  P a g e
 
Note: Complete molecular response previously defined as undetectable BCR-ABL1 mRNA 
transcripts by RT-qPCR in two consecutive blood samples of sufficient quality 
(sensitivity >104) has been replaced by molecularly undetectable leukaemia with 
specification of the number of the control gene transcript copies [41]. 
 
 
During treatment, real time quantitative PCR (RT-qPCR) is typically performed every 
three months until a MMR (assessed according to the international scale) is achieved, 
then subsequently every three to six months. In addition to, or instead of RT-qPCR, 
chromosome banding analysis of marrow cell metaphases may be carried out at three, 
six and twelve months until CCyR has been reached, then after every twelve months. In 
patients that fail treatment (Section 1.4.2) RT-qPCR, mutational analysis by 
conventional Sanger sequencing, and chromosome banding analysis of marrow cell 
metaphases should be performed. For those who progress into blast crisis 
immunophenotyping is carried out to define the blast lineage (myeloid or lymphoid). 
Finally, in those considered as ‘warning’ patients (Section 1.4.2) the molecular and 
cytogenetic tests are carried out more regularly and chromosome banding analysis of 
marrow cell metaphases is recommended in cases of myelodysplasia or clonal 
chromosome abnormalities in Ph- cells [41]. 
 
 
1.4.2 Treatment Response Definitions 
 
In the 2013 update of the earlier 2006 and 2009 ELN recommendations, two categories 
of response to treatment are described; optimal, and failure (Table 1.3). The 
cytogenetic and molecular criteria to meet these become more stringent with increasing 
time on treatment. They are dynamic, in that patients can move from one category to 
another. Optimal responders are patients who have the best long-term outcome as they 
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are achieving a response and therefore can safely remain on current treatment. Failure 
patients are those whose chances of achieving a better response on current treatment 
are very limited and should therefore switch therapy to reduce the risk of disease 
progression and death. Finally, there is an intermediate category previously described 
as ‘sub-optimal’ which has been re-categorised as ‘warning’ in the latest 2013 
definitions [41]. This cohort includes patients who need to be more frequently 
monitored to allow for appropriate therapy changes to reduce treatment failure [41].  
 
Table 1.3 The requirements for patient categorisation as described by the ELN 
Treatment Response Definitions 
Optimal 
3 months BCR-ABL1 ≤10% and/or Ph+ ≤35% 
6 months BCR-ABL1 <1% and/or Ph+ 0 
12 months BCR-ABL1 ≤0.1% 
>12months BCR-ABL1 ≤0.1% 
Warning 
3 months BCR-ABL1 >10% and/or Ph+ ≤36-95% 
6 months BCR-ABL1 1-10% and/or Ph+ ≤1-35% 
12 months BCR-ABL1 >0.1-1% 
>12months Clonal chromosome abnormalities in Ph- cells 
Failure 
3 months No complete haematological response and/or Ph+ >95% 
6 months BCR-ABL1 >10% and/or Ph+ >35% 
12 months BCR-ABL1 >1% and/or Ph+ >0 
>12months Loss of complete haematological response  
Loss of complete cytogenetic response  
Confirmed loss of major molecular response 
Mutations in the BCR-ABL1 kinase domain 
Clonal chromosome abnormalities in Ph+cells 
[41] 
Note: ‘BCR-ABL1’ is shorthand for BCR-ABL1/ABL1 ratio expressed as a percentage. 
 
 
Inclusion of the warning cohort (‘suboptimal’ in earlier ELN definitions) of patients in 
analysis within this thesis was not considered appropriate due to the group’s 
complexity in classification and treatment. Patients in the optimal and failure cohorts 
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are much better defined with treatment either being continued as it is, or switched, 
instead of a ‘wait and see’ strategy. The more precise cohort definitions also make it 
easier to determine which, if any, factors or biomarkers predict patient outcome. In 
contrast as the eventual outcome of warning patients is unknown and variable, it may 
be inaccurate to test them as a subset of patients, thus making it impossible to correlate 
levels with a treatment outcome that has not yet been achieved. It also must be taken 
into account that an additional reason why this cohort is complex is that there may be 
patient compliance issues which are hindering treatment response [44]. For these 
reasons warning patients will be removed from analysis in this thesis due to the 
difficulty in  obtaining any conclusive data.  
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1.5 Treatment 
 
1.5.1 Pre-Imatinib Era 
 
The first definitive description of a treatment for CML was arsenic. Developed by 
Thomas Fowler in 1786, it was administered to a CML patient in 1865 by Lissauer [2]. In 
1903 radiotherapy was introduced, and rapidly replaced arsenic. It proved to be 
extremely efficient at improving the patients’ health by reducing spleen size, and 
decreasing the leukocyte count, leading to the concept of ‘remission’ being coined. 
However it soon became clear that CML becomes refractory to radiotherapy treatment 
[2].  
 
It wasn’t until after the Second World War when alkylating agents became available that 
treatment advances occurred. The first synthetic compounds used in the management 
of CML were the chemotherapeutic agents busulphan and hydroxyurea (HU) [42]. In a 
randomised trial, a comparison was made between the efficiency of busulphan and 
hydroxyurea in 441 CML patients [45]. Results from the trial showed that treatment 
with hydroxyurea displayed a statistically significant survival advantage (P=0.02) with 
the median survival for patients receiving hydroxyurea as a primary treatment being 
5.6 years compared to 2.7 years with busulphan. In addition to this, hydroxyurea has 
fewer adverse side effects along with improved white blood cell counts after 18 and 24 
months treatment (43% and 34%, vs. 11% and 16% for hydroxyurea vs. busulphan 
respectively) [45]. 
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The development and introduction of interferon-α (IFNα) in the early 1980s gave CML 
patients a significantly increased survival advantage [46-48]. The UK Medical Research 
Council trial CML III reported an increase in median survival in patients treated with 
IFNα to 61 months compared with 41 months in patients treated with chemotherapy 
(busulphan or hydroxyurea) [48]. Additionally, long-term follow up (95-129 months) by 
the Italian cooperative study group showed 30% survival for patients treated with IFNα 
vs. 18% treated with conventional chemotherapy. Furthermore, the median survival for 
low risk patients was 104 months on IFNα vs. 64 months on chemotherapy [46]. Studies 
found that BCR-ABL1 is involved in regulating the sensitivity of CML cells to IFNα by 
inhibiting IFNα signalling and the response of the cells. This is achieved by accelerating 
the phosphorylation-dependent degradation of the IFNα receptor [49]. 
 
1.5.2 Stem Cell Transplant 
 
Allogeneic stem cell transplant (allo-SCT) was the first curative treatment developed in 
the late 1970s [50]. Its use has diminished with the development of TKIs and fewer 
patients progressing to accelerated phase and blast crisis, but it is still an important 
treatment for patients with resistance to therapy, and for those who have previously 
progressed to blast crisis but have been restored to a second chronic phase [51]. 
 
Due to a majority of patients who now receive allo-SCT being patients who have 
previously failed treatment, it was investigated whether previous therapy influenced 
the patients outcome after allo-SCT. It was shown that prior treatment with imatinib 
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(see Section 1.5.3.1) had no effect on the success of allo-SCT, unless the patients on 
treatment had achieved a major cytogenetic remission, whereby these patients had 
significantly less hazard of mortality (p=0.03) [50]. 
 
Only a minority of patients can receive curative therapy from CML by stem cell 
transplantation, therefore it has been an important area within CML research to 
discover and develop drugs which increase patient survival [42]. As such the 
development of TKIs was a significant breakthrough in the treatment of CML. 
 
 
1.5.3 Tyrosine Kinase Inhibitors (TKIs) 
 
1.5.3.1 Imatinib 
 
The discovery of the Ph1 chromosome and the resultant BCR-ABL1 fusion protein has 
enabled the development of drugs which target this protein, revolutionising treatment. 
It is known that the BCR-ABL1 fusion protein actively increases the transformation of 
cells from non-leukaemic to a malignant phenotype via an increase in tyrosine kinase 
activity [52]. 
 
 Imatinib mesylate (also known as STI571, or trade name Glivec), developed by Ciba-
Geigy (now Novartis Pharmaceuticals), was the first TKI developed for the treatment of 
CML [53]. It functions by inhibiting the BCR-ABL fusion protein by competing for the 
occupation of the adenosine triphosphate (ATP) binding site of the tyrosine kinase 
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domain. Imatinib prevents ATP from binding, thus blocking the activation of the 
tyrosine kinase. This causes a reduction in the tyrosine kinase activity, consequently 
decreasing the clonal expansion of the leukaemic stem cells (LSCs) [53, 54] (Figure 
1.3). 
 
The IRIS trial (International Randomised study of Interferon-alpha plus cytarabine 
versus ST1571) randomised treatment of 1106 newly diagnosed chronic phase CML 
patients on a 1:1 ratio. Patients either received 400mg of imatinib daily, or 5MU/m2 
IFN-α daily continuously plus 20mg/m2 cytarabine daily for 10 days per month [55]. 
Results show that imatinib significantly improved outcome, where at 18 months 76.2% 
of patients treated with imatinib achieved a CCyR compared to 14.5% of patients 
treated with IFNα plus cytarabine [55, 56]. Also, only 3.3% of imatinib treated patients 
underwent disease progression to accelerated or blastic phase compared to 8.5% of 
patients who received IFNα plus cytarabine [55]. Imatinib consequently became 
universally accepted as the gold standard first line therapy for newly diagnosed chronic 
phase CML, and similar trials in accelerated phase and blast crisis showed  advantages 
for imatinib treatment [55, 57].  
 
Cellular responses to imatinib treatment in cells expressing the BCR-ABL1 protein 
include inhibition of proliferation, induction of apoptosis, and restriction of 
phosphorylation of substrates including BCR-ABL1 autophosphorylation [58]. 
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Figure 1.3 A diagram to show the mechanism of action of imatinib on BCR-ABL1 
Imatinib binds to the ATP binding site on BCR-ABL1 stabilising it in its inactive 
conformation. This prevents the autophosphorylation of BCR-ABL1 and subsequently 
phosphorylation of its substrates. 
 
 
 
 
1.5.3.2 Imatinib resistance 
 
More than one-third of patients either fail to achieve, or lose their initial response to 
imatinib and develop a resistance to the drug [59].  Resistance arises due to cells 
developing mechanisms to sustain sufficient levels of BCR-ABL1 signalling, or by cells 
becoming BCR-ABL1 independent.  Mechanisms providing elevated levels of BCR-ABL1 
include gene amplification, gene mutation and incomplete BCR-ABL1 inhibition [58]. 
Furthermore, there could be the development of a new genetic lesion which is 
independent of BCR-ABL1. The most prevalent mutations which confer resistance (85-
90% of resistant cases) are located in the ABL1 kinase domain of the  BCR-ABL1 
protein, which prevents imatinib from binding and blocking the ATP binding site [53, 
60]. These include the development of point mutations that arise within the kinase 
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domain, decreasing its sensitivity towards imatinib [61]. These change the 
conformation of ABL1 and impede the affinity of imatinib for the ATP binding site. 
Mutations can also occur in regulatory domains within the fusion protein, for example 
in the activation loop of the protein where a mutation stabilises the protein in its active 
conformation, impeding imatinib’s ability to bind. Additionally, mutations can occur on 
contact residues preventing the formation of hydrogen bonds between imatinib and the 
protein, enhancing resistance [60], the  P-loop which interferes with phosphate binding, 
and the hinge region preventing the formation of the ATP-binding cleft due to the loss of 
contact between the C- and N- terminal lobes of the kinase domain [61]. 
 
The first described and most well-known mutation in the BCR-ABL1 kinase domain is 
the T315I mutation, whereby the wild type threonine (T) amino acid is substituted by 
an isoleucine (I) at codon 315 on the ABL1 protein after a cytosine to thymine base pair 
substitution [62]. The T315 residue is located at the back of the ATP binding site, and is 
known as the ‘gatekeeper position’. This location is the reason why this residue has a 
significant impact on imatinib resistance, as any changes in its properties lead to 
inhibition of the binding ability of imatinib and other TKIs. When the amino acid residue 
is a threonine, its hydroxymethylene side chain forms an essential hydrogen bond with 
imatinib. Conversely when a mutation occurs and the residue is subsequently changed 
to an isoleucine residue, the hydrogen bond with imatinib is unable to form. 
Furthermore, the conformation of the isoleucine residue stoichiometrically changes the 
ATP binding site so imatinib is no longer compatible, and hence BCR-ABL1 becomes 
imatinib resistant [61, 62]. 
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In addition to resistance arising due to BCR-ABL1, the mechanism of drug uptake also 
has implications on resistance development. The uptake of imatinib is mediated by 
human organic cation transporter 1 (hOCT1) [63, 64]. Studies of hOCT1 showed that the 
uptake of imatinib was greater in KCL22 cells (cell line established from a 32 year old 
woman with Ph+ CML in blast crisis) which had high expression of hOCT1 compared to 
those with low expression (P=0.002). The levels of hOCT1 were also found to correlate 
with patient outcome, with patients who have high pre-treatment hOCT1 levels having a 
higher probability of achieving a CCyR (P=0.008), along with increased progression-free 
and overall survival rates (P=0.01 and 0.004 respectively) [64]. 
 
1.5.4 Second Generation TKIs 
 
With the emergence of imatinib resistance, future therapies were developed to 
overcome the different mechanisms of resistance. These were named ‘second 
generation’  TKIs. 
 
1.5.4.1 Nilotinib 
 
Nilotinib (also known as AMN107, or trade name Tasigna) also developed by Novartis, 
acts similarly to imatinib by competitively inhibiting the ATP binding site of the tyrosine 
kinase domain of the BCR-ABL1 protein, stabilising it in its inactive conformation. 
However it is much more potent than imatinib by over 30-fold [65] due to an increased 
topological fit, and it has a much higher affinity for BCR-ABL1 of approximately 20 to 50 
fold [66].  Furthermore, nilotinib has increased specificity with the ABL1 kinase domain 
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caused by a decrease in the number of hydrogen bonds between the drug and protein 
from six to four, limiting the contact points and restricting the proteins that nilotinib 
targets [67]. This increase in affinity and specificity enhances nilotinib’s inhibitory 
action, enabling cytogenetic and molecular responses against most of the mutations 
which cause imatinib resistance[60]. Additionally, the uptake of nilotinib is not reliant 
on hOCT1 [68]. However, similarly to imatinib, the T315I mutation again confers 
resistance [69].  
 
A trial was initiated to compare the efficiency of nilotinib treatment  with imatinib, 
named the ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials 
Newly Diagnosed Patients [70]).  846 newly diagnosed chronic phase Ph+ patients were 
randomly allocated (1:1:1 ratio) to receive; 300mg nilotinib twice a day, 400mg 
nilotinib twice a day, or 400mg imatinib once a day [70]. The results from a three year 
follow up of the trial show nilotinib to be a significantly better treatment for CML than 
imatinib. It was shown that patients who received nilotinib (both 300mg and 400mg) 
achieved a significantly higher level of MMR (p<0.0001) than patients who received 
imatinib. In addition, significantly more patients who were allocated nilotinib achieved 
a deeper response of MR4 and MR4.5 (p<0.0001 for both). Alongside this, progression 
free survival was significantly higher in patients on 300 mg nilotinib treatment versus 
imatinib (p=0.0059) [71]. These findings indicate the superior efficacy of nilotinib 
compared to imatinib, and how nilotinib can overcome much of the resistance to 
imatinib (with the exception of a few mutations) suggesting nilotinib would be a good 
first line therapy in CML.  
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However, since being introduced there have been numerous reports of peripheral 
artery occlusion disease (PAOD) being observed in patients treated with nilotinib [72-
75]. An initial study by Aichberger et al., [72] found that three out of 24 CML cases 
treated with nilotinib developed PAOD. Furthermore, a subsequent study of 233 
patients receiving nilotinib treatment showed 5% of these cases developed PAOD [73]. 
This discovery has resulted in the reconsideration of nilotinib when selecting therapy 
for the treatment of CML.  
 
 
1.5.4.2 Dasatinib 
 
Dasatinib (also known as BMS-354825, or trade name Sprycel) is another second 
generation TKI, developed by Bristol-Myers Squibb, which in the START-R trial 
(SRC/ABL tyrosine kinase inhibition activity research trial - randomised) was shown  to 
be a more effective treatment for patients failing standard dose imatinib compared to 
dose escalation of imatinib [76]. Dasatinib is approximately 325-fold more potent than 
imatinib, and has the ability to be active against various imatinib-resistant BCR-ABL 
mutants. This is due to its ability to bind to BCR-ABL in both its active and inactive 
forms, whereas imatinib can only associate when BCR-ABL is inactive. Therefore 
imatinib is ineffective against BCR-ABL mutations which have destabilised its inactive 
form, whereas dasatinib is still effective against these changed conformations [77]. In 
addition, dasatinib is similar to nilotinib in that it does not rely upon hOCT1 for its 
uptake, making it an effective therapy for those patients with low hOCT1 levels [78]. 
There are however again some mutations where dasatinib is less effective, such as the 
missense mutation V299L and, as for the other TKIs T315I [79]. 
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The clinical trial comparing imatinib to dasatinib was named DASISION (DASatinib 
versus Imatinib Study In treatment Naive CML patients) whereby 519 newly diagnosed 
Ph+ chronic phase CML patients were randomised treatment on a 1:1 ratio, receiving 
either 100mg dasatinib daily  or 400mg imatinib daily  [80]. Results from the trial 
showed that after a 24 month follow up, there was a significant increase in both CCyR 
(p=0.0002) and MMR (p<0.0001) in patients allocated dasatinib.  The median time to 
achieve a MMR was 15 months on dasatinib vs. 36 months on imatinib, with 64% of 
patients receiving dasatinib achieving a MMR by 24 months compared to 46% of 
patients receiving imatinib [80]. There was also a non-significant trend to improved 
progression free survival with 3.5% of patients allocated dasatinib progressing to 
accelerated or blastic phase, compared to 5.8% of imatinib treated patients [80]. In 
addition to being effective in patients as a first line therapy, dasatinib is also an efficient 
treatment in imatinib-resistant or intolerant patients unable to achieve a MMR or CCyR. 
Furthermore, dasatinib was effective against accelerated or blast crisis CML patients, 
enabling the acquisition of a major haematological response. These responses were 
reached within 1-3 months and retained for a 1-5 year period [77]. These results again 
suggest dasatinib to be an effective therapy for the treatment of CML. 
 
In addition to acting on BCR-ABL1, dasatinib has been shown to be an inhibitor of 
downstream cellular pathways involved in cell proliferation and apoptosis. These 
include Stat5, SRC and MAPK pathways, of which inhibition enhances dasatinib’s 
antileukaemic properties [77]. 
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1.5.4.3 Additional therapies 
 
Further drug development has produced both bosutinib (another second generation 
TKI) and ponatinib (a third generation TKI). Bosutinib (also known as SKI-606, 
marketed by Pfizer with the trade name Bosulif) acts as a dual inhibitor by also 
inhibiting SRC more effectively than imatinib, but does not influence PDGF or c-KIT 
activity[81] . It has been shown to be an effective second line treatment for those 
patients who fail imatinib, dasatinib or nilotinib therapy; however as with the three 
previous TKIs it is ineffective against the T315I mutation. In patients who failed 
imatinib, bosutinib as a second line therapy resulted in 85% of patients achieving a 
CHR, 48% achieving a CCyR, and 35% achieving a MMR [82]. However in the Bosutinib 
Efficacy and safety in chronic myeloid LeukemiA (BELA) trial of first line bosutinib vs 
imatinib, results showed that CCyR response at 12 months treatment showed no 
significant difference between the drugs (P=0.601) [83]. The disadvantage of bosutinib 
therapy is the adverse side effects that accompany it. Common side effects  include 
diarrhoea, nausea, and vomiting, with thrombocytopenia the most common grade 3/4 
side effect [82, 83]. 
 
As all previous TKIs have been shown to be ineffective against the T315I mutation, 
ponatinib (also known as AP24534, or trade name Iclusig) was developed by ARIAD 
Pharmaceuticals for the treatment of patients with this previously incurable variation of 
the disease [84]. Results from the phase II trial showed that, in patients who were 
treated with ponatinib after failure on dasatinib or nilotinib, of those in chronic phase, 
46% achieved a CCyR, 34% achieved a MMR, and no resistance to ponatinib  occurred 
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via a single BCR-ABL1 mutation. Of those patients who received ponatinib in 
accelerated phase, 55% achieved a major haematological response and 39% achieved a 
major cytogenetic response. Finally, for patients in blast crisis who switched to 
ponatinib, 31% achieved a major haematological response, and 23% achieved a major 
cytogenetic response (as defined by the study) [84].   
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1.6 The Wnt/β-catenin Signalling Pathway 
 
There are three pathways which are involved in intracellular signalling via the Wnt-
protein ligand interactions. These are the β-catenin pathway, the planar cell polarity 
pathway, and the Wnt/Ca2+ pathway [85]. The Wnt/β-catenin signalling pathway is vital 
in a variety of signalling processes within embryonic development and tissue 
homeostasis, including; cell proliferation, cell polarity, and cell fate determination. 
Consequently when mutations arise within this pathway, they lead to human birth 
defects, cancer and other diseases as reviewed by Clevers et al.,[86]. 
 
1.6.1 Activation of the Wnt/β-catenin signalling pathway 
 
1.6.1.1 Regulation of Wnt ligand binding 
 
The regulation of Wnt signalling occurs through multiple mechanisms, summarised in 
Figure 1.4. Activation of the Wnt/β-catenin signalling pathway occurs through a family 
of secreted glycolipoproteins known as the WNT ligands. In humans these are made up 
of 19 different members [87]. Once these WNT ligands have been secreted, various 
binding partners control their activity. There is evidence indicating that heparan 
sulphate proteoglycans (HSPGs) function in stabilising and assisting the transport of 
WNT ligands [88]. The WNT ligands interact with two sets of co-receptors for efficient 
signalling: Frizzled (FZD) receptors, which are 7-transmembrane proteins that bind to 
WNT ligands via their cysteine-rich domains located on the N-terminus [89, 90], and 
low-density lipoprotein receptor-related proteins 5/6 (LRP-5/6) which are single-pass 
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transmembrane molecules [85, 91]. The FZD receptors are also normally associated 
with heterotrimeric G proteins, initiating  intracellular signal transduction [89], while 
the importance of LRP-5/6 is emphasised by the binding of potent extracellular 
inhibitors WISE and Dickkopf (DKK) which inhibit Wnt/β-catenin signalling by blocking 
the formation of the LRP-5/6, FZD, and WNT ligand complex [88, 91].  
 
In humans there are several DKK genes, of which DKK1 is widely involved in Wnt/β-
catenin signalling inhibition [92, 93]. DKK1 forms a complex with both LRP-5/6 and 
KREMEN and promotes LRP-5/6 internalisation, hence blocking Wnt/β-catenin 
signalling by making it unavailable for WNT ligand binding. KREMEN acts as a 
moderator of the inhibitory action of DKK as only specific KREMEN proteins enable DKK 
to inhibit Wnt/β-catenin signalling e.g. KREMEN2 [88, 92, 94]. The mechanism by which 
LRP-5/6 is internalised determines whether it is involved in normal Wnt/β-catenin 
signalling or whether it results in pathway inhibition by decreasing the accessibility of 
LRP-5/6 for WNT ligands. If internalisation of LRP-5/6 is via DKK-induced-CLATHRIN 
mediated internalisation, then this results in pathway inhibition. However, if 
internalisation is via CAVEOLIN-mediated LRP-5/6 internalisation, stimulated by WNT, 
then this results in normal Wnt/β-catenin signalling [95, 96]. In addition to DKK, other 
antagonists which act on LRP-5/6 include WISE/Sclerostin (SOST) proteins which act 
by preventing the interaction between LRP5/6 and WNT ligands[97, 98]. Inhibitors that 
bind to WNT ligands and block their interaction with the FZD receptor include Cerberus 
(CER) and FRZB-1 [85]. Furthermore, SHISA proteins prevent maturation of the FZD 
receptors and inhibit them from reaching the cell surface by confining them in the 
endoplasmic reticulum (ER) [99]. 
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Wnt inhibitory factor (WIF) acts as an antagonist to the WNT ligands by directly binding 
to them [87]. In addition, the secreted Frizzled related proteins (sFRPs) have homology 
to the cysteine rich domains of the FZD family of WNT receptors [100] and 
consequently either compete with the FZD receptor for WNT ligand binding, or bind 
directly to FZD forming an inactive complex preventing binding of WNT ligands [101].  
 
Figure 1.4 Regulation of WNT ligand binding 
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1.6.1.2 Transmission of the Wnt signal intracellularly 
  
In the presence of WNT ligands, the receptors transduce a signal to Dishevelled (DSH) 
and AXIN, which consequently may interact through a sequence of amino acids known 
as the DIX domain [102]. DSH is phosphorylated [100], which is moderated by protein 
kinases including PAR1 [103], and binds to FZD intracellularly [85]. DSH functions by 
blocking the degradation of β-catenin via the recruitment of glycogen synthase kinase 
binding protein (GBP)/FRAT-1 [85]. GBP/FRAT-1 acts as the intermediate between DSH 
and a complex of proteins known as the ‘destruction complex’, enabling them to 
interact. The destruction complex is responsible for regulating the degradation of β-
catenin through the phosphorylation status of β-catenin [104, 105]. When 
phosphorylated by this complex, β-catenin is degraded (section 1.6.2), however 
inhibition of the destruction complex causes β-catenin to remain un-phosphorylated at 
these key sites [106] and is able to translocate to the nucleus (section 1.6.1.3). FRAT-1 
is reported to function by moderating the dissociation of glycogen synthase kinase 3β 
(GSK3β) from the degradation complex, consequently stabilising β-catenin by inhibiting 
the ability of GSK3β to phosphorylate β-catenin, subsequently preventing its 
degradation [107]. DSH can be also be regulated by FRODO to enhance Wnt/β-catenin 
signal transduction [108], β-arrestin 1 (β-ARR1) which binds to DSH and enhances its 
interaction with AXIN [109], and Dapper (DPR) which is involved in DSH degradation 
[110].  
 
In addition to DSH regulating the transduction of the Wnt signal to the destruction 
complex to prevent phosphorylation of β-catenin, LRP-5/6 is involved in the 
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degradation of AXIN. The cytoplasmic tail of LRP-5/6 is known to contain a series of 
residues which can become phosphorylated subsequent to WNT ligand binding, which 
is mediated by GSK3β and casein kinase 1 (CK1) [95, 111, 112]. This phosphorylation 
creates a binding site for AXIN on LRP-5/6 enabling recruitment of AXIN to the plasma 
membrane and facilitating its degradation. This results in the disassembly of the 
destruction complex, rendering it incapable of marking β-catenin for degradation (see 
Figure 1.5) [111-113].  
 
1.6.1.3 Translocation of β-catenin into the nucleus  
 
Since β-catenin is not able to be phosphorylated by the destruction complex, it is unable 
to be degraded by the proteasome, and is instead stabilised in the cytoplasm. This 
increase in unphosphorylated β-catenin levels in the cytoplasm is the main 
characteristic which represents the activation of Wnt/β-catenin signalling [88]. The 
stabilised β-catenin is imported into the nucleus and binds to the transcription factors 
T-cell factor (TCF) and lymphoid enhancer factor (LEF) [114, 115]. The manner in 
which β-catenin is imported and retained in the nucleus involves various factors. It has 
been found that Wnt-induced activation of a Rac-JNK pathway by phosphorylation of β-
catenin at Ser191 and Ser605 mediates the nuclear import of β-catenin [116]. AXIN and 
adenomatous polyposis coli (APC) have been reported to export β-catenin into the 
cytoplasm [117, 118], while BCL9 and the TCF factors import β-catenin into the nucleus 
[119]. However, there is evidence that these proteins work via retention instead of 
active transport [120]. More recently, Chibby (CBY) has been associated with nuclear 
export of β-catenin via association with protein 14-3-3, along with acting as an 
antagonist for TCF/LEF binding [121].  
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1.6.1.4 Regulation of transcriptional activation 
 
Once in the nucleus, β-catenin can associate with the transcription factors TCF and LEF 
[114, 115] and activate the transcription of Wnt/β-catenin pathway target genes, which 
include C-MYC and CYCLIN D1 (see Figure 1.5) [122, 123]. The interaction of β-catenin 
with the transcription factors TCF/LEF causes the displacement of transcriptional 
repressors and recruitment of additional transcriptional co-activators [95]. Co-
activators include BRG-1 (also known as SMARCA4) which is involved in remodelling 
chromatin as part of the Switch/Sucrose non-fermentable (SWI/SNF) complex [124] 
and the histone acetylase CREB binding protein (CBP)/p300 which binds to the carboxy 
terminus of β-catenin and enhances transcriptional activation [125]. Additionally, 
Bc19/Legless (LGS) and Pygopus (PYGO) not only act to retain β-catenin in the nucleus, 
but also regulate the interaction between TCF/β-catenin complex and chromatin [119, 
126-128].  Transcriptional repressors include inhibitor of β-catenin and TCF (ICAT) 
which acts as an antagonist of Wnt target gene transcription by inhibiting the 
association of β-catenin with TCF [129] and furthermore, it dissociates β-catenin, LEF 
and CBP/p300 complexes [130]. Without WNT ligands to activate the pathway, TCF 
itself can function as a repressor of transcription of Wnt target genes as it forms a 
complex with a molecule called GROUCHO [131]. When β-catenin is present, it is able to 
displace GROUCHO from TCF to activate transcription [132].   
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Figure 1.5 The process of β-catenin translocation to the nucleus 
 
 
When WNT ligands are present they bind to 
the receptors Frizzled and LRP5/6 and cause 
the phosphorylation of the cytoplasmic tail of 
LRP.
This phosphorylation recruits AXIN to the 
membrane where it is degraded, 
disassembling the destruction complex.
Additionally the binding of WNT ligand causes 
phosphorylation of Dishevelled (DSH).
Phosphorylation of DSH causes it to associate 
with FZD and recruit GBP/FRAT which prevent 
GSK3β from phosphorylating β-catenin.
As β-catenin cannot be phosphorylated by 
GSK3β, this causes an increase in 
unphosphorylated β-catenin.
This unphosphorylated β-catenin translocates
to the nucleus where it binds to TCF/LEF and 
transcriptional co-activators and activates 
transcription.
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1.6.2 Inhibition of the Wnt/β-catenin signalling pathway 
 
In the absence of WNT ligands, the destruction complex is able to target β-catenin for 
degradation by the proteasome. The destruction complex is made up of multiple 
proteins including AXIN, APC, and GSK3β [133, 134] which associate with β-catenin and 
regulate its phosphorylation at specific residues. Phosphorylation of β-catenin is a dual 
kinase mechanism which involves CK1 and GSK3β. Firstly, CK1α phosphorylates β-
catenin on the N terminus at Ser45, which then facilitates the sequential 
phosphorylation of Thr41, Ser37 and Ser33 by GSK3β [104, 135, 136].  GSK3β is a vital 
component in the down regulation of β-catenin, consequently making it a potential 
tumour suppressor. It acts by phosphorylating multiple proteins involved in Wnt 
signalling [100], including AXIN [137] and APC (alongside CK1) enabling more β-catenin 
to associate with AXIN and APC, which in turn increases the amount of β-catenin that is 
phosphorylated and degraded [87, 104]. AXIN functions as a scaffold protein, and has 
specific binding sites for the other components of the destruction complex [138]. It is 
considered that AXIN acts as a limiting factor in Wnt/β-catenin signalling due to lower 
quantities of the molecule being present in the cells compared to the other components 
of the degradation complex. Increasing the concentration of AXIN in the cell reduced the 
half-life of β-catenin by 50%, unlike the other components of the destruction complex. 
This consequently means AXIN could be a key factor in regulating the stability of β-
catenin in the cell [139] (See Figure 1.6). Phosphorylation at Ser37 and Ser33 by GSK3β 
enables the E3 ligase, beta-transducin repeat containing protein (β-TrCP), to recognise 
β-catenin as a target for ubiquitinated degradation by the proteasome [135, 140-142]. 
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Figure 1.6 The process of β-catenin degradation 
 
 
Without the presence of WNT ligands, β-
catenin is able to associate with the 
destruction complex.
This allows phosphorylation of  β-catenin on 
Ser45 by CK1.
Phosphorylation by CK1 primes β-catenin on 
Ser33/37/Thr41 by GSK3β.
Phosphorylation of β-catenin recruits the E3 
ligase β-TrCP which ubiquitinates β-catenin
This ubiquitin tag targets β-catenin to the 
proteosome.  
The proteosome acts to degrade β-catenin.  
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1.6.3 The Wnt/β-catenin Signalling Pathway in CML 
 
Studies have shown that in CML, disease progression and relapse originate from an 
atypical population of LSCs. The development of these LSCs is via mutations which 
modify progenitor self-renewal, survival and differentiation[101]. Wnt/β-catenin 
signalling is crucial in maintaining the self-renewal of normal HSCs and when the 
signalling is disrupted, leukaemia consequently develops [143].  
 
BCR acts as a tumour suppressor by inhibiting the expression of proliferation-
promoting genes. It acts as a negative regulator of the Wnt/β-catenin signalling pathway 
by creating a complex with β-catenin, downregulating β-catenin/TCF-dependent 
transcription, which in turn negatively regulates the expression of various genes 
including C-MYC. Conversely, BCR-ABL1 has been shown to disrupt the BCR-β-catenin 
complex inhibiting the negative regulation BCR has on the Wnt/β-catenin pathway. This 
negative regulation can be reversed using imatinib [28]. 
 
The development of BCR-ABL1 has also been shown to have an adverse effect on Wnt 
signalling by phosphorylating specific tyrosine residues on β-catenin at Tyr86 and 
Tyr654 residues stabilising the protein. When β-catenin is phosphorylated on these 
residues by BCR-ABL1, it binds to the TCF4 transcription factor, enabling activation of 
transcription. Imatinib is able to reverse this effect by preventing the β-catenin/TCF-
dependent transcription by retaining the unphosphorylated β-catenin in the cytoplasm 
increasing its binding affinity for the destruction complex [144].  
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BCR-ABL1 has also been speculated to inhibit antagonists of the pathway including 
sFRPs. It has been shown that DNA methylation of specific sites within the promoter 
region of genes has led to the reduction of sFRP which consequently constitutively 
activates Wnt signalling. This mechanism has been found to be involved in various 
forms of cancer specifically leukaemia. Within CML it has been found to be an 
uncommon event, but when it does arise it correlates with therapeutic resistance [145]. 
 
  
63 |  P a g e
 
1.7 Beta-Catenin 
 
Beta-catenin is a non-enzymatic 781 amino acid protein encoded by the CTNNB1 gene 
which plays a crucial role in both cell adhesion and Wnt signalling. There are various 
parts of the β-catenin structure which play important roles in its  functionality. These 
include helix C which may be involved in the recruitment of the transcriptional 
coactivators needed to enable β-catenin’s activation of Wnt-responsive genes. 
Additionally, at the centre of the structure is a core made up of 12 armadillo repeats. 
This forms a positively charged domain which allows the binding of over 20 β-catenin 
binding partners, including TCF/LEF. This, along with the regulation of protein-protein 
interactions via its N- and C- terminal domains, gives β-catenin its ability to form 
multiprotein complexes. The N-terminus also functions in the degradation of β-catenin, 
as when it gets phosphorylated it is recognised by the β-TrCP ubiquitin ligase which 
ubiquitinates the protein allowing for it to associate and consequently be degraded by 
the proteasome [146] (Figure 1.7). 
 
Figure 1.7 Structure of β-catenin 
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Βeta-catenin is the central effector molecule of the Wnt signalling pathway and plays a 
key role in the transduction of the Wnt signal by transferring the signal from the 
cytoplasm into the nucleus, enabling the activation of gene transcription [87]. Under 
normal physiological conditions it is regulated by its phosphorylation status as this 
determines whether or not it will be degraded by the proteasome. It is primarily 
phosphorylated by CK1α on the N terminus at Ser45. This primes the protein and 
facilitates the phosphorylation of Thr41, Ser37 and Ser33 by GSK3β [104, 135, 136].  
Phosphorylation at Ser37 and Ser33 on β-catenin are what initiates ubiquitination of β-
catenin by βTrCP causing it to be degraded by the proteasome [135, 140-142]. 
 
In the absence of β-catenin phosphorylation, it is unable to be ubiquitinated by β-TrCP 
and hence is not degraded by the proteasome, instead being stabilised in the cytoplasm 
[100]. The stabilised unphosphorylated β-catenin is then imported into the nucleus 
(Section 1.6.1.3) and binds to the transcription factors TCF and LEF [114, 115]. This 
interaction of TCF/LEF with β-catenin causes the displacement of transcriptional 
repressors and, together with the recruitment of additional transcriptional co-activators 
initiates transcription [95] (Section 1.6.1.4 and Figure1.5). 
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Figure1.8 A diagram to show the complexes formed by β-catenin when it is either 
inactive and destined for degradation, or active and translocated to the nucleus to 
active transcription 
 
 
 
1.8.1 Beta-Catenin in CML 
 
Alongside phosphorylation by CK1 and GSK3β, further phosphorylation on residues 
Ser552 [147], Ser675 [148], and Ser191 [116] of β-catenin have been reported to 
enhance its signalling capacity, but there is insufficient understanding as to whether the 
phosphorylation on these residues can modify β-catenin activity on their own [149]. 
Significantly to CML, BCR-ABL1 itself can physically interact with β-catenin and 
phosphorylate specific tyrosine residues on β-catenin at Tyr86 and Tyr654 residues 
which direct β-catenin to translocate to the nucleus and bind to the TCF4 transcription 
factor, enabling activation of transcription and consequently the acquisition of 
leukaemic stem cell (LSC) properties [144]. 
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Investigation into β-catenin’s role in CML has shown that the Wnt/β-catenin signalling 
pathway is involved in the maintenance of HSCs by being required for regulating their 
self-renewal capacity[143] [150].  But in addition to β-catenin being involved in HSC 
maintenance, it is also key for the preservation of LSCs.  This was demonstrated by Hu 
et al., [151]. They found that β-catenin was up-regulated 2.5 fold in LSCs in CML mice. 
Furthermore when primary CML mice LSCs were transferred to secondary mice, they 
were incapable of inducing CML when there was a deficiency in β-catenin. This signifies 
the importance of β-catenin in the survival and self-renewal of LSCs[151], implying that 
β-catenin is an important factor in the development of CML. 
 
Previous to Hu et al., Jamieson et al., [150] found that in comparison to control cells 
there were elevated amounts of β-catenin present in CML patient myeloid progenitors 
in either accelerated phase or blast crisis, which subsequently normalised with imatinib 
treatment. Data showed a difference in active (unphosphorylated) β-catenin in HSC in 
comparison to granulocyte-macrophage progenitors (GMP), where in HSC there was no 
significant difference in levels of activated β-catenin between controls, patients with 
accelerated-phase CML and patients with blast crisis. In contrast in the GMPs there was 
a significant increase in activated β-catenin in patients with blast crisis and patients 
with imatinib resistant CML, in comparison to normal. To confirm these findings an 
activity assay (LEF/TCF-GFP reporter assay) was carried out and results substantiated 
what was previously shown with the HSC showing no significant difference between 
controls and the three phases of CML. In contrast, the GMPs again showed elevated 
levels of nuclear -catenin via increased levels of GFP in blast crisis patients. In addition 
to looking at levels of -catenin, the impact of these elevated levels was also assessed by 
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looking at the self-renewal capacity and proliferative potential. Results showed the re-
plating capacity was higher in CML GMPs compared to normal GMPs, and by inducing 
the expression of -catenin in normal GMPs their re-plating capacity was consequently 
elevated. In contrast transduction of AXIN, which acts as an inhibitor of -catenin 
signalling, decreased the re-plating capacity of the cells. These results show the 
importance of -catenin in the self-renewal of CML GMPs when patients are in blast 
crisis [150], however this work is yet to be confirmed by others.  
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1.8 Glycogen synthase kinase 3β (GSK3β) 
 
A key component in the regulation of β-catenin is GSK3β which, as previously stated, 
phosphorylates β-catenin targeting it for degradation. GSK3β is a proline directed 
serine/threonine kinase which phosphorylates substrates which have previously been 
phosphorylated by a different kinase, ‘priming’ the substrate for subsequent 
phosphorylation by GSK3β. In regards to GSK3β phosphorylating β-catenin, this occurs 
by CK1 on Ser45 [135, 136]. GSK3β is an 832 amino acid protein which contains a DSH 
homologous domain in its C-terminus. Additionally, it has both an AXIN and β-catenin 
binding site which allow it to form a multi-protein complex with these two proteins 
[134]. 
 
GSK3β is a constitutively active kinase, which is regulated by its phosphorylation status. 
Inactivation of the kinase occurs by phosphorylation at Ser9. When this 
phosphorylation occurs it is thought to create a pseudosubstrate which interacts with 
the active site of GSK3β, blocking its ability to phosphorylate its target proteins [152]. 
This process of inhibition is competitive with levels of substrate competing with the 
levels of pseudosubstrate [152], however the phosphorylation of Ser9 is well recognised 
as the method of GSK3β inhibition with a direct correlation to a decrease in kinase 
activity [153]. Numerous kinases have the ability to phosphorylate GSK3β at this 
residue, including; protein kinase B (Akt), integrin-linked kinase (ILK), protein kinase A 
(PKA) and p90Rsk, amongst others. Akt was primarily shown to phosphorylate and 
inhibit GSK3β through Ser9 phosphorylation via the phosphatidylinositide 3-kinase 
(PI3K) pathway [154].  Additionally, two other phosphorylations that can occur on 
69 |  P a g e
 
GSK3β have been linked with an increase in this inhibitory phosphorylation on Ser9. 
These are; phosphorylation of Thr43, which occurs by extracellular signal regulated 
kinase (ERK) and correlates with inhibition, and phosphorylation of Ser389 and 
threonine 390 by p38 mitogen activated protein kinases (MAPK), both of which increase 
the ability of Ser9 phosphorylation of GSK3β and hence enhance inhibition of the kinase 
[153, 155]. 
 
Although GSK3β is constitutively active, it has been found that phosphorylation of 
Tyr216 has the ability to enhance the activity of this kinase. This occurs by the 
phosphorylation of Tyr216 altering the conformation of GSK3β’s active site. When the 
Tyr216 residue is not phosphorylated, a side chain obstructs the base of the active site, 
reducing substrate binding ability to GSK3β. When the Tyr216 residue is 
phosphorylated, this acts by freeing up the active site allowing easier access by 
substrates, enhancing the activity of the kinase [152, 155, 156]. The method of 
phosphorylation on this site is uncertain; kinases including PYK-2 and FYN have been 
reported to be able to phosphorylate this residue, alongside MEK1/2 in mammalian 
fibroblasts [155]. However, it is also thought that there is a possibility of 
autophosphorylation being responsible for this increase in activity [155, 157]. 
Dephosphorylation of this site has been shown to correlate with a decrease in kinase 
activity, showing that although this site may not be required for GSK3β activity, it is 
significant in enhancing it [157]. Additionally, while inhibitors of GSK3β act by inducing 
inactivation by Ser9 phosphorylation, they do not have any effect on Tyr216 
phosphorylation. This could be indicating that this inactivation of GSK3β is sufficient to 
override activation [157]. 
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GSK3β is known to be involved in the degradation of numerous substrates other than β-
catenin [152]. Others that are of interest to this study include MCL-1, and c-Myc. MCL-1 
is a well-characterised member of the BCL-2 family [158] which has two isoforms; the 
longer isoform acts by inhibiting apoptosis and increasing cell survival (anti-apoptotic). 
In contrast the shorter isoform promotes apoptosis, inhibiting cell survival (pro-
apoptotic). Down regulation of MCL-1 may be required for the instigation of the 
apoptosis cascade, therefore inhibiting its function may be an effective treatment in 
malignancies where MCL-1 is involved in inhibiting apoptosis [159]. Along with 
apoptosis, data suggest that MCL-1 can act to disrupt the association of β-catenin with 
the destruction complex in the cytoplasm. This is as a result of MCL-1 acting as a 
substrate for GSK3β, preventing GSK3β from phosphorylating and targeting β-catenin 
for degradation and hence active β-catenin accumulates in the nucleus [160].  
 
In addition to β-catenin and MCL-1, C-MYC is also a target of GSK3β, and considering its 
role as an oncogene, could have major implications on cell homeostasis [161]. GSK3β is 
involved in the degradation of C-MYC through its phosphorylation on Thr58. This 
phosphorylation occurs once C-MYC has been stabilised by phosphorylation on Ser62 
by ERK. Subsequent to both phosphorylation by ERK and GSK3β, PP2A acts to remove 
the Ser62 phosphorylation which then allows for ubiquitination and degradation via the 
proteasome [162].  This implicates GSK3β as an important mediator of C-MYC turnover 
independent of the Wnt/β-catenin signalling pathway. 
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1.8.1 GSK3β in CML 
 
It is known that the Wnt/β-catenin pathway is activated when CML progenitors 
progress to myeloid blast crisis [150]. It was reported that, when patients progress from 
chronic phase and accelerated phase through to blast crisis, total GSK3β protein levels 
are significantly decreased and β-catenin transcriptional activity is elevated due to 
increased amounts of activated β-catenin [101]. 
 
Mutations in GSK3β give rise to splice isoforms which are deleted in exon 9, exon 11, or 
exon 9 and 11. Exon 9 and 11 deletions have been previously discovered in Parkinson’s 
disease [163], however the truncated isoforms of exon 8 and 9 which have been found 
in CML progenitors have not previously been found elsewhere [101]. Due to 
overexpression of the full-length GSK3β causing a decrease in activated β-catenin, it was 
said that GSK3β mis-splicing is a significant event in the development of LSCs and that 
restoration of the splicing events may have a possible therapeutic benefit. Abrahamsson 
et al., [101] proposed that the combination in CML of β-catenin stabilisation by BCR-
ABL1 and the decrease of negative regulators of the Wnt pathway including AXIN2 may 
act by heightening the effects of mutated-GSK3β on the activation of β-catenin. 
 
The mechanisms by which GSK3β splicing occur have yet to be determined. The 
expression of BCR-ABL1 in cord blood progenitors has particular relevance to CML 
development, which stimulates a rise in expression in genes implicated in alternative 
splicing. Changes in the splicing events can either inactivate tumour suppressors or 
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activate proteins which promote tumour development. Specific to CML the use of the 
splice isoforms in GSK3β can be used as an indicator of disease progression and as a 
therapeutic target for treatment of patients in advanced phase CML [101].  
 
In addition to this, Reddiconto et al., [164] showed that  CML progenitor cells contain  
an active pool of GSK3β marked by Tyr216 phosphorylation. They found that treating 
chronic phase CML progenitors with imatinib resulted in a dose dependent increase of 
Tyr216 phosphorylated GSK3β. Furthermore, it was suggested that BCR-ABL1 prevents 
the translocation of GSK3β into the nucleus and this  was restored on imatinib 
treatment. The study showed that targeting GSK3β may have therapeutic benefits for 
patients by increasing the apoptotic effects of imatinib on CML stem cells.  
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1.9 PP2A 
 
Protein phosphatase 2A (PP2A) is a serine/threonine protein phosphatase which is 
made up of various subunits. These consist of a core enzyme known as the ‘A subunit’, a 
catalytic subunit known as the ‘C subunit’ and regulatory subunits known as the ‘B 
subunits’ [165-167]. The B subunits contain four different families which contain 16 
members overall. The regulatory sub-families are; B (PR55), B’ (B56 or PR61), B’’ 
(PR72), and B’’’ (PR93/PR110) [165, 167].  
 
PP2A plays a role within multiple signalling pathways to regulate the function of 
activated kinases [167]. Of interest to this study, PP2A functions within the Wnt/β-
catenin signalling pathway as part of the destruction complex, however it is reported to 
have multiple roles both parallel to, and downstream of, β-catenin [168]. As part of the 
destruction complex, the catalytic subunit of PP2A binds to AXIN through amino acids 
632 and 836 [169], whilst the regulatory B’ (B56) family of subunits associate with APC 
[170]. In response to a Wnt signal, dephosphorylation of AXIN through PP2A has shown 
to dissociate β-catenin from the destruction complex reducing its degradation [171]. In 
contrast dephosphorylation of APC through the B56 subunit of PP2A down-regulates β-
catenin through enhancing its degradation [172]. PP2A has also been reported to act 
directly or indirectly on TCF3, one of the transcription factors of Wnt/β-catenin 
signalling, independently of β-catenin. This results in overexpression of the catalytic 
subunit of PP2A converting the function of TCF3 from a transcriptional repressor to a 
transcriptional activator [168].  
74 |  P a g e
 
1.9.1 PP2A in CML 
 
Within CML, PP2A has also been reported to function as a tumour suppressor 
downstream of BCR-ABL1. Within blast crisis it has been shown that PP2A is down 
regulated [173]. Two mechanisms of inhibition have been reported to regulate PP2A via 
different inhibitory proteins; SET (also known as I2PP2A) [173-175] and cancerous 
inhibitor of PP2A (CIP2A) [176]. SET is a specific inhibitor of PP2A whose activity is 
elevated through BCR-ABL1 via Janus kinase 2 (JAK2) [177]. Its activity has been shown 
to increase with disease progression, which correlates with the down-regulation of 
PP2A activity in blast crisis [173]. The activity of PP2A is regulated through 
phosphorylation of Tyr307. This phosphorylation has been shown to be decreased with 
both down-regulation of SET and treatment with imatinib [173]. Similarly, CIP2A also 
regulates PP2A through the inhibitory phosphorylation on Tyr307 with down-
regulation of CIP2A also decreasing inhibition of PP2A. CIP2A was also recognised as a 
predictive biomarker of disease progression, with elevated levels being found in 
diagnostic samples from  chronic phase  patients who later progressed to blast crisis 
[177].  
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1.10 TCF/LEF Transcription Factors 
 
The TCF/LEF family of transcription factors consist of four members; TCF1, TCF3, TCF4, 
and LEF1. Their structure is made up of an N-terminal β-catenin binding domain and a 
C-terminal high mobility group DNA binding domain which binds proteins involved in 
regulating transcription [178]. These transcription factors function by binding to Wnt 
responsive elements within the promoter of target genes e.g. CYCLIN D1 and C-MYC, 
activating their transcription [122, 123]. Their activity is enhanced and repressed by 
transcriptional co-activators including; CBP/p300, and transcriptional co-repressors 
such as GROUCHO (See section 1.7). Nuclear β-catenin functions by displacing the co-
repressors from TCF/LEF and permitting transcriptional activation[122]. Post 
translational modifications including phosphorylation, sumoylation, ubiquitination, and 
acetylation, also modify the potential of TCF/LEF transcription factors to interact with 
nuclear co-activators, repressors or DNA. An example of this is the phosphorylation of 
TCF/LEF by the activated NEMO like kinase (NLK)/Nemo, which is considered to reduce 
the binding affinity of the β-catenin/TCF/LEF complex with DNA, hence influencing 
transcriptional regulation of Wnt target genes [87, 95, 179, 180]. 
 
1.10.1 TCF/LEF in CML 
 
There have been limited reports on TCF/LEF transcription factors in CML, however it 
has been found in acute myeloid leukaemia (AML) that the expression of LEF1 
correlates with a favourable prognosis. LEF1 is known to be involved in normal 
haematopoiesis and leukaemogenesis independent of the Wnt/β-catenin signalling 
pathway. It has been found in cytogenetically normal AML (CN-AML) that an elevation 
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in LEF1 levels correlated with better cytogenetic response rate, overall survival, event-
free survival and relapse-free survival. Conversely, a decrease in LEF1 levels correlated 
with higher blast counts and disease progression [123]. These results contradict what 
has previously been shown with elevated levels of LEF1 inducing the development of 
myeloid and lymphoid leukaemias [181]. The reason for this discovery that LEF1 
correlates with better prognosis in CN-AML, considering increased Wnt signalling is 
regarded as bad, may be due to LEF1 acting independently of the Wnt/β-catenin 
pathway either on its own or as part of a different cellular pathway. Further reports on 
LEF1 acting within haematological malignancies show that mutations in LEF1 take place 
in T-cell acute lymphoblastic leukaemia, and enhanced LEF1 levels correlate with poor 
prognosis in B-cell acute lymphoblastic leukaemia[123]. This goes to show that 
different mechanisms of action exist. 
 
The significant discovery that the TCF/LEF transcription factors can act independently 
of the Wnt/β-catenin signalling pathway has been seen recently in haematological 
malignancies [178]. Grumolato et al. [178] showed an increase in TCF/LEF 
transcriptional activity in the cell lines Ramos, K562 and Jurkat, as well as primary 
material from lymphoma tumours, which did not correlate with an increase in nuclear 
β-catenin levels. To determine if the TCF/LEF transcription factors were acting 
independently of β-catenin, TCF1, LEF1 and TCF4 were expressed in 293T cells which 
are known to not have an active Wnt pathway [182]. Results showed that both TCF1 and 
LEF1 still increased the level of TCF/LEF reporter activity; however this did not occur 
with TCF4 expression. This was further supported by deletion of the β-catenin binding 
domain from TCF1 having limited effects on the TCF/LEF activation which only 
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decreased slightly. Additionally, mutation of TCF1 which obstructed β-catenin’s binding 
ability had no effect on the  transcriptional activity of TCF1. All this supports the theory 
that TCF1 can act independently of β-catenin and activate transcription [178]. 
Furthermore, Grumolato et al. [178]showed that the transcription factors ATF2 and 
ATF7 enhance both TCF1’s and LEF1’s transcriptional activity, measured by AXIN2 
expression, which decreased when ATF2 and ATF7 were suppressed by shRNA. This 
suggests a new method of transcriptional activation which is separate of β-catenin. 
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Aims 
 
1) Determine if the levels of β-catenin and its phosphorylated forms in MNCs are 
predictive of clinical outcome in imatinib treated patients or differ in relation to 
patient treatment response groups. 
2) Determine if BCR-ABL1 mediated -catenin phosphorylation on Tyr654 
correlates with disease progression. 
3) Investigate phospho-GSK3β Tyr216 and phospho-GSK3β Ser9 to determine if 
GSK3β’s activity differs in relation to patient outcome. 
4) Examine what regulates GSK3β’s activity in CML. 
5) Determine if GSK3β activity correlates with c-Myc degradation. 
6) Screen the Wnt pathway and analyse any of the genes which appear to be 
different between the response groups in a larger patient cohort. 
7) Investigate the transcription factors involved in the Wnt pathway to see if they 
are differentially expressed in the different patient cohorts. 
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Chapter 2 - Materials and Methods 
 
2.1 Patients 
 
All patients included in this research were aged 18 or older at diagnosis and were 
positive by metaphase cytogenetic analysis for the Philadelphia chromosome.  Minimum 
follow-up was 12 months.  Healthy volunteers were all fit and well at the time of 
donation and were 21 or more years of age.  All healthy volunteer and patient samples 
included in this study were given with informed consent in accordance with the 
declaration of Helsinki.  This work was approved by the Liverpool Central Committee of 
the UK National Research Ethics Service. 
 
2.2 Sample Collection and Preparation 
 
2.2.1 Total leukocytes 
 
Venous blood was collected and from this, erythrocytes were depleted using red cell 
lysis buffer (0.1M ammonium chloride, 10mM sodium bicarbonate and 1.3mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, Gillingham, Dorset)). 
Approximately 5ml of venous blood was mixed with 40ml of lysis buffer for 5 minutes 
then centrifuged at 770g for 10 minutes, washed with phosphate buffered saline (PBS), 
centrifuged for a further 5 minutes and then leukocytes were pelleted. For RNA 
extraction 5x106 total leukocytes were resuspended in 600μl RLT buffer (Qiagen, 
Crawley, West Sussex) containing 1% β-mercaptoethanol (Sigma-Aldrich) and stored at 
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-20°C for extraction at a later time point. Alternatively total leukocytes were used fresh 
as required. 
 
2.2.2 MNC preparation 
 
MNC were prepared from 20-30mls of peripheral blood collected into EDTA (Sigma-
Aldrich). MNCs were separated by density-dependent centrifugation (Lymphoprep, 
density 1.077 ± 0.001 g/ml, Axis-Shield, Cambridge, Cambridgeshire), washed in 
Roswell Park Memorial Institute 1640 (RPMI 1640), and resuspended in RPMI 1640 
containing 10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich) and 10% foetal calf 
serum (FCS; BioSera, Ringmer, Sussex) at 4°C and cryopreserved in liquid nitrogen.  
When required, cells were thawed rapidly at 37oC until partially thawed and the DMSO 
was diluted to <1% at room temperature over a period of 30 minutes via dropwise 
addition of thawing media (RPMI/10% Heparin Sodium (1,000 IU/ml from Wockhardt 
UK Ltd, Wrexham, Wrexham County Borough) using 5mls per sample.  After washing, 
cells were re-suspended at 2 x 106 /ml in ‘culture medium’ (RPMI 1640 containing 10% 
FCS, 1% L-glutamine and 2% penicillin / streptomycin; Invitrogen, Paisley, 
Renfrewshire), seeded into 6-well tissue culture plates (Becton Dickinson (BD), Oxford, 
Oxfordshire) and cultured under standard tissue culture conditions (5% CO2 in air, 
37°C, 100% humidity) overnight. MNC from normal healthy volunteers were freshly 
prepared and used immediately.  
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2.2.3 Preparation of CD34+ cells 
 
Samples were enriched for CD34+ cells using the CliniMACS system (Miltenyi Biotec, 
Auburn, California, USA) according to the manufacturer's instructions. They were then 
resuspended in 10% DMSO/10% FCS/RPMI at 4°C and cryopreserved in liquid 
nitrogen. All CD34+ cells were collected at diagnosis and then labelled according to the 
patients’ subsequent clinical outcome. In some experiments where purified CD34+ cell 
samples were not available, MNC were co-stained with CD34 antibody (BD), and FACS 
analysis was performed under gated conditions selected for CD34+ cells (see Section 
2.7). 
 
 
2.2.4 Patient samples used 
 
Table 2.1 shows a list of patients from which samples were used for experimental 
analysis, including their response, age at diagnosis, gender, white blood cell count and 
date of diagnosis. 
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Table 2.1 Patient samples used for experimental analysis  
Patient 
ID  
Response 
Age at 
Diagnosis 
Male/Female 
White Blood Cell 
Count (x109/l) 
Date of diagnosis  
1 Failure  73 Male 477 16.09.05 
2 Blast Crisis 58 Male x 04.08.05 
3 Optimal 59 Female 7.1 24.08.05 
4 Optimal 35 Female x 03.08.05 
5 Optimal 56 Female x 14.07.05 
6 Failure  63 Female 10.5 04.08.05 
9 Failure  49 Female 213 24.11.04 
10 Failure  54 Female 3.5 27.07.05 
13 Blast Crisis 24 Male x 16.01.06 
15 Optimal 59 Male 65.9 26.01.06 
20 Blast Crisis 33 Male 384.1 14.02.06 
28 Optimal 30 Female 58.2 04.04.06 
29 Optimal 55 Male 33.8 12.04.06 
30 Optimal 49 Male 168.7 03.05.06 
32 Optimal 47 Female 85.9 01.06.06 
33 Optimal 55 Male x 01.08.06 
34 Failure  33 Male x 10.08.06 
37 Blast Crisis 35 Male 4 21.08.06 
39 Blast Crisis 55 Female x 25.10.00 
40 Optimal 38 Female x 07.09.06 
43 Failure  32 Female x 12.02.03 
44 Failure  48 Female x 14.09.06 
51 Blast Crisis 31 Female x 23.03.05 
52 Blast Crisis 59 Female x 16.07.03 
58 Optimal 39 Male x 29.11.06 
90 Failure  65 Male 2.6 03.05.06 
107 Optimal 40 Male 78.4 07.03.07 
108 Blast Crisis 57 Male 81.8 21.02.07 
112 Blast Crisis 36 Female 8.9 14.03.07 
113 Optimal 27 Female x 04.04.07 
115 Blast Crisis 24 Male 222 03.07.07 
118 Optimal 55 Female 139.9 19.09.07 
119 Optimal 66 Male 87.3 19.09.07 
122 Optimal 47 Male x 28.09.07 
123 Failure  64 Male x 27.09.07 
124 Optimal 33 Male 119.2 02.10.07 
130 Optimal 43 Female 75.9 28.01.08 
204 Optimal 52 Female 182.9 09.07.08 
206 Failure  43 Female 41 23.07.08 
209 Optimal 46 Female 66.9 11.09.08 
218 Optimal 23 Male 77.6 23.10.08 
220 Blast Crisis 23 Male 542 30.10.08 
236 Blast Crisis 48 Male x 09.06.08 
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246 Optimal 29 Female x 17.02.09 
290 Failure  55 Female 11.1 24.04.09 
291 Optimal 30 Female x 25.02.09 
293 Failure  25 Male 393.2 11.06.09 
296 Failure  24 Male 476 22.06.09 
313 Optimal 39 Male x 10.08.09 
316 Blast Crisis 38 Male 45.9 18.11.09 
317 Blast Crisis 16 Male x 04.06.08 
321 Failure  42 Female 256.3 13.01.10 
323 Failure  79 Male 68.9 04.02.10 
324 Optimal 58 Female 37.3 17.03.10 
337 Optimal 84 Female 259 25.05.10 
366 Optimal 57 Female 405 08.09.10 
371 Optimal 50 male 357.9 04.10.10 
395 Failure  28 Female x 21.02.11 
414 Failure  68 Female 301.3 23.03.11 
426 Blast Crisis 42 Male x 13.05.11 
467 Failure  57 Male 359.4 23.10.11 
504 Blast Crisis 92 Female 22.3 16.05.12 
 
 
2.3 Cell Culture 
 
2.3.1 Maintenance of cells 
 
Four human BCR-ABL1 positive CML cell lines, KCL22, KYO-1, LAMA84 and K562 were 
used as  cell line models of CML and as controls in some experiments (donated by Prof 
Junia Melo from the LRF Leukaemia Unit, Hammersmith Hospital, London, UK). Cell 
lines were cultured under standard tissue culture conditions (37˚C, 5% CO2 in air, 100% 
humidity) at an approximate starting density of 3x105/ml in culture medium (RPMI, 
10% FCS, 1% L-glutamine and 2% penicillin and streptomycin, Invitrogen). Cultures 
were re-seeded into fresh media approximately every 3-4 days. Twenty-four hours 
prior to experimental use cell lines were resuspended in fresh culture medium to 
ensure optimal exponential growth prior to use. 
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2.3.3 In vitro cultures  
 
In vitro studies of drugs were carried out on both cell lines and patient samples. 
Conditions for this were as follows; 2x106 cells per ml were cultured in RPMI-1640 
supplemented media at 37°C for 24 hours with the drug concentrations shown in Table 
2.1. Patient samples were used 24 hours subsequent to thawing.  
 
Table 2.2 Concentrations of drugs/reagents used in in vitro cultures 
Drug/reagent Final 
Concentration 
Company 
Imatinib 5μM Novartis, Basel, Switzerland 
Dasatinib 150nM Bristol-Myers Squibb, NYC, New York, USA 
Nilotinib 5μM Novartis 
FTY720 2.5μM Millipore, Watford, Hertfordshire  
Okadaic Acid 6nM Sigma-Aldrich 
SB216763 5μM Sigma-Aldrich 
Wnt3a 25ng R&D Systems, Abingdon, Oxfordshire 
WIF1 1.5μg R&D Systems 
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2.4 Small interfering RNA 
 
Small interfering RNA (siRNA) against various targets was carried out using Cell Line 
Nucleofector (TM) Kit V (Lonza/Amaxa Biosystems, Cambridge, Cambridgeshire) and 
the Amaxa machine (setting T-16). K562 cells were used for siRNA to knock down both 
GSK3β (Santa Cruz Biotechnology, Heidelberg, Germany) and CIP2A (Santa Cruz 
Biotechnology)(Table 2.2). Cells were firstly washed three times in PBS (pH 7.2) to 
remove any residual medium which may affect the siRNA process. 1x106 cells were then 
resuspended in 100μl nucleofector solution in an Eppendorf tube. 100nM of scrambled 
control siRNA (Santa Cruz Biotechnology), and test siRNAs (Table 2.2) were added 
separately to the re-suspended cells, and then these suspensions were transferred to 
Amaxa cuvettes. Electroporation was carried out using the Amaxa instrument. After 
nucleofection, 0.5ml of pre-warmed culture media was added to each vial using a soft 
pipette, and the cells were transferred to a 24 well plate (BD) containing another 0.5ml 
of pre-warmed culture medium. The cells were then incubated for 72 hours and the 
effects of siRNA measured by polymerase chain reaction (PCR), fluorescence activated 
cell sorting (FACS) and western blotting.  
 
Table 2.3 siRNA used 
siRNA Catalogue Number Company 
GSK3β  sc-355527 Santa Cruz Biotechnology 
CIP2A sc-77964 Santa Cruz Biotechnology 
Control sc-37007 Santa Cruz Biotechnology 
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2.5 Transient Transfection 
 
The CIP2A-GFP transfection plasmid (PrecisionShuttle mammalian vector with C-
terminal tGFP tag, 10μg, PS100010, Origene, Rockville, Maryland, USA) was used to 
transiently transfect CIP2A into K562 cells. A schematic of the plasmid can be seen in 
Figure 2.1. A GFP-only transfection plasmid was used as a control. Similar to siRNA, 
transient transfection was carried out using the Cell Line Nucleofector (TM) Kit V 
(Lonza/Amaxa Biosystems) and the Amaxa machine (setting T-16). Cells were washed 
three times in PBS (pH 7.2) to remove any residual media which may affect the 
transfection process. 2x106 cells were then resuspended in 100μl nucleofector solution 
in an Eppendorf tube. 2μg/ml of the CIP2A-GFP (green fluorescent protein) tagged and 
GFP-only tagged plasmids were added to the re-suspended cells, and this suspension 
was transferred to an Amaxa cuvette. Electroporation was carried out using the Amaxa 
instrument. Following nucleofection, the cells were transferred to a 24 well plate 
containing 0.5ml of pre-warmed culture media. The cells were then incubated for 48 
hours and the effects of the transfection measured by PCR, FACS and western blotting.  
 
Prior to any analysis, the transfection efficiency was measured by GFP detection using 
fluorescence-cell analysis (FACScalibur, BD) and by propidium iodide (PI) (1μg/ml) 
staining for analysis of cell viability (see Section 2.7.2).  
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Figure 2.1 A schematic of the cloning sites for the CIP2A-GFP tagged transfection 
plasmid 
 
[183] 
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2.6 PCR Analysis 
 
2.6.1 RNA extraction 
 
RNA was extracted using RNeasy mini kit (Qiagen). Samples were thawed and 
transferred to a QIA shredder column sitting in a 2ml collection tube, and centrifuged at 
14,000g for 2 minutes in a microcentrifuge. 600l of 70% ethanol was added and mixed 
well with the flow through in the collection tube. 600l of sample was added to an 
RNeasy mini spin column sitting in a 2ml collection tube and centrifuged for 15 seconds 
at 14,000g. The flow through was discarded. 700l of kit RW1 buffer was added to the 
RNeasy column and left at room temperature for 5 minutes, followed by centrifugation 
at 14,000g for 5 minutes, and the flow through discarded. The RNeasy spin column was 
transferred to a new RNeasy collection tube. The RNeasy spin column was washed twice 
with 500l kit RPE buffer and centrifuged at 14,000g for 15 seconds. The RNeasy spin 
column was transferred into a new 1.5ml collection tube, and then 40l of RNase free 
water was added directly onto an RNeasy membrane and left at room temperature for 5 
minutes. RNA was eluted by centrifuging for 2 minutes at 14,000g. RNA was stored at -
70C until used.  
 
2.6.2 cDNA synthesis 
 
cDNA was synthesised using the RNA prepared above. 30µl of RNA was incubated with 
2µl (500ng/µl) of random hexamers (Promega, Southampton, Hampshire) at 70˚C for 10 
minutes then cooled on ice for 3 minutes. 16µl 5x reaction buffer (RT buffer), 8µl of 
0.1M DL-Dithiothreitol (DTT) and 4µl of 10mM deoxyribonucleotide triphosphate 
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(dNTP) (SuperScript III Reverse Transcriptase kit, Invitrogen) was added to the sample 
and incubated for 5 minutes at 25˚C for 10 minutes, then at 42˚C for 60 minutes, and 
finally at 70˚C for 15 minutes to stop the reaction. The cDNA was stored at -20˚C until 
used. 
 
2.6.3 Real time – quantitative Polymerase Chain Reaction (RT-qPCR) 
 
Pre-designed TaqMan real time PCR assays (Life Technologies, Paisley, Renfrewshire) 
were used in a 96 well assay plate. Each assay consists of a forward and reverse primer 
at a final concentration of 900nM and a 6-carboxyfluorescein (6-FAM) dye-labelled 
TaqMan minor groove binder (MGB) probe at a final concentration of 250nM.  The 
amount of cDNA was determined using the Nanodrop2000; 100ng of cDNA was used 
per 20µl reaction consisting of 4µl Distilled water, 10µl TaqMan gene expression master 
mix (Life Technologies), 1µl TaqMan gene expression assay (Table 2.3), and 5µl of 
cDNA.  Each sample was run in triplicate.  After loading the reaction mixture, the plate 
was sealed.  The real time PCR amplifications were performed using an ABI Prism 
7900HT System with the following conditions specified by the manufacturer: 50°C for 2 
minutes, 10 minutes at 95°C followed by 40 cycles of denaturation at 95°C for 15 
seconds and annealing/extension at 60°C for 1 minute.   
 
The relative expression level of a particular gene of a given sample was calculated by 
the comparative Ct method [184]. The comparative Ct method uses the 2-ΔΔCt formula to 
achieve results for relative quantification, where ΔΔCt is the normalised signal level in a 
sample relative to the normalised signal level in the calibrator sample.  In this study a 
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pool of cDNA from six healthy volunteers was used as calibrator and all the samples 
were normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) endogenous 
control.   
 
Table 2.4 Assay primers used for PCR 
Assay Product Code Company 
CTNNB1 (β-catenin) Hs00355049_m1 Life Technologies 
GSK3β (long and short) Hs01047719_m1 Life Technologies 
GSK3β (long only) Hs01053242_g1 Life Technologies 
RT2 Profiler PCR Array for 
the Human WNT Signalling 
Pathway  
PAHS-043Z Qiagen 
WNT1 Hs01011247_m1 Life Technologies 
WNT8A Hs00230534_m1 Life Technologies 
WNT9A Hs00243321_m1 Life Technologies 
FZD7 Hs00275833_s1 Life Technologies 
NKD1 Hs00263894_m1 Life Technologies 
APC Hs01568269_m1 Life Technologies 
TCF1 Hs00167041_m1 Life Technologies 
TCF3 Hs00413032_m1 Life Technologies 
TCF4 Hs00162613_m1 Life Technologies 
LEF1 Hs01547250_m1 Life Technologies 
C-MYC Hs00153408_m1 Life Technologies 
CYCLIN D1 Hs00765553_m1 Life Technologies 
GAPDH Hs99999905_m1 Life Technologies 
 
91 |  P a g e
 
2.6.4 Manual PCR 
 
Forward and reverse primers were diluted in double distilled (dd) H2O to give a mix 
containing 4μM concentration of each.  A mastermix was made containing 10μl 
expression mix, 1μl primer mix and 4μl ddH2O per sample, and then 15μl was pipetted 
into each required  well of a 96 well PCR plate.  5μl of cDNA from each sample and 
controls were then added, and the plate was sealed with a cover.  The plate was spun in 
a centrifuge, then the plate placed in the PCR block.  The following PCR conditions were 
used to run the samples: 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 
seconds, 56°C for 20 seconds, and 60°C for 45 seconds,  and then finally 72°C for 10 
minutes. 
 
The plate was then left at 4-8°C before  running on a 2% agarose gel (agarose and 
Safeview Nucleic Acid Stain (NBS biologicals, Huntingdon, Cambridgeshire) in 150ml of 
0.5M x Tris/Borate/EDTA (TBE).  Agarose and TBE were first mixed and heated in a 
microwave until the agarose was completely dissolved.  The gel was then poured into a 
mould with combs and left to set for approximately 30 minutes at room temperature.  
The gel was placed in a running tank, submerged in 0.5xTBE and the amplified samples 
(1:1 in running buffer) and any controls were loaded alongside a 50bp ladder.  Finally 
the gel was run for approximately 60 minutes at 120V and the gel photographed. 
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2.7 FACS Analysis 
 
Cells (~5x105) were fixed by resuspending in 500µl of 2% paraformaldehyde/PBS at pH 
7.2 (VWR, Lutterworth, Leicestershire) for 10 minutes at 37°C. Cells were then 
centrifuged at 770g for 3 minutes. 500µl of 90% methanol (Fisher Scientific, 
Loughborough, Leicestershire) was added to the cell pellet and the cells were vortexed 
and then incubated at room temperature for 30 minutes. Cells were then thoroughly  
washed with 1ml incubation buffer containing PBS and 0.5% bovine serum albumin 
(BSA) (Sigma-Aldrich), and centrifuged at 770g for 3 minutes. Cells were resuspended 
in 25µl incubation buffer and appropriate antibodies were added (Table 2.4). Cells 
were vortexed and incubated at room temperature for ≥45 minutes. Cells were then 
washed twice in incubation buffer and resuspended in 50µl incubation buffer 
containing 10µg/ml goat anti rabbit/mouse second layer Alexa Fluor 488 antibody 
(Invitrogen). Subsequently they were incubated at room temperature in the dark for at 
least 30 minutes, then washed twice in incubation buffer and analysed using flow 
cytometry (FACScalibur; BD), with Cellquest Pro software (BD) for data analysis. When 
analysing the data, events were gated on the live cell population, determined by forward 
and side scatter light properties, and antibody fluorescence was measured through this 
gate. The corresponding control value for each result was then subtracted to determine 
the protein level. 
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Table 2.5 Antibodies used for FACS analysis 
Primary Antibody Final 
Concentration 
Control Antibody Secondary Antibody 
Total-β-catenin (Cell 
Signalling Technology (CST), 
Beverly, Massachusetts, USA) 
0.032µg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
Unphosphorylated β-
catenin (Millipore) 
0.1µg/ml Mouse IgG1 Alexa Fluor 488 Mouse 
Phospho-β-catenin 
(S45/T41) (CST) 
0.4 µg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
Phospho-β-catenin 
(S33/37/T41) (CST) 
0.4 µg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
Phospho-β-catenin 
(Tyr654) (Abcam, 
Cambridge, Cambrigeshire) 
0.25µg/ml Mouse IgG1 Alexa Fluor 488 Mouse 
C-MYC (CST) 20 μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
C-MYC pT58 (Santa-Cruz 
Biotechnology (SCB), Dallas, 
Texas , USA) 
0.25μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
C-MYC pS62 (Abcam) 10 μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
PP2A (Millipore) 100 μg/ml Mouse IgG1 Alexa Fluor 488 Mouse 
PP2A pY307 (Abcam) 9 μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
SET (I2PP2A) (SCB) 20 μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
CIP2A (SCB) 16μg/ml Mouse IgG1 Alexa Fluor 488 Mouse 
E2F1 (SCB) 0.5μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
E2F1 pS364 (SCB) 0.5μg/ml Rabbit IgG Alexa Fluor 488 Rabbit 
 
Mouse IgG1 (BD, #349040) 
Rabbit IgG (R&D Systems, #AB-105-C) 
Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) (Life Technologies, #A-11001) 
Alexa Fluor 488 Goat Anti-Rabbit IgG (H+L) (Life Technologies, #A-11001) 
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2.7.1 CD34+ Staining. 
 
For analysis of CD34+ cells in MNC preparations, standard FACS protocol was carried 
out with the addition of 0.1mg/ml of CD34+ conjugated antibody (BD) added at the 
same time as the secondary antibody. Cells were then gated on the CD34+ population on 
analysis.  
 
2.7.2 Propidium Iodide (PI) Staining. 
 
To analyse cell viability PI staining was used. Prior to the FACS experiment, 50μl of 
approximately 2x105 cells were separated from each sample and transferred into a BD 
FACS tube. 50μl of PI (1μg/ml) was then added and the suspension was incubated on ice 
for 30 minutes. The cell death was then analysed by flow cytometry (FACScalibur, BD) 
with Cellquest Pro software (BD) for data analysis. From this the percentage viability of 
the cells was determined.  
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2.8 MTT Assay 
 
The ‘MTT reagent’ was prepared by adding 1ml of PBS (pH 7.2) to 5mg of MTT (MTT 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Life Technologies) and 
vortexing. 100μl (approximately 2x105 cells) of the treated cells were placed in 
triplicate in a 96 well flat bottomed plate. Additionally an empty well and a medium-
only well were included on the plate to act as controls. 20μl of the MTT reagent was 
added to each well as required and left for 3 hours under standard cell culture 
conditions. 100μl of the MTT lysis buffer (0.01M HCl (hydrochloric acid), 10% of sodium 
dodecyl sulphate (SDS, Sigma-Aldrich)) was added to the appropriate wells and left 
overnight under standard cell culture conditions. The plate was then read on a 
spectrophotometer at a wavelength of 575nM to determine cellular proliferation. 
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2.9 Western Blotting 
 
2.9.1 Lysate Preparation 
 
Lysates were prepared using 1x107 cells incubated on ice. First, cells were washed in 
PBS before being pelleted by centrifugation for 5 minutes at 770g and a protease 
inhibitor mix added (Table 2.5) before addition of 10µl of lysis buffer per 1x106 cells 
(Table 2.6). The mixture was vortexed before being sonicated (using a water sonicator 
at 4°C)  5 times at 30 second intervals with a 30 second break in between. The mixture 
was then spun down at 12000g for 5 minutes at 4°C and the supernatant was 
transferred into a fresh tube for subsequent protein determination (see Section 2.9.3).  
 
Table 2.6 Protease inhibitors used in lysate preparation 
Protease Inhibitors used Materials 
Protease inhibitor 
1mg/ml Chymostatin; dissolved in DMSO 
1mg/ml Leupeptin; dissolved in H2O 
1mg/ml Aprotonin; dissolved in H2O 
1mg/ml Pepstatin A; dissolved in DMSO 
1mg/ml Antipain; dissolved in H2O 
(all purchased from Sigma)  
Phosphatase and protease inhibitors Purchased from Roche (Basel, Switzerland) 
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Table 2.7 Lysis buffers used in lysate preparation 
Lysis Buffer Materials 
SDS Lysis Buffer 
1% SDS: 100µl of 10% SDS solution or 0.1g SDS 
50mM Tris pH 6.8: 1.2ml of 0.5M Tris 
5mM EDTA pH 6.8: 0.5ml of 0.1 EDTA 
1ml of 10% Glycerol 
7.2ml of H20 
RIPA Lysis Buffer 
100mls PBS 
1% nonyl phenoxypolyethoxylethanol (NP40) 
0.5% Sodium deoxycholate 
0.1% SDS 
 
 
2.9.2 Nuclear/Cytoplasmic Extraction 
 
Nuclear extraction was carried out to separate the cytoplasmic and nuclear 
compartments of the cell to distinguish protein localisation. Two methods were tested 
which were as follows; 
 
Method 1: Performed using a Nuclear Extract Kit (Active Motif, Kilkenny, Ireland) on 
ice. 2x107 cells were spun down for 5 minutes at 770g. The supernatant was removed 
and the cells were washed twice with ice cold PBS/phosphatase inhibitors (1.6ml 
10xPBS, 13.6ml ddH2O, 0.8ml phosphatase inhibitors) in a pre-chilled 15ml conical 
tube. The samples were spun down and the supernatant was discarded and cell pellet 
was kept on ice to progress and prepare the cytoplasmic fraction. 
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Next the cells were gently resuspended in 500µl of 1x hypotonic buffer (100µl 10x 
hypotonic buffer, 0.9ml ddH2O). The suspension was then transferred to a pre-chilled 
1.5ml Eppendorf tube and incubated for 15 minutes on ice. 25µl of provided detergent 
was added and the suspension was vortexed for 10 seconds at maximum setting. Then 
the suspension was centrifuged for 30 seconds at 14000g in a microcentrifuge pre-
cooled at 4°C. The supernatant which contains the cytoplasmic fraction was transferred 
into a pre-chilled Eppendorf tube and stored at -80°C until it was ready to be used. The 
cell pellet left was then used for nuclear fraction collection. 
 
To get the nuclear fraction, the cell pellet was resuspended in 50µl of Complete Lysis 
Buffer (10µl 10mM DTT, 89µl lysis buffer AM1, 1µl protease inhibitor cocktail) and 
vortexed for 10 seconds at maximum setting. The suspension was incubated for 30 
minutes on ice on a rocking platform set at 150rpm, before being vortexed for 30 
seconds at maximum speed. The suspensions were spun down for 10 minutes at 
14000g in a microentrifuge pre-cooled at 4°C and the supernatant which contains the 
nuclear fraction was transferred into a pre-chilled Eppendorf tube and stored at -80°C 
until it was ready to be used.  
 
 
Method 2: Cells were pelleted by centrifugation before being resuspended in 100μl of 
pre-cooled cytoplasmic lysis buffer per 106 cells (1% Triton, 10mM Tris at pH7.4, 
150mM NaCl, and protease inhibitors).  The suspension was incubated on ice for 10 
minutes and then spun at 4000g for 10 minutes at 4°C. The pellet obtained is the 
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nuclear compartment. The supernatant was removed as the cytoplasmic fraction and 
transferred into a separate Eppendorf tube. The nuclear pellet was then resuspended in 
300μl of the cytoplasmic buffer to remove any residual cytoplasmic contamination and 
then spun again at 4000g for 10 minutes at 4°C. The supernatant was discarded and the 
pellet resuspended in 100μl of SDS lysis buffer per 106 cells. This was then sonicated as 
per the normal lysate protocol. 
 
2.9.3 Protein Determination 
 
Protein determination was performed according to manufacturer’s recommendations 
(Bio-Rad, Hemel Hempstead, Hertfordshire). Firstly a set of standards were made to 
determine the unknown quantity of protein in the lysates. This was done using the 
required lysis buffer made to a stock of 10µg with 0.1% BSA in 10ml lysis buffer. The 
following dilutions were made to get the corresponding protein quantities (Table 2.7).  
 
Table 2.8 Protein determination standards 
Final Concentration (μg/ml) BSA Stock (10μg/ml) 1% Lysis Buffer 
0 (1000μl ddH20)  
0.5 50µl 950µl 
1 100µl 900µl 
1.5 150µl 850µl 
2 200µl 800µl 
2.5 250µl 750µl 
3 300µl 700µl 
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A 96 well flat bottom plate was used loading 5µl of both the standards and lysates in 
triplicate to the wells. 25µl of the working reagent was then added (20µl of reagent S 
per ml of reagent A), followed by 200µl of reagent B, each as supplied in the kit. The 
plate was then left in the dark for 15 minutes, and read on a spectrophotometer at a 
wavelength of 670nM. The quantity of protein was then calculated using Microsoft Excel 
using the linear equation generated by the standards to convert the lysate’s absorbance 
to protein quantity.  
 
2.9.4 Gel Electrophoresis 
 
Prior to loading, each sample was aliquoted with double strength SDS buffer (DSSB) 
before being heated for 5 minutes at 95°C. Simultaneously a polyacrylamide gel was set 
with a 12% resolving gel (3.5ml separating gel buffer, 7ml acrylamide, 3.5ml H2O, 75μl 
10% ammonium persulphate (APS, Sigma-Aldrich), 15μl tetramethylethylenediamine 
(TEMED)) and a 5% stacking gel (1.5ml stacking buffer, 1ml acrylamide, 3.5ml H2O, 50μl 
10% APS, 15μl TEMED). Samples were then loaded into the gels alongside a pre-stained 
protein ladder (Bio-Rad), which were then submerged in 1x electro buffer (25mM Tris, 
192mM glycine, 0.1% SDS, diluted 1:10) and run at 35mA per gel for approximately 90 
minutes. 
 
2.9.5 Membrane Transfer 
 
Subsequent to gel electrophoresis, the gel was removed from the running apparatus and 
the stacking gel was removed. A transfer cassette was then assembled according to 
manufacturer guidelines (Bio-Rad) which contained a layer of polyvinylidene difluoride 
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(PVDF, Bio-Rad) membrane soaked in 100% methanol.  The cassette was placed in a 
transfer tank next to an ice pack and covered in transfer buffer (25nM Tris, 0.2M 
glycine) with due regard to electrode placement to ensure protein transfer to the 
membrane. The transfer was then carried out at 400mA for 60 minutes.  
 
2.9.6 Antibody Incubation 
 
When the membrane transfer was complete, the PVDF membrane was removed from 
the cassette and blocked in 5% ECL Prime blocking reagent (GE Healthcare, Little 
Chalfont, Buckinghamshire) made up in TBS-T (Tris 20mM, NaCl 150mM, Tween20 
(0.1%), pH7.5) for 60 minutes at room temperature with rocking. The required 
antibodies (see Table 2.8) were then added directly to the milk and incubated for a 
minimum of 90 minutes at room temperature with rocking. Next the membrane was 
washed four times every 10 minutes in TBS-T. The appropriate secondary antibody was 
then added to the membrane (0.4µg/ml in 3% ECL Prime blocking milk in TBS-T) and 
incubated for a minimum of 30 minutes at room temperature with rocking. The 
membrane was then again washed four times every 10 minutes in TBS-T before being 
developed. ECL advance (GE Healthcare) was applied to the membrane for 1 minute, 
before membrane exposure and band visualisation using UNITEC Alliance 2.7 software.     
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Table 2.9 Antibodies used for western blot analysis 
Primary Antibody Concentration 
Secondary 
Antibody 
Molecular 
Weight (kDa) 
Total-β-catenin (CST) 8ng/ml Anti-rabbit IgG 92 
Unphosphorylated β-catenin 
(Millipore) 
1 μg/ml Anti-mouse IgG 86 
Phospho-β-catenin 
(S45/T41) (CST) 
0.115 μg/ml Anti-rabbit IgG 92 
Phospho-β-catenin (Tyr654) 
(Abcam) 
0.1 μg/ml Anti-mouse IgG 86 
Total GSK3β (BD) 0.25 μg/ml Anti-mouse IgG 46 
Phospho-GSK3α/β (Ser21/9) 
(CST) 
0.3 μg/ml Anti-rabbit IgG 
α: 51 
β: 46 
Phospho-GSK3β (Tyr216) 
(Abcam) 
1μg/ml Anti-rabbit IgG 47 
MCL-1 (SCB) 0.2 μg/ml Anti-rabbit IgG 
Long: 40 
Short: 32 
Anti-β-Actin (Sigma) 0.2 μg/ml Anti-mouse IgG 42 
Anti-mouse IgG, HRP-linked Antibody (CST, #7076) 
Anti-rabbit IgG, HRP-linked Antibody (CST, #7074) 
 
 
2.9.7 Membrane Stripping 
 
Stripping buffer was made using 12.1g of 1M Tris, 10ml of 20% SDS, made up to 100ml 
with H20. 10ml of this was used per membrane to which 70µl β-mercaptoethanol was 
added. The ECL from previous exposure was washed off with 1xTBS-T and the 
membrane was added to a sealed bag with the stripping buffer and heated to 55˚C for 
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10 minutes. The stripping buffer was then washed off with 1xTBS-T three times. The 
membrane was then cleared to be reprobed. 
 
Monoclonal Anti-β-Actin antibody (Sigma) (Table 2.8) was used as a loading control on 
blots. The membrane was blocked in 5% ECL Prime blocking reagent (GE Healthcare) as 
per western protocol (Section 2.9.6), and then incubated with the β-actin antibody at a 
1:10,000 dilution for 1 hour at room temperature. After washing, the membrane was 
incubated with anti-mouse HRP (CST) for an hour at room temperature, washed again 
and then visualised as per western protocol (Section 2.9.6). 
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2.10 Confocal Microscopy 
 
Slides were prepared by coating in 10% poly-L-Lysine (Sigma) for 5 minutes. These 
were then allowed to dry at 37°C for 60 minutes. A circle of approximately 3cm2 was 
marked on the slide using a hydrophobic liquid blocker pen and allowed to dry for 30 
minutes prior to adding the cells.  
 
The cells were prepared as before for FACS analysis; cells (~5x105) were fixed by 
resuspending in 500µl of 2% paraformaldehyde at pH 7.2 (VWR) for 10 minutes at 37˚C. 
Cells were then centrifuged at 770g for 3 minutes. 500µl of 90% methanol (Fisher 
Scientific) was added to the cell pellet and the cells were vortexed and then incubated at 
room temperature for 30 minutes. Cells were then washed thoroughly  with 1ml 
incubation buffer containing PBS and 0.5% BSA (Sigma-Aldrich), and centrifuged at 
770g for 3 minutes. Cells were resuspended in 25µl incubation buffer and appropriate 
antibodies were added (see Table 2.7). Cells were vortexed and incubated at room 
temperature for at least 45 minutes. Cells were then washed twice in incubation buffer 
and resuspended in 50µl incubation buffer containing 10µg/ml goat anti rabbit/mouse 
second Alexa Fluor 488 antibody (Invitrogen). Subsequently they were incubated at 
room temperature in the dark for at least 30 minutes, and then washed twice in 
incubation buffer. Finally the cells were resuspended in 50μl of incubation buffer and 
pipetted onto the appropriate slide. The slides were left in the dark overnight at 4°C for 
the cells to adhere to the slides. Before analysis 10μl of CyGel (BioStatus Limited, 
Shepshed, Leicestershire) was added to a cover slip and pressed firmly onto the slide to 
avoid air bubbles. The slides were then ready to be analysed by the Zeiss Confocal LSM 
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710.  Images were analysed using Zen software and all images for each antibody were 
taken together using the same detector settings. The following settings were used for 
analysis; Plan-Apochromat 63x/1.4 oil DIC M27 objective was used with a 488 laser. 
Detector Ch1 was selected for use with a rainbow coarse spectrum and the 1024x1024 
frame size. 
 
Table 2.10 Antibodies used for Confocal Microscopy 
Primary Antibody Concentration Control Antibody Secondary Antibody 
Unphosphorylated β-
catenin (Millipore) 
0.1µg/ml Mouse IgG1 Alexa Fluor 488 
Mouse 
Phospho-β-catenin 
(S45/T41) (CST) 
0.4 µg/ml Rabbit IgG Alexa Fluor 488 
Rabbit 
Phospho-β-catenin 
(S33/37/T41) (CST) 
0.4 µg/ml Rabbit IgG Alexa Fluor 488 
Rabbit 
Phospho-β-catenin 
(Tyr654) (Abcam) 
0.25µg/ml Mouse IgG1 Alexa Fluor 488 
Mouse 
 
Mouse IgG1 (BD Biosciences, #349040) 
Rabbit IgG (R&D Systems, #AB-105-C) 
Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) (Life Technologies, #A-11001) 
Alexa Fluor 488 Goat Anti-Rabbit IgG (H+L) (Life Technologies, #A-11001) 
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2.11 Statistical Analysis 
 
Two tests for statistical analysis were used. The student T-test using Microsoft Excel 
was used when testing two independent or paired groups of data which had a normal 
distribution. The Mann-Whitney u test using SPSS was used to test two independent 
samples that were not normally distributed.  Bonferroni correction was used when 
comparing the various patient cohorts to allow for multiple comparisons.   
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Chapter 3 - The role of β-catenin in CML 
outcome 
 
3.1 Introduction 
 
 
Beta-catenin acts as an essential protein in the Wnt/β-catenin signalling pathway by 
playing a central role in the regulation of transcriptional activation. It has previously 
been described in CML that -catenin is key in the preservation of LSCs by its 
involvement in self-renewal [151, 185]. 
 
Beta-catenin is a non-enzymatic protein whose activity in the Wnt/β-catenin signalling 
pathway is controlled by its phosphorylation status [105]. On interaction within a 
complex known as the ‘destruction complex’ its action is prevented, and β-catenin is 
targeted for destruction via the proteasome. The destruction complex consists of 
multiple proteins including Axin which acts as a scaffold protein, and CK1 and GSK3β 
which phosphorylate β-catenin. CK1 first ‘primes’ β-catenin by phosphorylation on 
Ser45, which then allows for phosphorylation on Thr41, Ser37 and Ser33 by GSK3β 
[135]. This series of phosphorylation events enables the ubiquitin ligase, β-TrCP, to 
recognise β-catenin as a target for ubiquitinated degradation by the proteasome [135]. 
When this destruction complex is disrupted/prevented, phosphorylation of β-catenin 
cannot occur, leaving β-catenin un-phosphorylated at these key sites [106]. The 
translocation of β-catenin into the nucleus can consequently occur, whereby it can 
108 |  P a g e
 
associate with the transcription factors TCF and LEF [114, 115]. As a result it can then 
activate the transcription of multiple genes including c-Myc and cyclin D1 [122, 123]. 
 
Other phosphorylation sites of β-catenin which are of high relevance to CML are on the 
tyrosine residues 86 and 654. These sites can be directly phosphorylated by BCR-ABL1 
[186], stabilising β-catenin in its active conformation, and reducing the binding affinity 
of β-catenin to Axin preventing the action of the destruction complex. This allows for 
translocation into the nucleus and activation of transcription due to enhanced binding 
ability to the transcription factor TCF4. It has been shown that imatinib retains this 
form of β-catenin in the cytoplasm by increasing its binding affinity to Axin and 
subsequently enables the degradation of β-catenin [186].  
 
A particularly interesting paper that investigated the role of β-catenin and its self-
renewal capacity within CML was Jamieson et al., [150]. They observed that the 
committed GMPs from CML patients who were either in blast crisis or who were 
resistant to imatinib had significantly increased levels of activated -catenin in 
comparison to normal GMPs, and that these elevated levels of β-catenin correlated with 
the enhanced self-renewal capacity of the cells [150]. These results indicate that -
catenin may be important in CML progression and/or imatinib resistance by increased 
activity and consequent increased transcriptional activation. 
 
The work of Jamieson et al., [150] focussed on the levels of -catenin in the GMP 
compartment. However, it was of interest to investigate if -catenin levels are also 
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detectable in the later, more mature, MNCs as they are more readily available from the 
patient, easier to isolate, and less labour intensive and cheaper in terms of cost of 
purification. Furthermore, given that phosphorylation of -catenin is needed for its 
degradation, it is important to also look at phosphorylated levels of -catenin as these 
may indicate whether there is a fault in the degradation of -catenin, which may be the 
reason for possible elevated levels. In addition to the phosphorylated forms which 
target β-catenin for degradation it is important for CML to look at BCR-ABL1 mediated 
β-catenin phosphorylation of Tyr654, to determine if BCR-ABL1 is having an effect on β-
catenin turnover. 
 
  
110 |  P a g e
 
3.2 Aims 
 
The aims of this chapter are; 
1) To investigate whether -catenin protein and/or mRNA expression levels can be 
predictive of clinical outcome in imatinib treated patients. 
 
2) To determine if -catenin phosphorylation status and degradation differ in 
relation to patient outcome. 
 
3) To determine if BCR-ABL1 mediated -catenin phosphorylation on Tyr654 
correlates with disease progression. 
 
4) To determine if high levels of -catenin found in GMPs correlate with levels in 
MNC. 
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3.3 Optimisation of techniques  
 
3.3.1 Optimisation of β-catenin (CTNNB1) mRNA analysis  
 
3.3.1.1 Validation of the β-catenin primers by manual PCR  
 
Manual PCR was performed (Materials and Methods section 2.6.4) to validate the 
primers being used for β-catenin detection. Patient samples were tested alongside a 
negative control (Neg Cont). Results showed that the primers were identifying the 
correct gene product with an amplicon length of 80Kb (Figure 3.3.1) and therefore 
were used in all further experimentation for the detection of β-catenin mRNA. 
 
Figure 3.3.1 Validation of the β-catenin primers by manual PCR 
Manual PCR was carried out using patient samples and a negative control to test 
whether the β-catenin primers are detecting the correct gene product. Results show a 
band at 80Kb in the patient samples indicating the accurate detection of β-catenin. 
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3.3.2 Optimisation of antibodies for the detection of β-catenin (CTNNB1) protein 
(using cell lines) 
 
3.3.2.1 Optimisation of β–catenin antibodies by FACS 
 
Cellular protein levels of -catenin were determined using FACS (Material and 
Methods section 2.7).  Initially the CML cell lines were tested using 0.008µg/ml 
(concentration recommended by the company) of total β-catenin antibody (Material 
and Methods, Table 2.4)  to determine which CML cell line had the highest -catenin 
levels and could be used for further concentration optimisation experiments. Events 
were gated on the live cell population, as determined by forward and side scatter light 
properties, and antibody fluorescence was measured through this gate. The cell lines 
K562, LAMA-84, KCL-22, and KYO-1 were assessed (Figure 3.3.2). Results show, as 
determined by the degree of fluorescence peak shift between test and control cells, that 
LAMA-84 cells have the highest -catenin levels (Figure 3.3.2 b). 
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Figure 3.3.2 Optimisation of the β-catenin FACS protocol in the CML cell lines; 
K562, LAMA-84, KCL-22 and KYO-1 
A concentration of 0.008µg/ml of total β-catenin antibody was initially used to 
determine the optimum cell line to use for future concentration optimisation 
experiments.  Results show this to be LAMA-84 cells. 
 
 
 
 
 
Using LAMA-84 cells, the optimum concentration of total β-catenin antibody was 
determined for subsequent use on primary material. Figure 3.3.3A shows that the 
optimum concentration, of those tested, for the total β-catenin antibody is 0.064µg/ml. 
However due to the expense of the antibody and the fact that there is still good peak 
separation at 0.032µg/ml, this concentration of antibody was used in all further 
experimentation. 
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In addition to testing total -catenin, levels of unphosphorylated (Figure 3.3.3 B) and 
phosphorylated (Figure 3.3.3 C and D) forms of β-catenin were examined (Material 
and Methods, Table 2.4). The unphosphorylated-β-catenin antibody binds β-catenin 
which is not phosphorylated on either Thr41 or Ser37, and targets the form of -catenin 
which is considered to be ‘active’ [106] and can translocate to the nucleus to activate 
transcription. An initial dilution of 1:200 was made, and then six concentrations were 
tested.  The results (Figure 3.3.3B) show that the optimum concentration, as 
determined by fluorescent peak shift, is a final concentration of 0.1µg/ml. 
 
Phospho-β-catenin antibody (Ser45/Thr41) detects -catenin phosphorylated on 
residues Ser45 (via the action of the kinase CK1) and Thr41 (via the action of GSK3) 
and represents the form of -catenin targeted for degradation by the proteasome [135]. 
Figure 3.3.3C indicates that the optimum antibody concentration to use for this 
antibody is a final concentration of 0.4µg/ml. 
 
Finally, phospho-β-catenin antibody (Tyr654) was used to represent the form of -
catenin phosphorylated directly by BCR-ABL1, which functions by targeting -catenin to 
the nucleus [186]. The optimum antibody concentration to proceed with was a final 
concentration of 0.5µg/ml (Figure 3.3.3D). However, again due to the expense of the 
antibody and the fact there is still good peak separation at 0.25µg/ml, this 
concentration of antibody was used in all further experimentation. 
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Figure 3.3.3 Optimisation of β-catenin antibodies concentration in LAMA-84 cells 
Antibodies optimised include:  
A) Total β-catenin - optimum antibody concentration is 0.064µg/ml.  
B) Unphosphorylated β-catenin - optimum antibody concentration to continue with is 
0.1µg/ml. 
C) Phospho-β-catenin(Ser45/Thr41) - optimum antibody concentration to use is 
0.4µg/ml. 
D) Phospho-β-catenin(Tyr654) - optimum antibody concentration is 0.5µg/ml.  
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3.3.2.2 Optimisation of the western blotting technique with the β-catenin 
antibodies 
 
The technique of western blotting (Materials and Methods section 2.9) was used to 
study the levels of β-catenin and its phosphorylated variants as confirmation of FACS 
derived data. The three CML cell lines K562, LAMA-84 and KCL22 were used, as was the 
colon cancer cell line HT-29, which is known to demonstrate over-expression of Wnt 
signalling [187, 188] which was included as a control. Multiple cell lysis buffers were 
also utilised during optimisation of signal detection e.g. SDS and RIPA lysis buffers. 
Three protein lysate concentrations were tested on loading; 10μg, 15μg and 20μg, and 
antibody dilutions from 1:4000 to 1:1000 were tried. Additionally, membranes were 
incubated overnight either at room temperature, to maximise the kinetics of the 
reaction, or at 4˚C.  Following initial experimentation further modifications were made 
to the preparation of lysates in order to enhance signal detection. These included using 
a water bath sonicator instead of a probe sonicator, meaning lysates were sonicated 
more efficiently. Also lysates were spun down following sonication and the supernatant 
was used to remove residual membrane contamination of the lysate which meant 
achieving a cleaner blot. In addition, when incubating the membrane with the 
antibodies, the antibody was added directly to the blocking buffer instead of diluting the 
blocking buffer in TBS-T before addition of the antibody. This again ensured a cleaner 
blot on development by decreasing background noise.   
 
Figure 3.3.4 shows the results achieved via western blotting of whole cell lysates. 
Results show that although total-β-catenin and unphosphorylated β-catenin are readily 
detectable in HT29 cells, they are difficult to detect in the CML cell lines tested. 
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Phospho-β-catenin(Ser45/Thr41) was higher in the CML cell lines compared to HT-29 
cells. Phospho-β-catenin(Tyr654) appeared to be absent from all cell lines, however it 
would not be predicted to be found in HT-29 cells, as Tyr654 phosphorylation of β-
catenin is BCR-ABL1 dependent.  
 
Figure 3.3.4 Optimisation of the β-catenin antibodies by western blotting in the 
CML cells lines K562, LAMA-84 and KCL22 alongside HT-29 colon cancer cells 
 
  
 
 
 
Overall, β-catenin did not prove to be easily detectable via western blot therefore it was 
decided to use another experimental technique and confocal microscopy was optimised. 
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3.3.2.3 Optimisation of the β-catenin antibodies using confocal microscopy 
 
Protein levels of the various forms of -catenin were also analysed by confocal 
microscopy. As the LAMA-84 cell line was shown to have the highest β-catenin protein 
levels via FACS analysis this cell line was used for confocal optimisation. The same 
antibody concentrations used for FACS analysis were used for confocal microscopy. 
Single slice images from different cells were used to show maximum signal and results 
show (Figure 3.3.5) all forms of β-catenin are detectable by confocal microscopy. 
 
Key:  
 
Figure 3.3.5 The optimisation of β-catenin antibodies by confocal microscopy in 
LAMA-84 cells 
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3.3.2.4 Optimisation of in vitro bortezomib treatment in cell lines  
 
K562 and LAMA-84 cells were incubated in vitro with bortezomib for 24 and 48 hours 
using a range of concentrations (0.1μM, 1μM and 5μM) (Materials and Methods 
section 2.3.3). Cellular viability following treatment was tested by propidium iodide 
(PI) exclusion, as determined by FACS analysis (N=3), and a MTT tetrazolium 
colourimetric assay (Materials and Methods section 2.7 and 2.8) to determine the 
drug’s effect on cell proliferation (N=3) (Figure 3.3.6). From results, it was decided to 
use 24 hours incubation for all further experiments. 
 
Figure 3.3.6 The effects of bortezomib on cell viability measured by PI/FACS and 
MTT assay 
Cells were incubated with bortezomib for 24 and 48 hours to test its effect on cell 
viability and cell proliferation. Results show incubation with 5μM of bortezomib for 24 
hours was optimum (N=3). 
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3.4 Results 
 
 
Having optimised β-catenin detection in cell lines, the next stage was to detect and 
compare β-catenin and its phosphorylated variants in different clinical scenarios 
relevant to treatment outcomes in CML. Blood samples were taken from patients and 
the MNCs were extracted and frozen down to be stored in the Liverpool biobank 
(Materials and Methods section 2.2.2). On use of this material, the samples were 
thawed and allowed to recover overnight before experimentation was carried out.  
 
Patient samples were split into three patient outcome cohorts in line with the ELN 
definitions [41] (as described in section 1.4.2); optimal responders, failure patients and 
blast crisis patients. Patients who would be classified as ‘sub-optimal’ (ELN 
recommendations 2009 [43]) or warning (ELN recommendations 2013 [41]) were not 
included in analysis. For mRNA levels, patient material was available from both optimal 
responders and failure patients at diagnosis and 12 months, and from patients who 
subsequently transformed into blast crisis at diagnosis, 12 months and when they had 
transformed into blast crisis. For protein levels, patient material was available for both 
optimal responders and failure patients at both diagnosis and 12 months. However, for 
patients who subsequently transformed into blast crisis, material was only available 
from when they had transformed into the final stage of the disease due to limitations on 
resources at diagnosis.  
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3.4.1 Protein levels of β-catenin are elevated in primary CML material  
 
To determine whether investigation into β-catenin levels was worthwhile, the protein 
levels of β-catenin and its phosphorylated forms were investigated in primary CML 
MNCs by FACS analysis (Materials and Methods section 2.7) and confocal microscopy 
(Materials and Methods section 2.10). Due to the difficulty with optimising the 
western blot technique, this was not performed. Results showed that the levels of β-
catenin and its phosphorylated forms are elevated in primary CML MNCs 
(representative images shown in Figure 3.4.1) therefore it was considered relevant to 
continue with this line of investigation to determine if there is a difference in β-catenin 
mRNA and protein levels between patient outcomes.  
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Figure 3.4.1 Protein levels of β-catenin are elevated in primary CML material  
The levels of β-catenin were measured by FACS and confocal in primary CML material 
showed there is elevated levels of total β-catenin (A.) unphosphorylated β-catenin (B.) 
phospho-β-catenin (Ser45/Thr41) (C.) and phospho-β-catenin (Ser33/37/Thr41) (D.) 
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3.4.2 Comparison of β-catenin mRNA levels between different CML clinical groups 
 
3.4.2.1 mRNA transcript levels of β-catenin demonstrate no correlation with 
predicting patient outcome 
 
Initially, mRNA transcript levels of -catenin were investigated in imatinib treated 
patients to determine if there was a difference between patient cohorts. Both diagnostic 
and 12 month samples were studied from each cohort, as well as samples from patients 
who had transformed into blast crisis. At diagnosis results showed that β-catenin 
expression was elevated in CML patients compared to healthy individuals. When 
comparing patient cohorts at initial diagnosis of chronic phase there was no 
distinguishable difference between the groups (Figure 3.4.2). Beta-catenin levels 
appeared to be reduced after 12 months of standard imatinib treatment (400mg/day) 
to a level similar to that seen within healthy individual samples. This reduction could be 
anticipated as the leukaemic cell burden is replaced with non-leukaemic cells following 
treatment. Interestingly there is a reduction in  -catenin levels in optimal responders 
and failure patients after 12 months treatment. . This finding could be a reflection of 
altered morphology and cell make up after 12 months imatinib treatment. Notably, β-
catenin mRNA levels of transforming patients initially reduce on imatinib treatment, but 
then rise again at transformation to levels similar to those found in those patients at 
initial diagnosis.  
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Figure 3.4.2 mRNA expression levels of β-catenin do not correlate with patient 
outcome in imatinib treated patients 
mRNA expression levels of patient MNC samples were measured in optimal, failure and 
blast crisis patients at both diagnosis (N=19, 6 and 6 respectively) and 12 months 
(N=19, 6 and 5 respectively), and in addition when patients were in blast crisis (N=6). 
Levels were also measured in four healthy individual MNC samples as a comparator 
with patient results.  
Results showed no correlation between mRNA expression at diagnosis and patient 
outcome to treatment. As expected, levels decrease after treatment, with the exception 
of blast crisis patients where the levels rise again at transformation into blast crisis. 
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3.4.2.2 mRNA transcript levels of β-catenin demonstrate no correlation with 
patient progression 
 
When comparing β-catenin mRNA levels between samples taken from patients in 
chronic phase and those actually in blast crisis, the data show no difference in the levels 
of β-catenin mRNA (Figure 3.4.3). This indicates that mRNA expression of β-catenin 
does not change between disease stages, suggesting that protein levels may be more 
important in distinguishing between disease states in MNCs. 
 
Figure 3.4.3 mRNA expression levels of β-catenin do not correlate with disease 
progression in imatinib treated patients 
mRNA levels were stratified according to chronic phase (N=30) or blast crisis (N=6). 
Results showed there was no significant difference between the two groups indicating 
β-catenin mRNA levels do not alter at disease progression. 
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3.4.2.3 Imatinib decreases β-catenin mRNA expression in vitro 
 
To investigate the effects that imatinib is having on the levels of β-catenin mRNA 
expression, LAMA-84 cells were cultured with imatinib for 24 hours (Materials and 
Methods section 2.2.3) and cDNA was extracted (N=3) (Materials and Methods 
section 2.6.1 and 2.6.2). Results show that imatinib reduces the levels of β-catenin 
expression in vitro (P=0.069) (Figure 3.4.4) indicating that imatinib can act either 
directly or indirectly on β-catenin to alter its expression levels. 
 
Figure 3.4.4 Imatinib reduces β-catenin mRNA levels in vitro 
LAMA-84 cells were incubated with IM in vitro for 24 hours to determine the effect on 
β-catenin mRNA levels (N=3). Results show that IM reduces the expression of β-catenin 
in comparison to untreated (P=0.069). 
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3.4.2.4 mRNA transcript levels of β-catenin in patients treated with dasatinib or 
nilotinib 
 
The data of Figures 3.4.2 and 3.4.3 were derived from patients receiving imatinib 
treatment. Subsequently, the levels of -catenin expression were also studied in a group 
of patients who received either dasatinib or nilotinib from original diagnosis. As with 
imatinib treatment (P=0.006, Figure 3.4.2) β-catenin expression was significantly 
lower after 12 months of dasatinib and nilotinib treatment in the optimal responders 
(P=0.05 and 0.001 respectively) (Figure 3.4.5). This adds to the premise that patients 
who respond well to treatment, irrespective of what type of drug they receive, have a 
significant reduction in their β-catenin levels, which could be due to changes in the 
constituent cell population. The decrease in β-catenin expression was not statistically 
significant in patients who failed dasatinib treatment (P=0.06, N=2), possibly due to the 
small cohort studied. No patients failed nilotinib treatment so trends in β-catenin 
expression between different response groups treated with these second generation 
drugs could not be assessed. Similarly no patients progressed to blast crisis when 
receiving either dasatinib or nilotinib. 
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Figure 3.4.5 mRNA expression levels of β-catenin in patients treated with the 
second generation TKIs dasatinib and nilotinib 
The levels of β-catenin mRNA were determined in patients treated with either dasatinib 
or nilotinib. Results show that in the optimal responders β-catenin levels significantly 
reduced after 12months treatment (dasatinib P=0.05, nilotinib P=0.001). There was no 
significant difference between the optimal responders and failure patients at diagnosis 
who were treated with dasatinib. This could not be assessed in nilotinib treated patients 
as there were no patients who had failed treatment. Additionally, no patients 
transformed to blast crisis on either drug.  
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3.4.3 Comparison of β-catenin total protein levels between the different CML 
clinical groups 
 
Following investigation of β-catenin mRNA expression levels and the observation that 
they have no value as either a prognostic marker for subsequent blast crisis or as an 
indicator of disease progression, the total β-catenin protein levels were next examined 
by FACS analysis (Materials and Methods section 2.7). Events were gated on the live 
cell population, as determined by forward and side scatter light properties, and 
antibody fluorescence was measured in this gate. 
 
 
3.4.3.1 Protein levels of total β-catenin demonstrate no correlation with 
predicting patient outcome or disease transformation 
 
Total levels of β-catenin were initially investigated to determine if there was a change in 
overall levels of total β-catenin between patient cohorts. The results were analysed in 
accordance with patient outcome, with optimal response and failure patients being 
analysed at diagnosis and 12 months, and blast crisis patients being analysed when 
patients had transformed into blast crisis.  
 
Figure 3.4.6 shows that in patients at diagnosis the levels of total β-catenin were higher 
than those observed in normal MNC, and did not alter significantly following 12 months 
of imatinib treatment. Interestingly, the total level of β-catenin protein in patients 
transformed into blast crisis was similar to healthy individuals. Overall, the results 
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indicate that total levels of β-catenin protein cannot be used to distinguish between 
different patient cohorts on imatinib treatment. 
 
Figure 3.4.6 Protein levels of total β-catenin do not correlate with patient 
outcome in imatinib treated patients 
Using MNC samples protein levels of total β-catenin were measured in optimal (N=7), 
and failure patients (N=7) at diagnosis and following 12 months of treatment (N=6 and 
5 respectively). In addition samples taken when patients were in blast crisis (N=6) were 
also tested. Levels were also measured in MNC samples from healthy individuals (N=6). 
Results showed higher levels at both diagnosis and following 12 months imatinib 
treatment compared to healthy MNCs. The total level of β-catenin protein in patients 
transformed into blast crisis was similar to that in cells from healthy individuals. 
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The data from the separate clinical cohorts were combined and re-stratified into 
chronic phase vs blast crisis to see if there was a difference in levels of total β-catenin at 
disease progression (figure 3.4.7). Results showed the total β-catenin levels decreased 
in blast crisis compared to chronic phase diagnostic samples, however, this was not 
significant indicating that, along with mRNA levels of β-catenin, total β-catenin protein 
levels cannot be used to assess patient outcome or disease progression in CML. 
 
Figure 3.4.7 Protein levels of total β-catenin do not correlate with disease 
progression in imatinib treated patients 
Protein levels were re-stratified according to chronic phase (N=14) or blast crisis (N=6). 
Results showed a decrease in levels however this difference did not reach statistical 
significance. 
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3.4.3.2 Imatinib reduces the level of total β-catenin protein in vitro 
 
To examine the effects that imatinib is having on the levels of total β-catenin protein, 
LAMA-84 cells were cultured with the clinically achievable dose of 5µM imatinib for 24 
hours (Materials and Methods section 2.3.3) and levels were measured by FACS 
analysis (N=3) (Materials and Methods section 2.7). Results showed a significant 
reduction of total β-catenin levels with imatinib treatment (P=0.045) (Figure 3.4.8).  
This shows that the reduction in β-catenin mRNA levels by imatinib (Figure 3.4.4) also 
translates to total protein levels. Why this decrease is not reflected in the patient 
samples on imatinib treatment it unknown (Figure 3.4.6).  
 
Figure 3.4.8 Imatinib reduces the level of total β-catenin in vitro in LAMA-84 cells  
LAMA-84 cells were incubated with 5µM imatinib in vitro for 24 hours and measured by 
FACS to determine its effect on total β-catenin. Results show a reduction in levels on 
imatinib incubation (N=3). 
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3.4.4 Does β-catenin protein phosphorylation status correlate with clinical 
outcome? 
 
Beta-catenin activity is controlled by its phosphorylation status.  When β-catenin is 
unphosphorylated it is unavailable for ubiquitination by βTrCP, and thus is free to enter 
the nucleus where it can initiate transcription. Conversely, phosphorylation of β-catenin 
by CK1α at Ser45 primes β-catenin for further phosphorylation by GSK3β at Thr41, 
Ser37 and Ser33 [104, 135, 136]. Specifically, the phosphorylation at Ser37 and Ser33 
by GSK3β permits βTrCP to initiate ubiquitination leading to the degradation of β-
catenin by the proteasome [135, 140-142]. 
 
The following variants were considered for further investigation and using 
commercially available antibodies specific to these forms. 
1. Unphosphorylated β-catenin, which represents the ‘active’ form of β-catenin 
that can translocate into the nucleus from the cytoplasm and activate 
transcription.  
2. Phospho-β-catenin (Ser45/Thr41), which is phosphorylated on Ser45 by CK1 
and on Thr41 by GSK3β and is targeted for degradation by the proteasome. 
Without the phosphorylation on Ser45 by CK1, GSK3β cannot phosphorylate the 
subsequent sites.  
3. Phospho-β-catenin (Ser33/37/Thr41), which is similar to phospho-β-
catenin(Ser45/Thr41) whereby it is targeted for degradation by the 
proteasome, it is phosphorylated solely by GSK3β on all 3 residues subsequent 
to CK1 phosphorylation.  
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3.4.4.1 Protein levels of unphosphorylated β-catenin and phospho-β-catenin 
(Ser45/Thr41) demonstrate no correlation with predicting patient outcome but 
do alter at disease transformation 
 
Phospho-β-catenin (Ser33/37/41) was removed from analysis when looking at patient 
samples due to the limited amount of cells available, and as it would be expected to 
show similar results to phospho-β-catenin (Ser45/Thr41). Patients analysed were the 
same as those examined for total β-catenin (see Section 3.4.3.1). 
 
The levels of unphosphorylated β-catenin were assessed (Figure 3.4.9 A) to represent 
the active form of β-catenin able to activate transcription [106]. Results for this form 
showed low levels in the optimal responders both pre and post 12 month imatinib 
treatment compared to failure patients, patients in blast crisis and levels from healthy 
donor MNCs. There was no statistically significant difference between any groups.  
 
Figure 3.4.9 B shows the protein levels for the combined phosphorylation sites Ser45 
(by CK1) and Thr41 (by GSK3β), representing the form of β-catenin targeted for 
degradation by the proteasome [135]. Low levels of phospho-β-catenin (Ser45/Thr41) 
were detected in MNC at diagnosis in both optimal responders and failure patients, and 
in patients transformed into blast crisis. However, there was no difference seen 
between patient cohorts.  Following 12 months of imatinib treatment, levels were 
reduced to undetectable amounts, similar to levels seen in healthy MNCs. 
Phosphorylation of β-catenin at Ser45 and Thr41 indicates that the protein will be 
degraded. This could occur rapidly and hence may explain why only very low levels of 
the protein are detected.  
135 |  P a g e
 
Overall, the outcome from data shown in Figure 3.4.9 is that both unphosphorylated β-
catenin and phospho-β-catenin (Ser45/Thr41) protein levels cannot be used to 
differentiate between clinical outcomes in CML.  
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Figure 3.4.9 Protein levels of unphosphorylated β-catenin and phospho-β-catenin 
(Ser45/Thr41) do not correlate with patient outcome 
Protein levels of unphosphorylated β-catenin and phospho-β-catenin (Ser45/Thr41) 
were measured in MNC cells in optimal and failure patients at both diagnosis (N=7 for 
both) and after 12 months imatinib treatment (N= 6 and 5 respectively) and when 
patients had transformed into blast crisis (N=6). Additionally levels were tested in six 
MNC samples from healthy donors. Results showed that neither unphosphorylated β-
catenin, nor phospho-β-catenin (Ser45/Thr41) protein levels could be used to 
differentiate between clinical outcomes following imatinib treatment in CML.  
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Stratification of the data into chronic phase vs blast crisis showed an expected trend of 
what would happen to the levels of β-catenin protein as patients progress into blast 
crisis (see figure 3.4.10). Results showed an increase in unphosphorylated β-catenin in 
patients that have transformed into blast crisis (see figure 3.4.10 A), which fits with 
what has previously been seen and with the hypothesis that unphosphorylated β-
catenin acts to increase transcription in blast crisis [150]. In addition to this, there is a 
decrease in levels of phospho-β-catenin (Ser45/Thr41) at transformation into blast 
crisis (see figure 3.4.10 B), which is also to be expected as a decrease in phospho-β-
catenin (Ser45/Thr41) indicates a reduction in the levels of β-catenin being degraded 
by the proteasome. However, these results did not reach a statistical significance. 
 
Figure 3.4.10 Beta-catenin protein levels stratified as chronic phase vs blast crisis 
fits the trend associated with CML 
Re-stratification of the data into chronic phase (N=14) vs blast crisis (N=6) shows a 
trend towards an increase in unphosphorylated β-catenin (A) and a decrease in 
phospho-β-catenin (Ser45/Thr41) (B). 
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3.4.4.2 Imatinib reduces the level of unphosphorylated and phospho- β-catenin 
protein in vitro 
 
Imatinib was tested in vitro on LAMA-84 cells to determine its effect on 
unphosphorylated β-catenin and the two phospho- forms. Cells were incubated with 
5µM imatinib in vitro for 24 hours (Materials and Methods section 2.3.3) and levels 
were assessed by FACS analysis (N=3) (Materials and Methods section 2.7). Results 
demonstrated a reduction in levels of all β-catenin forms with imatinib treatment 
(Figure 3.4.11). These results appear to indicate that, instead of altering β-catenin 
function by either enhancing its activity or its degradation, imatinib acts by reducing all 
levels of β-catenin protein, possibly due to a reduction in the transcription of β-catenin 
(Figure 3.4.4). The reduction seen for each form was not significant, possibly due to the 
small N number (N=3), however the reduction was greater for unphosphorylated β-
catenin compared to the two phospho- forms (Ser45/Thr41 and Ser33/37/Thr41) 
(P=0.082, 0.218 and 0.164 respectively). 
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Figure 3.4.11 Imatinib reduces the levels of unphosphorylated and phospho β-
catenin in vitro in LAMA-84 cells  
LAMA-84 cells were incubated with 5µM imatinib in vitro for 24 hours and protein 
levels of β-catenin were measured by FACS analysis. Its effects on; A. unphosphorylated 
β-catenin, B. phospho-β-catenin (Ser45/Thr41), and C. phospho-β-catenin 
(Ser33/37/Thr41) were determined. Results show a reduction in all forms tested on 
imatinib treatment (N=3). 
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3.4.4.3 Subcellular localisation of the phospho- variants of β-catenin 
 
It has previously been reported that the status of certain phosphorylation residues 
determines the sub-cellular localisation of β-catenin [100]. When β-catenin is 
unphosphorylated it translocates to the nucleus where it can initiate transcription. 
Phosphorylation on Ser45, Thr41, Ser33, and Ser37 localise β-catenin to the cytoplasm 
when it can be targeted by the proteasome. To test this, nuclear and cytoplasmic 
extractions were performed using K562 and LAMA-84 cells (Materials and Methods 
section 2.9.2). These were then examined by western blotting (Materials and 
Methods section 2.9). 
 
Total β-catenin was tested at the same time as unphosphorylated β-catenin and 
phospho-β-catenin (Ser45/Thr41). Results showed that total -catenin was located 
mainly in the cytoplasm, with less in the nucleus (Figure 3.4.12). Unphosphorylated -
catenin was found mainly in the nucleus, confirming that the absence of β-catenin 
phosphorylation causes it to translocate to the nucleus. Phospho--catenin (45/41) was 
also detected mainly in the nucleus. This is in contrast to what was anticipated, as this 
phosphorylation is a marker for degradation, which occurs in the cytoplasm. Therefore 
it is unexpected for this form to be able to bypass this and translocate into the nucleus. 
However, evidence was published which supports this finding, whereby β-catenin 
phosphorylated on Ser45/Thr41 can localise to the nucleus, unlike β-catenin 
phosphorylated on Ser33/37/Thr41 [149]. This therefore means that phospho-β-
catenin (Ser45/Thr41) is not a good marker to use for β-catenin degraded by the 
proteasome.  
141 |  P a g e
 
Figure 3.4.12 Investigating the localisation of β-catenin by nuclear and 
cytoplasmic extraction 
K562 and LAMA-84 cells were separated into their nuclear and cytoplasmic 
compartments and examined by western blotting alongside a whole cell lysate (WCL) to 
assess the localisation of the β-catenin variants. Results showed total β-catenin to be 
localised mainly in the cytoplasm with a small amount in the nucleus. 
Unphosphorylated β-catenin was found primarily in the nucleus, as was phospho-β-
catenin (Ser45/Thr41).  
 
 
 
 
It was intended that this analysis of cellular localisation would be followed by looking at 
this in patient samples as confirmation of the FACS results; however, the technique 
makes heavy use of cell number (2x107 cells) which would have been a significant drain 
on the limited material available. Instead confocal microscopy was used (Figures 
3.4.13-15).   
 
 
142 |  P a g e
 
3.4.4.4 Analysis of β-catenin by confocal microscopy 
 
Levels were analysed (Materials and Methods section 2.10) in optimal responders 
and failure patients at diagnosis, patients at diagnosis who subsequently transformed 
into blast crisis, and patients who have transformed into blast crisis. Samples from 
patients after 12 months imatinib treatment were eliminated from analysis as they were 
not providing any additional information due to replacement of the diagnostic 
leukaemic cell population by normal cells. Additionally, total β-catenin was excluded 
from analysis and replaced by phospho-β-catenin (Ser33/37/Thr41) to give a more 
accurate representation of β-catenin being degraded by the proteasome.  
 
Results for unphosphorylated β-catenin (Figure 3.4.13) show low levels in the 
optimally responding patients, with a slight increase in the failures and those who have 
transformed into blast crisis. Interestingly, levels are elevated in diagnostic samples 
from patients who subsequently transform into blast crisis. This could suggest that an 
increase in unphosphorylated β-catenin could be predictive of blast crisis. 
Unfortunately this preliminary finding could not be confirmed due to the lack of 
availability of further cells from this cohort of patients.   
 
Figure 3.4.14 shows results for phospho-β-catenin (Ser45/Thr41). Levels were 
elevated in the patients who had transformed into blast crisis.  Additionally, there were 
also higher levels in the failure patients at diagnosis, while the optimal responders and 
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the patients at diagnosis who subsequently progress into blast crisis had lower levels of 
the protein.  
 
Finally, the study of phospho-β-catenin (Ser33/37/Thr41) (Figure 3.4.15) showed that 
although there were slight elevations in the protein detected in one of the optimal 
responders (#209) and one of the patients at diagnosis who subsequently progressed 
into blast crisis (#115), there was no overall correlation between phospho-β-catenin 
(Ser33/37/Thr41) levels and patient outcome (uncropped data shown in Appendix 
Figures 8.1-8.3). 
 
Key:  
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Figure 3.4.13 Protein levels of unphosphorylated β-catenin visualised by confocal 
microscopy 
Protein levels of unphosphorylated β-catenin were visualised in CML MNCs by confocal 
microscopy in two optimal responders (#130 and #209) and two failure patients (#296 
and #308) at diagnosis, alongside two blast crisis patients at diagnosis (#115 and #13), 
and two cases after transformation of chronic phase into blast crisis (#20 and #13). 
Results show elevated levels of active β-catenin in blast crisis patients at diagnosis, 
alongside one of the blast crisis patients after transformation into blast crisis from 
chronic phase.  
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Figure 3.4.14 Protein levels of phospho-β-catenin (Ser45/Thr41) visualised by 
confocal microscopy 
Protein levels of phospho-β-catenin (45/41) were visualised in CML MNCs by confocal 
microscopy, using the same samples as in Figure 3.4.11. 
Results show much higher levels in the patients who have progressed to blast crisis. 
Additionally levels are elevated in one of the optimally responding patients and both 
failure patients. 
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Figure 3.4.15 Protein levels of phospho-β-catenin (Ser33/37/Thr41) visualised 
by confocal microscopy 
Protein levels of phospho-β-catenin (33/37/41) were visualised in CML MNCs by 
confocal microscopy, using the same samples as in Figure 3.4.11 and 3.4.12. 
Results show higher levels in one of the optimal and one of the blast crisis patients at 
diagnosis and in the blast crisis patients in blast crisis. This random distribution shows 
there is no correlation between phospho-β-catenin (33/37/41) levels and patient 
outcome. 
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Next, the unphosphorylated β-catenin, representing the active form, and phospho-β-
catenin(Ser33/37/Thr41), representing the form targeted for degradation, were 
examined to see how they inter-relate within an individual patient. From this, a 
relationship can be seen between expression levels in individual patients (Figure 
3.4.16). It appears that when levels of phospho-β-catenin (Ser33/37/Thr41) are 
elevated, the levels of unphosphorylated β-catenin are low, indicating when 
phosphorylated β-catenin is being degraded and is unable to activate transcription. This 
could be said for patient #209 which was a diagnostic sample from an optimal 
responder, and patient #13 when the patient had transformed into blast crisis. 
Conversely, when unphosphorylated β-catenin levels were higher, this correlated with 
low levels of phospho-β-catenin (Ser33/37/Thr41). This was seen in the chronic phase 
diagnostic sample from patient #13 (who later progressed to blast crisis). This shows 
that the mechanism by which β-catenin activity is regulated is active in CML, however it 
may not be involved in the progression of the disease. 
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Figure 3.4.16 The relationship between the various forms of β-catenin in 
individual patients 
Unphosphorylated β-catenin and phospho-β-catenin (Ser33/37/Thr41) were examined 
within individual patients to see if there was a correlation between levels.  
Results show that when levels of phospho-β-catenin (Ser33/37/Thr41) are elevated, 
the levels of unphosphorylated β-catenin are low (seen in patients #209 optimal 
responder at diagnosis, and #13 blast crisis). Also when unphosphorylated β-catenin 
levels were higher, this correlated with low levels of phospho-β-catenin 
(Ser33/37/Thr41) (seen in the diagnostic sample from patient #13 who later developed 
into blast crisis). 
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3.4.5 Why are the levels of β-catenin not correlating with disease outcome in CML 
MNCs? 
 
As the results observed did not show a difference in the various forms of β-catenin 
between patient cohorts, it was hypothesised that β-catenin might be rapidly degraded 
by the proteasome. To investigate this, a proteasome inhibitor, bortezomib, was used to 
determine the effects on the levels of β-catenin when it is prevented from being 
degraded. 
 
 
3.4.5.1 Inhibition of the proteasome leads to increased levels of β-catenin 
 
The CML cell lines K562 and LAMA-84 were used to examine the effects of bortezomib 
on CML cells. The levels of β-catenin were measured by FACS analysis (Materials and 
Methods section 2.7) in untreated and 0.1μM, 1μM and 5μM bortezomib treated cells 
(data not shown) after 24 hours incubation (optimised in section 3.3.2.4) to 
determine the effects of proteasome inhibition on the levels of total β-catenin, 
unphosphorylated β-catenin, phospho-β-catenin (Ser45/Thr41), and phospho-β-catenin 
(Ser33/37/Thr41). Results showed that 5μM bortezomib displayed optimum results 
(Figure 3.4.17). In both cell lines tested, levels of total β-catenin increased with 
bortezomib incubation. This trend was also seen for both unphosphorylated β-catenin 
and phospho-β-catenin (Ser45/Thr41). The increase in unphosphorylated β-catenin 
was significant in LAMA 84 cells (P=0.050). Results for phospho-β-catenin 
(Ser33/37/Thr41) show a decrease in levels with bortezomib incubation, which again 
reached statistical significance in the LAMA 84 cells (P=0.043). These data suggest that 
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under normal conditions, when the proteasome is not being inhibited, β-catenin is being 
degraded by the cell. 
 
Figure 3.4.17 The effects of the proteasome inhibitor bortezomib on the cellular 
levels of the various forms of β-catenin 
The levels of β-catenin were measured by FACS in untreated (UNT) and 5μM 
bortezomib treated K562 (N=3) and LAMA-84 cells (N=3) after 24 hour incubation. 
Results show an increase total β-catenin, unphosphorylated β-catenin (P=0.050 in 
LAMA 84 cells), and phospho-β-catenin (Ser45/Thr41). Levels of phospho- β-catenin 
(Ser33/37/Thr41) decreased or bortezomib treatment (P=0.043 in LAMA 84 cells). 
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3.4.6 Does -catenin phosphorylation by BCR-ABL1 have any correlation with 
disease progression? 
 
Beta-catenin can also be phosphorylated by BCR-ABL1, amongst other kinases, on the 
residue Tyr654 [186]. This targets β-catenin to the nucleus where it can activate 
transcription. As BCR-ABL1 is considered a driving force in CML [17, 189], therefore it is 
of interest to see if BCR-ABL1 mediated β-catenin phosphorylation of Tyr654 is having 
an effect on β-catenin turnover in CML cells. 
 
3.4.6.1 Protein levels of phospho-β-catenin (Tyr654) demonstrate no correlation 
with predicting patient outcome but do significantly change with disease 
transformation 
 
Again, the results were analysed in accordance with patient outcome, with optimal 
response and failure patients being analysed at diagnosis and after 12 months imatinib 
treatment, and blast crisis patients being analysed when patients had transformed into 
blast crisis.  
 
Analysed by FACS analysis (Materials and Methods section 2.7), Figure 3.4.18 
indicates that there is no difference in Tyr654 between patient cohorts at diagnosis, 
consistent with the view that BCR-ABL1 activity is broadly similar across patients at 
initial diagnosis [190].Tyr654 levels decrease after 12 months of imatinib treatment; 
however this is to be expected as the BCR-ABL1 driven phosphorylation of β-catenin is 
removed as leukaemic cells are replaced with normal cells. Additionally, Figure 3.4.18 
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shows that when patients have transformed into blast crisis, there is no evidence of β-
catenin being phosphorylated directly by BCR-ABL1, which is in line with the view that 
CML can become BCR-ABL1 independent at disease transformation [191].  
 
Figure 3.4.18 Protein levels of phospho-β-catenin (Tyr654) do not correlate with 
patient outcome in imatinib treated patients 
Protein levels of patient MNC samples were measured in optimal responders, and 
failure patients at both diagnosis (N=7) and after 12 months imatinib treatment (N=6 
and 5 respectively), and in addition when patients were in blast crisis (N=6). Levels 
were also measured in 6 healthy donor MNC samples to compare with patients. Results 
showed no difference between patient cohorts at diagnosis and that levels decrease 
after 12 months of imatinib treatment. Levels found in patients transformed into blast 
crisis are lower than in healthy donors. . 
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When the data were re-stratified into chronic phase vs blast crisis, levels of phospho-β-
catenin (Tyr654) were significantly lower in patients transformed into blast crisis 
compared to chronic phase (p=0.012) (Figure 3.4.19).  Again, this is in line with the 
view that the disease can become BCR-ABL1 independent at disease transformation 
[191]. 
 
Figure 3.4.19 Phospho-β-catenin (Tyr654) protein levels are significantly lower in 
patients who have transformed into blast crisis compared to chronic phase 
Re-stratification of the data into chronic phase (N=14) vs blast crisis (N=6) shows a 
significant decrease (P=0.012) in the levels of phospho-β-catenin (Tyr654) when 
patients had transformed into blast crisis. 
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3.4.6.2 Imatinib significantly reduces the levels of phospho-β-catenin (Tyr654) in 
vitro in LAMA-84 cells 
 
As before, LAMA-84 cells were incubated with 5µM imatinib in vitro for 24 hours and 
the levels of phospho-β-catenin (Tyr654) were measured by FACS to determine its 
effect (Figure 3.4.20). Results showed a significant decrease in the levels of phospho-β-
catenin (Tyr654) on imatinib incubation (P=0.024). This confirms what would be 
expected due to the direct inhibition of BCR-ABL1 by imatinib. 
 
Figure 3.4.20 Imatinib significantly reduces the levels of phospho-β-catenin 
(Tyr654) 
LAMA-84 cells were incubated in vitro for 24 hours with 5μM imatinib. Results show a 
significant reduction in phospho-β-catenin (Tyr654) levels (P=0.024) (N=3). 
 
 
 
  
155 |  P a g e
 
3.4.6.3 Subcellular localisation of phospho-β-catenin (Tyr654) 
 
Phosphorylation of β-catenin on Tyr654 is reported to target β-catenin to the nucleus 
where it can activate transcription [186]. To test this, nuclear and cytoplasmic 
extractions were performed using K562 and LAMA-84 cells (Materials and Methods 
section 2.9.2). These were then examined by western blotting (Materials and 
Methods section 2.9). Results showed that there are slightly elevated levels of 
phospho--catenin (Tyr654) in the nucleus compared to the cytoplasm, re-confirming 
its role in targeting -catenin to the nucleus (Figure 3.4.21). 
 
Figure 3.4.21 Investigating the localisation of phospho-β-catenin (Tyr654) by 
nuclear and cytoplasmic extraction 
K562 and LAMA-84 cells were separated into their nuclear and cytoplasmic 
compartments using nuclear and cytoplasmic extraction. These compartments were 
then examined by western blotting to assess the localisation of the β-catenin variants. 
Results showed there are slightly higher levels of phospho-β-catenin (Tyr654) located 
in the nucleus. 
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As in section 3.4.4.3, this method could not be extended to clinical samples as it uses an 
excess of cells which would deplete our store considerably. Confocal microscopy, which 
is much more economical on cell numbers was employed. Levels were analysed in 
optimal responders and failure patients at diagnosis, patients at diagnosis who 
subsequently transformed into blast crisis, and patients who were in blast crisis.  
 
Results from confocal microscopy (see Figure 3.4.22) showed a similarity in levels of 
phospho-β-catenin (Tyr654) at diagnosis with a slight decrease in patients that have 
transformed into blast crisis. This concurs with the results from the FACS as they also 
suggest that BCR-ABL1 activity is broadly similar across patients at initial diagnosis. 
Additionally, with the reduction in phospho-β-catenin (Tyr654) in patients that have 
transformed into blast crisis, this fits with the view that CML can become BCR-ABL1 
independent at disease transformation [191] (uncropped data shown in Appendix 
Figures 8.4).  
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Figure 3.4.22 Protein levels of phospho-β-catenin (Tyr654) assessed by confocal 
microscopy 
Protein levels of phospho-β-catenin (Tyr654) were visualised in MNC cells by confocal 
microscopy in optimal responders (#130 and #209) and failure patients (#296 and 
#308) at diagnosis and blast crisis patients at diagnosis (#115 and #13), and when 
patients had transformed into blast crisis (#20 and #13). Results show a similarity in 
levels between optimal responders, failure and blast crisis patients at diagnosis, and 
then a slight decrease in patients transformed into blast crisis. 
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3.4.7 Do the levels of β-catenin found in MNCs correlate with levels in CD34+ 
cells? 
 
CD34+ cells, obtained by selection from leukapheresis at original diagnosis (see 
Methods section 2.2.3), were studied in optimal responders and failure patients. They 
were used as representative of the progenitor compartment to determine if there was a 
difference between a) MNC and CD34+ cells, and b) patient cohorts. CD34+ samples 
from patients at diagnosis who subsequently went into blast crisis were not available 
for analysis due to limitations on resources. This unfortunately limited the observations 
made in addressing this part of the study.  
 
It was observed that the levels were significantly higher in the CD34+ cells compared to 
the MNCs (Figure 3.4.23) for phospho-β-catenin (Tyr654) in the  optimal responders 
MNCs vs both the optimal responders and failure paitents CD34+ levels (P=0.044 and 
0.050 respectively. This corresponds to higher expression of BCR-ABL1 in the more 
primitive CD34+ compartment [17]. However for the other β-catenin forms there was 
no significant difference between the patient cohorts. This could not be fully assessed 
due to the lack of samples available from the blast crisis patients. For the optimal 
responders and failure patients a similar trend was seen in both MNCs and CD34+ cells, 
but this did not achieve statistical significance.  
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Figure 3.4.23 Comparison of β-catenin levels between MNCs and CD34+ cells 
Levels of the various forms of β-catenin were measured by FACS in matched MNCs and 
CD34+ cells from optimal responders and failure patients at diagnosis. 
Results demonstrate that there are higher levels of all forms of β-catenin in the CD34+ 
cells, however this trend does not reach statistical significance, except for phospho-β-
catenin (Tyr654) (P=0.044 in the optimal responders MNCs vs CD34+, and P=0.050 in 
the optimal responders MNCs vs failure patients CD34+). 
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3.4.8 Is the Wnt pathway regulating the levels of β-catenin in CML MNCs? 
 
3.4.8.1 The Wnt Pathway does not have the expected effects on β-catenin levels in 
CML cell lines 
 
The Wnt pathway functions to regulate the activity of β-catenin which then translates to 
transcriptional activity [105]. Following on from the above experiments, which 
indicated that degradation by the proteasome may be an explanation why no change 
was seen between β-catenin levels in patient samples, the overall contribution of the 
Wnt pathway on β-catenin activity was measured. Cells were incubated with a Wnt 
pathway activator (WNT3A) and a Wnt pathway inhibitor (WIF1) [192] to see if 
modification of the Wnt pathway had an effect on the levels of β-catenin. On activation 
of the pathway with WNT3A, an increase in levels of unphosphorylated β-catenin would 
be expected. Conversely, with inhibition of the pathway by WIF1, an increase in the 
levels of phospho-β-catenin (Ser33/37/Thr41) would be expected. 
 
LAMA-84 and HT-29 cells were incubated with 25ng WNT3A or 1.5μg WIF1 for 24 
hours in vitro (N=3) (Materials and Methods section 2.3.3). HT-29 cells were used as 
a control as they are known to have an active Wnt pathway [187, 188]. Levels were 
measured by FACS analysis (Materials and Methods section 2.7) and results show 
that in LAMA-84 cells both WNT3A and WIF1 do not have any effect on total β-catenin 
levels (Figure 3.4.24 A). There is an elevation in unphosphorylated β-catenin levels 
with WNT3A incubation but this is not a significant change (Figure 3.4.24 B). Figure 
3.4.24 C shows that both WNT3A and WIF1 increase levels of phospho-β-catenin 
(Ser45/Thr41) compared to untreated levels. Finally, levels for phospho-β-catenin 
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(Ser33/37/Thr41) show a decrease with WNT3A, but no change in levels with WIF1 
compared to untreated (Figure 3.4.24 D). This could be indicating that β-catenin is 
being maximally degraded within CML MNCs; however these experiments on cell lines 
need to be further verified in patient samples.  
 
Figure 3.4.24 The effects of WNT3A and WIF1 on the levels of β-catenin variants in 
LAMA-84 cells 
The levels of β-catenin were measured by FACS in untreated, 25ng WNT3A, and 1.5μg 
WIF1 treated LAMA-84 cells (N=3) after 24 hour incubation. Results show A. total β-
catenin, B. unphosphorylated β-catenin, C. phospho-β-catenin (Ser45/Thr41), and D. 
phospho-β-catenin (Ser33/37/Thr41) do not show the expected trend with either 
WNT3A or WIF1 treatment. 
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HT-29 cells were used as a control as they are known to have an active Wnt pathway 
[187, 188]. Results show that for total β-catenin, WNT3A does not change levels, while 
WIF1 causes an increase compared to untreated (Figure 3.4.25 A). There is an 
elevation in unphosphorylated β-catenin levels with WNT3A incubation which was 
expected as the Wnt pathway is activated in these cells (Figure 3.4.25 B).  Phospho-β-
catenin (Ser45/Thr41) levels decrease with both WNT3A and WIF1 incubation (Figure 
3.4.25 C). Finally, levels for phospho-β-catenin (Ser33/37/Thr41) (Figure 3.4.25 D) 
show a decrease with WNT3A as the pathway is activated and hence less β-catenin is 
degraded. In contrast, with WIF1 incubation there are significantly higher levels of 
phospho-β-catenin (Ser33/37/Thr41) than with WNT3A incubation (P=0.032), which 
correlates with inhibition of the pathway leading to increased degradation of β-catenin. 
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Figure 3.4.25 The effects of WNT3A and WIF1 on the levels of β-catenin variants in 
HT-29 cells 
The levels of β-catenin were measured by FACS in untreated, 25ng WNT3A, and 1.5μg 
WIF1 treated LAMA-84 cells (N=3) after 24 hour incubation. Results show A. total β-
catenin, B. unphosphorylated β-catenin, C. phospho-β-catenin (Ser45/Thr41), and D. 
phospho-β-catenin (Ser33/37/Thr41). WNT3A incubation increases levels of 
unphosphorylated β-catenin, while WIF1 incubation increases levels of phospho- β-
catenin (Ser33/37/Thr41). 
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3.5 Main conclusions 
 
Beta-catenin is a central component of the Wnt signalling pathway playing an essential 
role in mediating the activity of the pathway. Jamieson et al., [150] previously showed 
an increase in unphosphorylated β-catenin in GMPs of those patients in blast crisis. As a 
consequence, the aim of this chapter was to pursue the study of β-catenin and its role 
within CML cells as previously described in section 3.2.  
 
The main conclusions obtained from this chapter were the following;  
1) After initial detection of elevated levels of β-catenin in primary CML MNCs, 
investigation into mRNA expression and total protein levels determined that these 
levels cannot be used to distinguish between different patient response cohorts and 
do not differentiate between stages of disease progression. 
 
2) Analysis of 12 month samples showed a reduction in mRNA levels of β-catenin. 
However this reduction can be explained by the concept that after 12 months 
imatinib treatment leukaemic cells were replaced with normal cells. This was also 
seen in the second generation TKIs (dasatinib and nilotinib) with a significant 
reduction in β-catenin mRNA levels in the optimal responders after 12 months 
treatment (P=0.05 and 0.001 respectively). 
3) Analysis of unphosphorylated β-catenin and phospho-β-catenin (Ser45/Thr41) was 
carried out to determine whether the activity and degradation of β-catenin differs 
in relation to patient outcome. Results showed levels to be similar between patient 
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cohorts. Re-stratification of the data into chronic phase vs blast crisis showed the 
expected trend with higher levels of unphosphorylated β-catenin in patients that 
have transformed into blast crisis. Additionally, phospho-β-catenin (Ser45/Thr41) 
levels decrease when patients have transformed into blast crisis. However, these 
results did not reach statistical significance, which could be because more 
differentiated cells are less dependent on β-catenin signalling for their survival 
[185]. This would then explain why the results found for GMPs by Jamieson et 
al.,[150] are not reproducible in MNCs. 
 
4) Analysis of sub-cellular localisation confirmed that unphosphorylated β-catenin is 
found predominantly in the nucleus, however this was also found for phospho--
catenin (Ser45/Thr41), opposite to what was anticipated with it being a marker for 
degradation in the cytoplasm. Maher et al. [149] also found this to be the case 
whereby β-catenin phosphorylated on Ser45/Thr41 can localise in the nucleus, 
unlike β-catenin phosphorylated on Ser33/37/Thr41. This therefore means that 
phospho-β-catenin (Ser45/Thr41) is not a good marker to use for β-catenin 
degradation by the proteasome.  
 
5) Analysis by confocal microscopy alluded to a relationship between 
unphosphorylated β-catenin and the phospho-β-catenin forms in individual 
patients. This was shown by higher levels of unphosphorylated β-catenin 
correlating with low levels of phospho-β-catenin (both Ser45/Thr41 and 
Ser33/37/Thr41). Conversely, when the levels of phospho-β-catenin (again, both 
Ser45/Thr41 and Ser33/37/Thr41) were elevated, there were lower levels of 
unphosphorylated β-catenin. This indicates that regulation of β-catenin by its 
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phosphorylation status is still functioning in CML MNCs; however, the levels cannot 
be used to distinguish between patient cohorts. 
 
6) Inhibition of the proteasome in CML cell lines using bortezomib corresponded with 
an increase in unphosphorylated β-catenin and a decrease in phospho-β-catenin 
(Ser33/37/Thr41) indicating that in CML cells, β-catenin is actively degraded by the 
cell. This could be why no difference in the levels of β-catenin is being detected 
between patient cohorts. To test this further, patient samples could be cultured in 
vitro with bortezomib to determine if the results seen in cell lines are replicated in 
patients.  
 
7) Analysis of phospho-β-catenin (Tyr654) showed no difference between patient 
cohorts at diagnosis, consistent with the view that BCR-ABL1 activity is broadly 
similar across patients at initial diagnosis [190]. There are significantly lower levels 
of phospho-β-catenin (Tyr654) in blast crisis CML MNCs compared to chronic phase 
(p=0.012) which correlates with the premise that CML can become BCR-ABL1 
independent at disease transformation [191].  
 
8) CD34+ cells were used to represent the progenitor cell population and alongside 
MNCs, protein levels were assessed to answer the question of whether the high 
levels of -catenin found in the more primitive cells correlate with levels in MNCs. 
Limitations to patient material meant that this part of the study could not be fully 
addressed. However, it was observed that the levels were higher in the CD34+ cells 
compared to the MNCs, significantly so for phospho-β-catenin (Tyr654) which had 
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higher levels in the optimal responders CD34+ cells (P=0.044). This corresponds to 
higher expression of BCR-ABL1 in the more primitive CD34+ compartment [17]. 
 
9) LAMA-84 cells cultured with WIF1 (Wnt pathway inhibitor) and WNT3A (Wnt 
pathway activator do not show the expected trend on β-catenin levels, suggesting 
that the Wnt pathway/β-catenin is not actively enhanced in CML MNCs.  
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Chapter 4 – Does glycogen synthase 
kinase 3β (GSK3β) have a role in CML? 
 
4.1 Introduction   
 
Glycogen synthase kinase 3β (GSK3β) is a constitutively active serine/threonine kinase 
which, within the Wnt signalling pathway, acts as a tumour suppressor by functioning 
as a key component in the degradation of β-catenin [105].  The activity of this kinase is 
itself controlled by its phosphorylation status with phosphorylation on Ser9 inhibiting 
its activity by forming a pseudosubstrate which blocks the active site of GSK3β [152]. 
Alternatively, phosphorylation at Tyr216 enhances the activity of GSK3β by altering its 
conformation, enabling substrate access to its active site (Introduction section 1.9) 
[152, 155, 156]. GSK3β substrates must be phosphorylated by another, different, kinase 
to ‘prime’ the substrate prior to phosphorylation by GSK3β [149].  
 
The phosphorylation status of GSK3β is regulated by various kinases which are able to 
phosphorylate GSK3β at Ser9 to inhibit its activity. These include; Akt, ILK, PKA and 
p90Rsk [153, 155].The method of phosphorylation on Tyr216 is ambiguous with 
kinases including PYK-2, FYN, MEK1/2 and SRC-family kinases all being reported to be 
able to phosphorylate this residue [155, 164]. However, there is also a possibility of 
autophosphorylation being responsible for phosphorylation of GSK3β at this site [155, 
157, 164].  
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Abrahamsson et al., [101] have reported in CML that there is a decrease in GSK3β 
protein expression at disease progression as determined by FACS analysis. In these 
samples splice variants were discovered with mutations giving rise to splice isoforms in 
which exon 9, exon 11, or both are deleted. Exon 9 and 11 deletions have been 
previously discovered in Parkinson’s disease [163], however the particular truncated 
isoforms of exon 8 and 9 which have been found in CML progenitors have not 
previously been reported. Due to overexpression of the full-length GSK3β causing a 
decrease in activated β-catenin, it can be said that GSK3β mis-splicing is a significant 
event in the development of LSCs and that restoration of the splicing events may have a 
possible therapeutic benefit [101]. The mechanisms which occur to induce this mis-
splicing have yet to be determined. Changes in splicing events can either inactivate 
tumour suppressors or activate proteins which promote tumour development. In CML, 
assessment of the splice isoforms in GSK3β might be useful as an indicator of disease 
progression, and might also form a therapeutic target for treatment of patients in 
advanced phase CML [101]. 
 
In addition to mis-splicing of GSK3β having an impact on disease progression, GSK3β is 
also of interest as it has been shown to be crucial in the modulation of HSCs by 
controlling the decision between self-renewal and differentiation through both the Wnt 
and mTOR pathways, with Wnt stimulating self-renewal, and mTOR enhancing lineage 
commitment [193]. Furthermore, GSK3β has been reported to be involved in the 
maintenance and function of a quiescent HSC pool, independent of signalling pathways 
[164, 194].  
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SB216763, developed by GlaxoSmithKline (GSK), is an ATP-competitive inhibitor of 
GSK3β [195] which has been shown to reduce levels of Tyr216 phosphorylation of 
GSK3β in CML progenitor cells [164]. Additionally, it diminishes the levels of 
phosphorylated β-catenin targeted for degradation, while increasing the 
unphosphorylated levels[164]. The results obtained from this GSK3β inhibitor in vitro 
have encouraged the development of a GSK3β inhibitor to be used in vivo [164, 193, 
194]. In addition to SB216763, another GSK3β inhibitor,  CHIR-911, has been tested to 
determine its effects on HSC activity in vivo in mice transplanted with either mouse or 
human HSCs. Results found that the inhibitor increased haematopoietic repopulation by 
amplifying the yield of the progenitor population, as well as prolonging the survival of 
transplanted mice, indicating the value of GSK3β inhibition on the repopulation ability 
of HSCs [194].  
 
As no difference was found in the levels of β-catenin forms between patient cohorts in 
the previous chapter, it was of interest to see if GSK3β was performing a role within 
CML. It would be expected that changes in GSK3β would be reflected in the levels of β-
catenin. However, as GSK3β has been reported to function independently of the Wnt 
pathway [164], it may also have an effect on CML disease progression independent of β-
catenin. Additionally, although it has been reported that there is a decrease in GSK3β 
protein expression, its phosphorylated forms and their impact on disease progression 
have not been previously investigated.  
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4.2 Aims 
 
The aims of this chapter are; 
 
1) To determine the effects of GSK3β inhibition by SB216763 on β-catenin levels, 
considering that there was no difference in the various forms of β-catenin 
between patient outcomes in the previous chapter. 
 
2) To investigate whether the mRNA transcript levels of GSK3β can be predictive of 
clinical outcome in imatinib treated patients. 
 
3) To look at phospho-GSK3β Tyr216 and phospho-GSK3β Ser9, to determine if 
GSK3β’s activity differs in relation to patient outcome. 
 
4) To investigate what regulates GSK3β’s activity in CML. 
 
5) To determine whether GSK3β activity correlates with C-MYC degradation. 
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4.3 Optimisation of techniques 
 
All optimisation was performed on experimentation in cell lines prior to patient sample 
use.  
 
4.3.1 Optimisation of the GSK3β antibodies by western blotting 
 
Lysates were prepared from CML cell lines K562 and LAMA-84 and western blots were 
carried out (Materials and Methods section 2.9). Initial antibody concentrations 
tested were taken from the supplied data sheet with final concentrations of phospho-
GSK3β (Ser9) being 0.3μg/ml, phospho-GSK3β (Tyr216) being 1μg/ml and total GSK3β 
being 0.25μg/ml. A representative blot is shown in Figure 4.3.1. 
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Figure 4.3.1 Optimisation of the GSK3β antibodies 
Antibodies were optimised for detection of GSK3β with a final concentration of 
phospho-GSK3β (Ser9) being 0.3μg/ml, phospho-GSK3β (Tyr216) being 1μg/ml and 
total GSK3β being 0.25μg/ml. The molecular weight for phospho-GSK3β (Ser9) and total 
GSK3β is 46kDa, and the molecular weight of phospho-GSK3β (Tyr216) is 47kDa. Both 
phospho-GSK3β (Ser9) and phospho-GSK3β (Tyr216) show a double band due to the 
additional detection of GSK3α. Actin was used as a loading control.  
 
 
4.3.2 Optimisation of the GSK3β inhibitor SB216763 in K562 cells 
 
The optimum concentration of the GSK3β inhibitor SB216763 was verified prior to 
experimentation. K562 cells were incubated with different concentrations of the 
inhibitor (2.5μM, 5μM, and 7.5μM) in vitro for 24 hours (Materials and Methods 
section 2.3.3). Lysates were then prepared from the cultures and a western blot was 
carried out (Materials and Methods section 2.9). The levels of phospho-GSK3β (Ser9), 
phospho-GSK3β (Tyr216), and total GSK3β were measured and results showed that 
5μM SB216763 gave the optimum increase in phospho-GSK3β (Ser9) and decrease in 
phospho-GSK3β (Tyr216) (Figure 4.3.2). This concentration was used for all further 
experimentation. 
MW 46 kDa 
MW 47 kDa 
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Figure 4.3.2 Optimisation of SB216763 
K562 cells were incubated in vitro with SB216763 for 24 hours to determine which 
concentration is optimal. Results show that 5μM SB216763 showed optimal trade-off 
between increased levels of Ser9 phosphorylation and decreased levels of Tyr216 
phosphorylation. 
 
 
 
 
 
In addition to determining the optimum concentration of SB216763, K562 and LAMA-
84 cells were incubated with 5μM SB216763 for 24 and 48 hours to ascertain whether 
incubation with the drug affects cellular proliferation and the viability of the cells. 
Cellular proliferation was measured by MTT assay (N=3) (Materials and Methods 
section 2.8) and the viability of the cells were tested by PI and FACS analysis (N=3) 
(Materials and Methods section 2.7.2). Results showed (Figure 4.3.3) SB216763 has 
no effect on proliferation at 24 hours and increases it after 48 hours of culture. In 
addition it has no effect on cell viability at both 24 and 48 hours. It was decided that 24 
hour incubation should be used for all further experimentation. 
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Figure 4.3.3 SB216763 has no effect on proliferation at 24 hours and increases it 
after 48 hours of culture. In addition it has no effect on cell viability at both 24 
and 48 hours 
Cells were incubated with SB216763 for 24 and 48 hours to test its effect on cell 
proliferation and viability. Results show SB216763 has no effect on proliferation at 24 
hours but increases it after 48 hours of culture. It has no effect on cell viability at both 
24 and 48 hours. 
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4.4 Results 
 
4.4.1 Is GSK3β having an effect on the levels of β-catenin? 
 
As a result of there being no significant difference found in the levels of β-catenin forms 
in correlation with patient outcome, it was relevant to determine the effects, if any, that 
GSK3β has on β-catenin levels. This was examined using the GSK3β inhibitor SB216763 
to see if there were any changes in β-catenin forms when GSK3β activity was inhibited.  
 
The levels of total β-catenin, unphosphorylated β-catenin, and phospho- β-catenin 
(Ser33/37/41) were measured to determine the effect inhibition of GSK3β has on the 
levels of β-catenin (N=3) (Figure 4.4.2). Results showed that in both K562 and LAMA-
84 cell lines there was a trend towards a decrease in total β-catenin levels on incubation 
with SB216763. Focussing on unphosphorylated β-catenin and phospho-β-catenin 
(Ser33/37/Thr41), results confirmed that inhibition of GSK3β has the predicted 
outcome on β-catenin levels, with unphosphorylated β-catenin increasing with 
inhibition of GSK3β, and phospho-β-catenin (Ser33/37/Thr41) decreasing. This shows 
that inhibition of GSK3β decreases the amount of β-catenin degraded, elevating 
unphosphorylated protein levels which can translocate to the nucleus and activate 
transcription. The differences in these levels are not significant, which could either be 
due to the small number of replicates, or may be indicative of why there was not a 
significant difference found in the levels of β-catenin in the previous chapter. 
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Figure 4.4.1 Inhibition of GSK3β increases the levels of unphosphorylated β-
catenin and decreases the levels of phospho-β-catenin (Ser33/37/41) 
K526 and LAMA-84 cells were incubated in vitro for 24 hours with 5μM SB216763 and 
FACS analysis was used to determine the effects this inhibitor has on β-catenin levels 
(N=3). Results show a trend towards a decrease in total β-catenin levels, an increase in 
unphosphorylated β-catenin levels, and a decrease in phospho-β-catenin 
(Ser33/37/Thr41) levels in both cell lines. 
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4.4.2 Comparison of GSK3β levels in the different CML patient cohorts 
 
To analyse the difference in GSK3β between the various clinical groups, patient samples 
were again split into three patient outcome cohorts in line with the ELN definitions (as 
described in section 1.4.2); optimal responders, failure patients and blast crisis 
patients, exactly as was performed in the previous chapter. For mRNA levels, patient 
material was available to look at both optimal responders and failure patients at 
diagnosis, and patients who subsequently transformed into blast crisis at diagnosis, and 
patients when they had transformed into blast crisis. For protein levels, patient material 
was available for both optimal responders and failure patients at diagnosis. However, 
for patients who subsequently transform into blast crisis, material was only available 
from when they had transformed into the final stage of the disease and not at diagnosis.  
 
 
4.4.2.1 GSK3β mRNA transcript levels are elevated in patients with poor prognosis 
 
Similarly to the previous chapter, GSK3β mRNA transcript levels were first investigated 
to see if there was a difference between patient cohorts. As with previous findings, the 
decrease in levels shown in 12 month samples is likely due to the leukaemic cells being 
replaced with normal cells.  These 12 month data were therefore eliminated from the 
study.  
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Two different primer sequences were used to examine the GSK3β transcript levels 
(Materials and Methods, Table 2.3). Firstly, a primer sequence was used which 
detects both the long (normal) and short (spliced variant lacking exon 8 and 9) form of 
GSK3β by using primers within exons 1-2 found in both variants. Secondly, a primer 
sequence was used which detects only the long (normal) form of GSK3β by using 
primers within exons 8-9, which are deleted in the splice variant.  
 
Results showed an increase in levels of GSK3β (long and short) transcript in diagnostic 
samples from patients who subsequently transformed into blast crisis (N=11), and in 
patients already in blast crisis (N=11), compared to optimal responders (N=14) and 
failure patients (N=12) at diagnosis. However, these observations were not statistically 
significant (Figure 4.4.3).  
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Figure 4.4.3 mRNA transcript levels of all splice variants of GSK3β (long and 
short) show increasing levels of expression with worsened outcome 
mRNA expression levels of the long and short transcript types of GSK3β were 
investigated in optimal, failure and blast crisis patients at both diagnosis (N=14, 12 and 
11 respectively), and when patients were in blast crisis (N=11). Levels were also 
measured in 3 samples from healthy donors to compare with patients. Results showed 
an increase in levels of GSK3β mRNA in diagnostic samples from patients who 
subsequently transformed into blast crisis, and patients who are in blast crisis in 
comparison to optimal responders and failure patients at diagnosis. This observation 
was not statistically significant. 
 
 
 
 
 
When looking at the long (normal) transcript type of GSK3β independently (Figure 
4.4.4) levels were again higher in both the patients at diagnosis who subsequently 
transformed into blast crisis, and the patients already in blast crisis, compared to 
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optimal responders and failure patients. Again these observations were not statistically 
significant..  
 
Figure 4.4.4 mRNA transcript levels of long form GSK3β show significantly higher 
levels of expression with worsened outcome 
mRNA expression levels of the long transcript type of GSK3β were investigated in the 
same cohort of patients as in Figure 4.4.3 Results showed levels of long form GSK3β 
were again higher in patients at diagnosis who subsequently transformed into blast 
crisis  and patients in blast crisis compared to optimal responders at diagnosis and 
failure patients. These observations were not statistically significant.  
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Splice variant analysis was performed by a Dr L Wang to look at the following transcript 
types of GSK3β; GSK3β with no deletion, GSK3β with exon 9 deletion, and GSK3β with 
exon 8 and 9 deletion, with regards to differences in splice variation between patient 
cohorts, however the results showed that the splice variants were found in all patient 
cohorts as well as healthy donors and the line of investigation was discarded.  
 
Due to the role of GSK3β as a tumour suppressor, this may explain why its transcription 
is upregulated in blast crisis, in an attempt to balance the oncogenic potential of blast 
crisis cells. However, the activity of GSK3β is regulated through its phosphorylation 
status so this was investigated next to determine if there is a difference in GSK3β 
activity between patient outcomes. 
 
 
4.4.2.2 GSK3β protein levels reveal that there are significantly decreased levels of 
GSK3β activity in patients who have transformed into blast crisis 
 
The two phosphorylated forms of GSK3β which were of interest by their regulation on 
GSK3β activity were phospho- GSK3β Ser9 which inhibits GSK3β, and phospho-GSK3β 
Tyr216 which enhances GSK3β’s activity. In addition, total GSK3β and levels of actin 
were used as controls. 
 
Western blotting (Materials and Methods section 2.9) was used to analyse 31 CML 
samples. Optimal responders (N=13) and failure patients (N=10) were analysed at 
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diagnosis, and blast crisis samples were analysed when patients had transformed into 
blast crisis (N=8). Unfortunately, as before, samples from patients at diagnosis who 
subsequently transformed into blast crisis were not available for analysis. Due to the 
lack of samples available from this group it is not possible to determine if GSK3β could 
be a predictive biomarker. Analysis was carried out according to chronic phase vs blast 
crisis where chronic phase included optimal responders and failure patients at 
diagnosis (N=23), and blast crisis were the patients who had transformed (N=8). Levels 
were measured using antibodies against phospho-GSK3β Ser9 and phospho-GSK3β 
Tyr216. These were then calibrated to actin and total GSK3β. Densitometry was used to 
obtain quantitative data on the results so statistical analysis could be done using a 
Mann-Whitney u test to determine whether the difference is statistically significant. A 
common lysate of K562 cells was used to ensure consistency between different blots. 
 
Results show (Figure 4.4.6) that there was a significant decrease in GSK3β activity 
demonstrated by opposing trends in Ser9 and Tyr216 phosphorylation. The results for 
phospho- GSK3β Ser9 (Figure 4.4.6 A), showed elevated levels in those patients who 
had transformed into blast crisis compared to those in chronic phase (P=0.026). This 
reveals higher levels of GSK3β inhibition in those patients who have transformed into 
blast crisis. This finding was further substantiated by the results for phospho- GSK3β 
Tyr216 (Figure 4.4.6 B) which showed that there is significantly higher levels in the 
chronic phase patients compared to the patients who have transformed into blast crisis 
(P<0.001). The inhibition of GSK3β alongside a reduction in Tyr216 phosphorylation 
suggests a significant decrease in GSK3β activity in those patients who have 
transformed into blast crisis.  
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Figure 4.4.6 Protein levels of GSK3β indicate a significant decrease in GSK3β 
activity demonstrated by opposing trends in Ser9 and Tyr216 phosphorylation of 
GSK3β 
Analysis was carried out according to chronic phase (N=23) vs blast crisis (N=8). Levels 
were measured via western blotting using antibodies against phospho-GSK3β Ser9 and 
phospho-GSK3β Tyr216. The results for phospho- GSK3β Ser9 showed increased levels 
in patients who had transformed into blast crisis compared to chronic phase 
(P=0.026).The results for phospho-GSK3β Tyr216 showed significantly higher levels in 
the chronic phase patients compared to patients in blast crisis (P<0.001). A 
representative blot is shown in C. 
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4.4.2.3 Confirming data using MCL-1 as a read out of GSK3β activity 
 
MCL-1 is a member of the BCL-2 family [158]. There are two isoforms of MCL-1; the 
longer isoform acts by inhibiting apoptosis and increasing cell survival (anti-apoptotic), 
while the shorter isoform promotes apoptosis, inhibiting cell survival (pro-apoptotic) 
[159]. 
Along with apoptosis, data suggest that MCL-1 promotes the Wnt pathway by disrupting 
the association of β-catenin with the destruction complex in the cytoplasm. This is as a 
result of MCL-1 acting as a substrate for GSK3β, preventing GSK3β from 
phosphorylating and targeting β-catenin for degradation [160].  
 
GSK3β is known to phosphorylate MCL-1 on serine 159 and initiate its degradation by 
the proteasome [196]. Therefore, MCL-1 was used as a read-out of GSK3β activity. As it 
was previously found that GSK3β activity significantly decreased in patients who had 
transformed into blast crisis, the levels of MCL-1 were measured by western blotting 
(Materials and Methods section 2.9) statistical analysis using a Mann-Whitney u test 
was carried out to see if the protein levels correlated with the results obtained for 
GSK3β. The two isoforms were detected by the antibody used; MCL-1 (MW 40kDa) 
represents the anti-apoptotic form, while MCL-1 (MW 32kDa) represents the pro-
apoptotic form. Results showed that the levels of both isoforms of MCL-1 significantly 
increased in the patients who had transformed into blast crisis compared with chronic 
phase patients (P<0.001 for both isoforms of MCL-1) (Figure 4.4.7). This supports the 
finding of decreased GSK3β activity in patients who have transformed into blast crisis as 
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it correlates with an increase in MCL-1 levels which may be due to a decrease in 
phosphorylation, and thus degradation.  
 
Figure 4.4.7 MCL-1 protein levels are significantly higher in patients who have 
transformed into blast crisis 
Chronic phase (N=23) samples were compared to blast crisis (N=8) and levels of MCL-1 
were measured via western blotting and calibrated to actin. Results showed that the 
levels of both isoforms of MCL-1 significantly increased in the patients who had 
transformed into blast crisis compared chronic phase (P<0.001 for both isoforms of 
MCL-1). A representative blot is shown in C. 
 
 
C. 
 
 
 
  
Actin
Chronic phase
K
5
6
2
MCL-1 MW 40 kDa
MW 32 kDa
Blast Crisis
K
5
6
2
187 |  P a g e
 
4.4.3 What regulates GSK3β activity? 
 
Following the finding of a significant decrease in GSK3β activity in samples from 
patients who had transformed into blast crisis, the next question to ask is; what is 
regulating this activity? 
 
4.4.3.1 The TKIs have no effect on GSK3β activity 
 
Initially, the effect of the TKIs was investigated to determine if GSK3β activity was 
under the control of BCR-ABL1. K562 and LAMA-84 cells were treated with 5μM 
imatinib, 150nM dasatinib, and 5μM nilotinib for 24 hours in vitro (Materials and 
Methods section 2.3.3), lysates were made and the levels of GSK3β were measured by 
western blot (Materials and Methods section 2.9). These were compared to an 
untreated control to determine the effects of the TKIs on GSK3β (N=4). A representative 
blot is shown in Figure 4.4.8. Densitometry was used to obtain quantitative data on the 
results so statistical analysis could be done using a T-test to determine whether the 
difference is statistically significant. Results showed that for K562 cells, all three TKIs 
had no effect on the levels of phospho-GSK3β Ser9. This was also true for the LAMA-84 
cells. Additionally, for both K562 and LAMA-84 cells there was a decrease in levels of 
phospho-GSK3β Tyr216 in the treated cells, especially with dasatinib and nilotinib 
treatment but these differences did not reach statistical significance.  
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Figure 4.4.8 TKIs have no effect on GSK3β levels 
K562 and LAMA-84 cells were incubated with 5μM imatinib (IM), 150nM dasatinib 
(DAS), and 5μM nilotinib (NIL) for 24 hours in vitro and compared to an untreated 
control (UNT) (N=4). Results showed in K562 cells, all three TKIs had no effect on the 
levels of phospho-GSK3β Ser9 (MW 46kDa), which was also found for the LAMA-84 
cells. In both cell lines the treated cells showed a decrease in levels of phospho-GSK3β 
Tyr216 (MW 47kDa), in particular DAS and NIL but these differences were not 
statistically significant.  
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4.4.3.2 WNT3A acts to inhibit GSK3β by reducing Tyr216 phosphorylation, while 
WIF-1 has no effect on GSK3β levels 
 
The significant decrease in GSK3β activity in patients who had transformed into blast 
crisis did not appear to be controlled by BCR-ABL1. Therefore it was of interest to see if 
the Wnt pathway was responsible for regulating the activity of GSK3β. To examine this, 
K562 and LAMA-84 cells were incubated with both WIF-1 which acts as a Wnt pathway 
inhibitor [192], and WNT-3A which functions as a Wnt pathway activator. Cells were 
incubated for 24 hours in vitro (Materials and Methods section 2.3.3), lysates were 
made and the levels of GSK3β were measured by western blot compared to an 
untreated sample (Materials and Methods section 2.9).  
 
With inhibition of the pathway by WIF-1 it would be anticipated that there would be an 
increase in GSK3β activity shown by a decrease in Ser9 phosphorylation, and an 
increase in Tyr216 phosphorylation. Results show no change in GSK3β levels with WIF-
1 treatment in a single experiment (Figure 4.4.9). 
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Figure 4.4.9 The in vitro effects of WIF-1 on CML cell lines K562 and LAMA-84  
K562 and LAMA-84 cells were incubated with various concentrations of WIF-1 for 
24hours in vitro and the levels of GSK3β were measured by western blot. Results show 
no change in GSK3β levels with increasing concentrations of WIF-1  (N=1). 
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With activation of the pathway using WNT3A, it would be expected for GSK3β activity to 
decrease, shown by an increase in Ser9 phosphorylation, and reduction in Tyr216 
phosphorylation. Results show no change in the levels of phospho GSK3β Ser9, however 
there is  a dose dependent decrease in levels of phospho-GSK3β Tyr216 with increased 
concentrations of Wnt3A in both K562 and LAMA-84 cells (Figure 4.4.10).  
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Figure 4.4.10 The in vitro effects of WNT-3A on CML cell lines K562 and LAMA-84 
K562 and LAMA-84 cells were incubated with various concentrations of WNT-3A for 
24hours in vitro and the levels of GSK3β were measured by western blot. Results show 
decreased levels of phospho-GSK3β Tyr216 (both K562 and LAMA-84 cells) with 
increased concentrations of Wnt3A (N=1). 
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The combination of both WIF-1 having limited effect on GSK3β levels, alongside Wnt3A 
reducing activation suggests that the Wnt pathway may be maximally inhibited in these 
cells. This is a possible reason as to why there was no difference in the β-catenin levels 
between patient cohorts. 
 
 
4.4.3.3 PP2A acts to regulate GSK3β activity 
 
PP2A as a serine/threonine phosphatase is known to de-phosphorylate GSK3β on serine 
9 [197] and therefore could be involved in the regulation of GSK3β by removing the 
inhibitory phosphorylation. Compounds have been developed which regulate the 
activity of PP2A including FTY720 which is known to activate PP2A, and okadaic acid 
which inhibits it. Consequently, K562 cells were incubated in vitro for 24 hours with 
2.5μM FTY720 (FTY) and 6nM okadaic acid (OA) (previously optimised by Dr Lucas) 
(Materials and Methods section 2.3.3) and western blotting was used to see their 
effects on GSK3β levels and to determine whether PP2A is playing a role in regulating 
the activity of GSK3β (N=3) (Materials and Methods section 2.9). Figure 4.4.11 
shows a representative blot and densitometry was used to obtain quantitative data for 
statistical analysis by a T-test to verify whether the difference is statistically significant. 
 
Results show (Figure 4.4.11) that on incubation with FTY720 the levels of phospho-
GSK3β Ser9 reduce compared to untreated (P=0.074). In contrast, incubation with OA 
increases the levels of Ser9 phosphorylation (P=0.053). This supports the view that 
PP2A is acting as a regulator of GSK3β activity in CML cells, as activation of PP2A via 
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FTY720 increases dephosphorylation of serine 9, while inhibition of PP2A by okadaic 
acid prevents GSK3β from being dephosphorylated by PP2A, resulting in the increased 
levels of serine 9 phosphorylation shown. Statistical analysis revealed that the 
difference did not reach statistical significance, which may be due to the small number 
of replicates, however a definite trend can be seen which correlates with the action of 
PP2A on GSK3β. Both compounds reduce tyrosine 216 phosphorylation, but not to a 
significant level. 
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Figure 4.4.11 GSK3β is activated on incubation with FTY720, and inhibited on 
incubation with okadaic acid suggesting GSK3β’s activity could be controlled by 
PP2A 
K562 cells were incubated in vitro for 24 hours with 2.5μM FTY720 (FTY) and 6nM 
okadaic acid (OA). Results show that on incubation with FTY, the levels of phospho-
GSK3β (Ser9) reduce compared to untreated. In contrast, incubation with OA increases 
the levels of Ser9 phosphorylation. Both drugs appear to reduce Tyr216 
phosphorylation but not significantly. 
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4.4.4 Is the decrease in GSK3β activity responsible for increased C-MYC levels in 
blast crisis? 
 
GSK3β is not only involved in the degradation of β-catenin and MCL-1; phosphorylation 
by GSK3β is also involved in regulating the degradation of several other substrates 
[152]. One of these substrates which is of importance in malignancies is C-MYC. It has 
been shown in CML that C-MYC is involved in disease progression by the development 
of C-MYC knockout mice. While control mice developed blast crisis within five weeks, 
the mice with the C-MYC knockout did not develop the characteristics of CML [198]. The 
mechanism by which C-MYC degradation occurs can be seen in Figure 4.4.12. Initially, 
C-MYC is phosphorylated by ERK on Ser62 which primes C-MYC for phosphorylation on 
Thr58 by GSK3β. PP2A next has to dephosphorylate C-MYC on Ser62 to allow for the 
addition of a ubiquitin tail and degradation by the proteasome to occur [162]. 
Considering the decrease in GSK3β activity shown to occur in the patient samples in 
blast crisis, it was hypothesised that this would lead to a decrease in phosphorylation of 
C-MYC on Thr58 which in turn would reduce the degradation of C-MYC in blast crisis.  
 
  
197 |  P a g e
 
Figure 4.4.12 Mechanism of C-MYC degradation 
 
 
[162] 
 
 
As previously shown there is a significant decrease in GSK3β activity in blast crisis 
compared to chronic phase represented by a significant decrease in Tyr216 
phosphorylation (Figure 4.4.13 A) and a significant increase in Ser9 phosphorylation 
(Figure 4.4.13 B).  The levels of total C-MYC were measured by FACS analysis 
(Materials and Methods section 2.7) and results showed significantly higher levels of 
total C-MYC in blast crisis patients compared to chronic phase (P=0.024) (Figure 4.4.13 
C), suggesting there is a defect in the degradation of C-MYC in blast crisis. The levels of 
phospho C-MYC (Thr58) were next measured to determine if the decrease in GSK3β 
activity correlated with a decrease in C-MYC phosphorylation and hence a decrease in 
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degradation. Results showed (Figure 4.4.13 D) there was no difference in the levels of 
Thr58 phosphorylation of C-MYC in chronic phase patients compared to blast crisis, 
indicating that the phosphorylation of C-MYC by GSK3β is not controlling the 
degradation of C-MYC. 
 
 PP2A is also crucial in the degradation of C-MYC as without removal of the serine 62 
phosphorylation C-MYC cannot be ubiquitinated and hence degraded. Consequently, 
PP2A levels were measured and results showed that there were significantly higher 
levels of PP2A in the blast crisis patients compared to chronic phase (see Figure 4.4.13 
E). This is opposite to what would be expected as higher levels of PP2A would correlate 
with increased removal of the Ser62 phosphorylation, allowing C-MYC to be degraded. 
To determine if PP2A is active and able to dephosphorylate C-MYC, or inactive and 
unable to dephosphorylate C-MYC, inactive PP2A was investigated by measuring the 
levels of phospho-PP2A (Tyr307). Results showed a non-significant elevation in the 
levels of phospho-PP2A (Tyr307) in the blast crisis cohort compared to chronic phase 
(see Figure 4.4.13 F). This suggests the significantly higher levels of PP2A found in the 
blast crisis patients is active and able to dephosphorylate C-MYC at Ser62. These data 
demonstrate that PP2A, along with GSK3β is not controlling the degradation of C-MYC. 
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Figure 4.4.13 Neither GSK3β or PP2A are the controlling factors of C-MYC 
degradation.  
Results previously showed there is a significant decrease in GSK3β activity in blast crisis 
through Tyr216 P<0.001(A) and Ser9 P=0.026 (B) phosphorylation. Additionally there 
is a significant increase in total c-Myc levels in blast crisis P=0.024 (C) however there is 
no difference between Thr58 phosphorylation of c-Myc (D). Results for PP2A levels 
show there are significantly higher levels of total PP2A in blast crisis P=0.013 (E), with 
increased levels of inactive PP2A (Tyr307) however this difference is not significant (F). 
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4.5 Main conclusions 
 
GSK3β is an important regulator of multiple cellular functions[199]. It is fundamental in 
the regulation of the Wnt signalling pathway, and has more recently become of interest 
independently of signalling pathways as a component involved in the maintenance and 
function of a quiescent HSC pool [164, 194]. Due to no difference being found in the 
various forms of β-catenin between patient outcomes in the previous chapter, it was of 
interest to investigate whether GSK3β is still playing a role in CML. The main 
conclusions drawn from this chapter are;  
 
1. GSK3β has the predicted outcome on β-catenin levels. SB216763 was used to inhibit 
GSK3β to determine its effects on β-catenin. Results showed unphosphorylated β-
catenin (active) increasing with inhibition of GSK3β, while phospho-β-catenin 
(Ser33/37/Thr41) decreased with inhibition indicating GSK3β is still effective at 
regulating the degradation of β-catenin. 
 
2. GSK3β mRNA transcript levels are elevated in patients with poor prognosis for both 
the normal and spliced variant (exons 8 and 9) transcript type and for the normal-
only transcript type. 
 
3. GSK3β activity is significantly reduced in patients who have transformed into blast 
crisis compared to chronic phase. This was demonstrated by opposing trends in 
Ser9 and Tyr216 phosphorylation. Elevated levels of phospho- GSK3β Ser9 were 
found in those patients who had transformed into blast crisis compared to those in 
chronic phase (P=0.026), which correlated to lower levels of phospho- GSK3β 
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Tyr216 in the patients who have transformed into blast crisis compared to the 
chronic phase patients (P<0.001). This result was corroborated by MCL-1 levels 
being significantly higher in patients in blast crisis (P<0.001 for both forms), 
confirming that GSK3β’s activity is impaired and therefore it cannot act to 
phosphorylate and degrade MCL-1. 
 
4. GSK3β activity is not under the control of BCR-ABL1 in CML.  
 
5. WNT3A reduces GSK3β activity in CML cell lines, while WIF-1 has limited effects on 
GSK3β levels. Results showed with WNT3A treatment in vitro that there was a dose 
dependent decrease in levels of phospho-GSK3β Tyr216 with increased 
concentrations of Wnt3A in both cell lines. This in combination with limited effects 
with WIF-1 treatment may suggest that the Wnt pathway could be maximally 
inhibited in these cells.  
 
6. PP2A is involved in the regulation of GSK3β activity in CML cells, by controlling its 
inhibition. Incubation with the PP2A activator (FTY720) causes a reduction in the 
levels of phospho-GSK3β serine 9. In contrast, incubation with the PP2A inhibitor 
(okadaic acid) increases the levels of serine 9 phosphorylation.  
 
7.  Neither GSK3β nor PP2A are controlling the rate of C-MYC degradation. Results 
showed that there was no difference in the GSK3β dependent Thr58 
phosphorylation on C-MYC in chronic phase patients compared to blast crisis. 
Additionally, analysis of PP2A levels showed that there were significantly higher 
levels of PP2A in blast crisis in combination with the levels of inactive PP2A being 
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elevated but not significantly higher in blast crisis. This is opposite to what would 
be expected if PP2A was regulating C-MYC degradation. Instead, the E3 ubiquitin 
ligase FBXW7, responsible for the ubiquitination of C-MYC, could be controlling the 
level at which C-MYC is degraded [198, 200, 201]. 
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Chapter 5 – Is GSK3β involved in the 
PP2A pathway? 
 
5.1 Introduction 
 
The activity of GSK3β can be regulated by PP2A via the dephosphorylation of Ser9 
alleviating inhibition of GSK3β [197]. This was demonstrated in the previous chapter 
with inhibition of PP2A increasing Ser9 phosphorylation, and activation of PP2A 
reducing serine 9 phosphorylation of GSK3β. 
 
The relationship between GSK3β and PP2A is known to be reciprocal, with GSK3β also 
acting indirectly to regulate PP2A activity, via the inhibitory phosphorylation on Tyr307 
[202, 203]. As GSK3β is a serine /threonine kinase, it cannot act on this regulatory 
domain itself, but it regulates protein tyrosine phosphatase 1B (PTP1B) which in turn 
regulates Tyr307 phosphorylation, and consequently the inhibition of PP2A. It was 
found that a decrease in GSK3β activity decreases the phosphorylation of PP2A, while 
activation of GSK3β increased levels of phospho-PP2A (Tyr307). This occurs by 
inhibition of GSK3β increasing PTP1B and enabling the dephosphorylation of PP2A to 
occur, while activation of GSK3β decreases PTP1B which prevents PTP1B 
dephosphorylating PP2A at Tyr307. Knocking out PTP1B by siRNA increased Tyr307 
phosphorylation that was previously suppressed by GSK3β inhibition. GSK3β can act to 
regulate PTP1B by either its transcription or its phosphorylation status [202]. 
204 |  P a g e
 
PP2A is known to play an important role in CML due to it being a recipient of BCR-ABL1 
regulation. BCR-ABL1 acts to inhibit PP2A preventing its tumour suppressive 
characteristics by inhibiting the ability of PP2A to auto-dephosphorylate itself on 
Tyr307. BCR-ABL1 appears to regulate the activity of PP2A via two mechanisms (see 
Figure 5.1.1).  Firstly, via a mechanism including SET, whereby BCR-ABL1 kinase 
activity increases SET expression, which then enables SET to inactivate PP2A directly. A 
decrease in SET expression, by inhibition of BCR-ABL1 via imatinib treatment, 
correlated with a reduction in PP2A inhibition via Tyr307 phosphorylation. SET was 
found to be elevated in CML blast crisis which subsequently correlated with inactivation 
of PP2A [175]. Secondly via CIP2A which has been shown to co-localise with PP2A 
reducing its phosphatase activity [204]. Elevated levels of CIP2A were found in those 
patients at diagnosis who are destined to progress to blast crisis in comparison to 
optimal responders and failure patients at diagnosis, with 100% of patients with high 
levels of CIP2A transforming to blast crisis within 21 months. CIP2A may therefore be a 
useful biomarker of disease progression. Lucas et al., [176] also showed that high levels 
of CIP2A correlated with high levels of phospho-PP2A (Tyr307), and when CIP2A was 
knocked out by siRNA, this resulted in a decrease in phospho-PP2A (Tyr307) indicating 
that when CIP2A levels are reduced PP2A is able to remain in its active conformation. 
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Figure 5.1.1 Mechanism of PP2A regulation 
 
      Lucas et al., [176] 
 
Activation of PP2A promoted inactivation and subsequently degradation of BCR-ABL1 
via the tyrosine phosphatase SHP-1 dephosphorylating BCR-ABL1, indicating a two way 
mechanism by which PP2A is also able to regulate BCR-ABL1 activity [173, 175]. 
Additionally, PTP1B has been linked to dephosphorylation of BCR-ABL1 in K562 cells. 
This shows PP2A to be a useful therapeutic target via activation of its phosphatase 
activity [175]. 
 
In addition CIP2A and PP2A are known to be involved in a feedback mechanism with 
E2F1, whereby increased levels of E2F1 result in an increase in CIP2A, this then 
transposes to inactivate PP2A, which then stabilises E2F1 as it is unable to 
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dephosphorylate E2F1 on Ser364 [205].  E2F1 is also known to correlate with increased 
levels of active β-catenin in human liver cancer [206, 207] possibly linking the PP2A and 
Wnt/β-catenin pathways even further.  
 
Considering the reciprocal regulatory relationship between PP2A and GSK3β, and the 
significant decrease in GSK3β activity found in blast crisis patients in the previous 
chapter it was of interest to understand the relationship between GSK3β and the PP2A 
pathway in CML. 
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5.2 Aims 
 
The aims of this chapter are to; 
 
1. Determine if there is any correlation between PP2A, CIP2A or SET and GSK3β in 
patients. 
 
2. Investigate whether GSK3β inhibition has any effect on the PP2A and CIP2A 
pathway. 
 
3. Investigate whether CIP2A regulation affects GSK3β and β-catenin levels. 
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5.3 Optimisation of techniques 
 
The optimisation of GSK3β antibodies was shown in the previous chapter (see Chapter 
4 – Optimisation of techniques Figure 4.3.1) as were the conditions for SB216763 
treatment (see Chapter 4 – Optimisation of techniques Figure 4.3.2). Antibody 
optimisation conditions for the various members of the PP2A pathway were performed 
by Dr Lucas. 
 
5.3.1 Optimisation of GSK3β siRNA 
 
K562 cells were used to test the protocol conditions for GSK3β as stated by Santa Cruz 
Biotechnology  to determine if they sufficiently suppressed GSK3β in my hands. 10μM of 
both the control siRNA and the GSK3β siRNA was used per 1x106 cells (Materials and 
Methods section 2.4). Lysates were prepared from the cultures and western blotting 
was used to measure the effect on GSK3β levels (Materials and Methods section 2.9). 
As can be seen in Figure 5.3.1, results showed that 10μM of the GSK3β siRNA 
sufficiently suppressed the expression of all forms of GSK3β compared to the untreated 
and control siRNA. This was therefore the concentration used for all further 
experimentation. 
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Figure 5.3.1 Optimisation of GSK3β siRNA in K562 cells 
The levels of phospho-GSK3β (Ser9), phospho-GSK3β (Tyr216), and total GSK3β were 
measured by western blot in untreated (UNT), control siRNA, and GSK3β siRNA treated 
cells. Results show a decrease in all forms of GSK3β in GSK3β siRNA treated cells 
compared to control siRNA and untreated cells. 
 
 
 
 
5.3.2 Optimisation of CIP2A transfection 
 
K562 cells were used for transient CIP2A transfection to temporarily increase CIP2A 
levels within the cell. Cells were either untreated, GFP transfected, or CIP2A-GFP 
transfected (Materials and Methods section 2.5). The transfection efficiency was 
analysed after 24 hours by both FACS analysis by gating on GFP positive cells, and by 
microscopy to determine if the plasmid vector had been incorporated into the K562 
cells sufficiently. Using GFP detection by FACS, results showed that the control and 
CIP2A plasmid had been successfully incorporated into the cells with ≥70% transfection 
210 |  P a g e
 
efficiency (Figure 5.3.2). This was also seen via microscopy (Figure 5.3.3). PI was also 
used to ensure the vector was not affecting the viability of the cells. Results showed that 
≥80% of the cells were viable subsequent to transfection (Figure 5.3.2).  
 
Figure 5.3.2 Transfection efficiency of CIP2A transient transfection by FACS (GFP 
detection and PI) 
The efficiency of transfection was measured by GFP detection (A.) and results for both 
GFP-only transfection, and CIP2A-GFP transfection was ≥70% (N=3). 
PI was also tested (B.) to ensure the transfection was not affecting cell viability. The 
percentage of live cells was ≥80% (N=3). 
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Figure 5.3.3 Transfection efficiency of CIP2A transient transfection by microscopy 
K562 cells were visualised under a light microscope to determine if transfection had 
been successful by observing the presence of GFP fluorescence. Results showed that 
both GFP-only and CIP2A-GFP transfection had been incorporated successfully into the 
cells. 
 
 
 
 
 
CIP2A levels were measured by FACS to test whether the transient transfection had 
successfully increased the levels of CIP2A by gating on GFP positive cells (N=3) (Figure 
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5.3.4). Results showed that there are significantly higher levels of CIP2A in the CIP2A-
GFP transfected cells compared to the GFP-only transfected cells (P=0.05). 
 
Figure 5.3.4 Optimisation of CIP2A transfection in K562 cells 
CIP2A levels were measured in GFP positive K562 cells to determine whether CIP2A-
GFP transfection had effectively increased levels of CIP2A (N=3). Results show 
significantly higher levels in comparison to the GFP-only transfected cells (P=0.05). 
 
 
 
 
  
P=0.05 
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5.4 Results 
 
5.4.1 Is there any correlation between GSK3β and PP2A/CIP2A/SET? 
 
5.4.1.1 A decrease in GSK3β activity correlates with an increase in inactive PP2A 
 
It was previously found that patients in blast crisis had significantly reduced GSK3β 
activity compared to patients in chronic phase (Chapter 4 – Results section 4.4.2.2). 
Additionally, it was demonstrated that PP2A can regulate the activity of GSK3β in CML 
cells (Chapter 4 – Results section 4.4.3.3). Therefore, it was of interest to determine 
whether the levels of PP2A correlate with the levels of GSK3β. It is hypothesised that an 
increase in GSK3β inhibition could either a) cause an increase in PTP1B and subsequent 
dephosphorylation of PP2A on Tyr307, or b) correspond with higher levels of phospho- 
PP2A Tyr307 (inactive) in those patients with high levels of GSK3β inhibition as PP2A 
would not be dephosphorylating Ser9 of GSK3β. Lucas et al., [176] previously showed 
that the level of phospho-PP2A Tyr307 is significantly higher in blast crisis MNCs 
compared to normal MNCs (P=0.004). Therefore, it was of interest to see whether, in 
matched patient samples, GSK3β levels correlated with PP2A levels to give an indication 
of the relationship between GSK3β and PP2A in CML cells.  
 
Levels of total PP2A and phospho-PP2A (Tyr307) were examined by FACS analysis (see 
Methods section 2.7) in patient samples matched to those also measured for GSK3β 
levels.  Results show that levels of total PP2A do not change between chronic phase and 
blast crisis. The proportion of inactive PP2A is higher in blast crisis than in chronic 
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phase, but not to a statistically significant level. The higher levels of phospho-PP2A 
Tyr307 seen in the blast crisis patients are indicative that PP2A is regulating GSK3β by 
preventing the dephosphorylation of serine 9. The reason as to why the difference in 
phospho-PP2A Tyr307 levels is not significant may be due to a feedback mechanism 
whereby in blast crisis phospho-PP2A Tyr307 is unable to dephosphorylate GSK3β on 
serine 9 increasing its inhibition which consequently increases PTP1B and 
dephosphorylates PP2A on Tyr307 (Figure 5.4.2).  
 
Figure 5.4.1 Inactive PP2A is higher in blast crisis patients 
Levels of total PP2A and phospho-PP2A (Tyr307) were measured in chronic phase 
patients (N=11) and patients who had transformed into blast crisis (N=4). Results show 
no difference between the cohorts for total PP2A (A.). There are elevated levels of 
phospho-PP2A (Tyr307) in blast crisis patients but the difference is not statistically 
significant (P=0.226). 
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Figure 5.4.2 Feedback mechanism of PP2A and GSK3β 
Inhibited PP2A (phospho PP2A Tyr307) prevents the dephosphorylation of the 
inhibitory Ser9 phosphorylation on GSK3β. This inhibition of GSK3β increases the levels 
of PTP1B which then dephosphorylates PP2A at Tyr307. 
 
 
 
 
 
5.4.1.2 A decrease in GSK3β activity correlates with an increase in SET 
 
As for levels of PP2A, SET protein levels were examined by FACS analysis (Materials 
and Methods section 2.7) in matched patient samples to those measured for GSK3β 
levels. Results show (Figure 5.4.3) that there are increased levels of SET in the blast 
crisis patients compared to chronic phase (P=0.078), correlating with levels of phospho-
PP2A (Tyr307) being higher in this cohort of patients. This provides evidence that, in 
patients who have transformed into blast crisis, an increase in SET levels increases the 
inhibition of PP2A which, in turn, can prevent the dephosphorylation of GSK3β on Ser9 
increasing inhibition of GSK3β activity. 
GSK3β 
PP2A 
 
 
PTP1B 
Tyr307 
Ser9 
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Figure 5.4.3 SET protein levels are higher in blast crisis patients compared to 
chronic phase 
Levels of SET were measured in chronic phase (N=11) and blast crisis (N=4) patients. 
Results show that SET levels are elevated in patients in blast crisis (P=0.078). 
 
 
 
5.4.1.3 A decrease in GSK3β activity does not correlate with a change in CIP2A 
levels. 
 
As before, CIP2A protein expression was examined by FACS analysis (Materials and 
Methods section 2.7) in patient samples matched to those measured for GSK3β levels.  
Results show that levels of CIP2A protein do not change between chronic phase and 
blast crisis (Figure 5.4.4). This indicates that CIP2A does not correlate with the activity 
of GSK3β when stratified by patient outcomes. However, CIP2A has been recognised as 
a predictive biomarker for CML by Lucas et al., [176] and therefore patient outcome can 
be stratified according to either high or low CIP2A protein expression levels. The data 
were subsequently revised based on this division (see Section 5.4.1.4). 
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Figure 5.4.4 There is no difference in CIP2A levels between chronic phase and 
blast crisis 
Levels of CIP2A were measured in chronic phase patients (N=14) and patients who had 
transformed into blast crisis (N=6). Results show no difference between the cohorts 
(P=1.00). 
 
 
 
 
5.4.1.4 GSK3β levels are lower overall in the high CIP2A patients 
 
When re-stratifying the levels of GSK3β with CIP2A, the patient data were paired and 
then separated according to their CIP2A levels with high CIP2A having a MFI>7 and low 
CIP2A having a MFI<7 (as previously defined by Lucas et al., [176]) to determine what 
happens to the levels of phospho-GSK3β (Ser9) and phospho-GSK3β (Tyr216). Results 
show (Figure 5.4.5) that both forms of phospho-GSK3β are lower in the patients with 
high CIP2A compared to low CIP2A, indicating that CIP2A may promote the degradation 
of GSK3β. These results however do not reach statistical significance.  
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Figure 5.4.5 Both forms of GSK3β are reduced in patients with high CIP2A levels  
Patients were split into low CIP2A (N=16) and high CIP2A (N=4) and the levels of 
phospho-GSK3β (Ser9), and phospho-GSK3β (Tyr216) were analysed. Results show 
both forms of phospho-GSK3β are lower in the patients with high CIP2A (Ser9 P=0.104, 
Tyr216 P=0.310). 
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5.4.2 Does inhibition of GSK3β affect the PP2A pathway? 
 
Due to the two-way regulatory relationship between GSK3β and PP2A, it was of interest 
to see whether inhibition of GSK3β had any effect on PP2A, CIP2A, SET and BCR-ABL1 
activity. The levels of c-Myc were also analysed as GSK3β and PP2A are involved in c-
Myc degradation (even though they may not be rate-limiting components) to see if there 
is any impact on c-Myc degradation with altering levels of GSK3β.  
 
It would be predicted that inhibition of GSK3β would lead to a decrease in the levels of 
phospho-PP2A (Tyr307) enabling the phosphatase activity of PP2A to occur. In theory, 
this could lead to a decrease in BCR-ABL1 activity as PP2A could act to inactivate and 
degrade BCR-ABL1 [173, 175]; this would in turn reduce levels of both SET and CIP2A. 
 
 
5.4.2.1 Inhibition of GSK3β using SB216763 decreases inhibition of PP2A and up 
regulates CIP2A and SET 
 
SB216763 is an ATP-competitive inhibitor of GSK3β which was selected for use over 
lithium chloride (LiCl) as LiCl does not selectively inhibit GSK3β complicating data 
interpretation [195]. K562 cells were incubated with SB216763 in vitro for 24 hours 
(Materials and Methods section 2.3.3) and then analysed by FACS analysis (N=6) 
(Materials and Methods section 2.7). Results show (Figure 5.4.6) that inhibition of 
GSK3β by incubation with 5μM SB216763 in K562 cells reduces the levels of phospho-
PP2A (Tyr307) as well as total levels of PP2A. This fits with inhibition of GSK3β acting 
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to activate PP2A through a reduction in its inhibitory phosphorylation via PTP1B.  The 
levels of CIP2A and SET protein increase, alongside BCR-ABL1 activity (p-CrKL/CrKL 
ratio), which is opposite to what would be predicted; potentially suggesting a feedback 
mechanism within the malignancy whereby a down regulation in inactive PP2A 
(Tyr307) triggers an increase in the PP2A inhibitors CIP2A and SET, to restore 
inhibition of PP2A in the malignant cells. 
 
 Additionally inhibition of GSK3β resulted in a decrease in phospho C-MYC (Thr 58) 
(Figure 5.4.6) which confirms expectations as GSK3β phosphorylates C-MYC directly 
on this site. Inhibition has no effect on Ser62 phosphorylation of C-MYC and slightly 
increases total levels of C-MYC.  
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Figure 5.4.6 Inhibition of GSK3β using SB216763 
K562 cells were incubated in vitro with SB216763 for 24 hours. Levels of the various 
PP2A pathway components were then measured by FACS analysis (N=6). Results show 
the trend that inhibition of GSK3β decreases total and inactive (Tyr307) PP2A levels, 
increases CIP2A, and SET levels, as well as BCR-ABL1 activity (p-CrKL/CrKL ratio), and 
increases total C-MYC levels, decreases phospho C-MYC (Thr58), and has no effect on 
serine 62 phosphorylation of C-MYC. 
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5.4.2.2 Inhibition of GSK3β using siRNA 
 
GSK3β inhibition by siRNA was again measured by FACS analysis (N=4) (Materials and 
Methods section 2.4 and 2.7), however, results had the opposite effect on the PP2A 
pathway as was seen with SB216763 mediated GSK3β inhibition (Figure 5.4.7). 
Knocking out GSK3β reduced total levels of PP2A, similar to the effect seen with 
SB216763 inhibition, however in contrast the levels of inhibitory phospho-PP2A 
(Tyr307) increased with the knockdown of GSK3β. The opposite results to that with 
SB216763 incubation were also found with CIP2A and SET, with both their levels 
decreasing with GSK3β knockdown, together with decreased BCR-ABL1 activity (p-
CrKL/CrKL ratio). This shows that inhibition of GSK3β through ATP competition has a 
different impact on the substrates of GSK3β compared to down-regulation of the 
protein. This difference can be explained as inhibition of GSK3β by SB216763 increases 
Ser9 phosphorylation (Chapter 4, Figure 4.3.2), which in turn would decrease levels of 
phospho-PP2A Tyr307 seen in Figure 5.4.6. However, knockdown of GSK3β reduces 
Ser9 phosphorylation (Figure 5.3.1), which consequently would increase levels of 
Tyr307 (Figure 5.4.7) as GSK3β cannot increase levels of PTP1B which therefore 
prevents PTP1B from dephosphorylating PP2A at Tyr307. Again the results for CIP2A, 
SET and BCR-ABL1 activity (p-CrKL/CrKL ratio) are opposite to what would be 
predicted, implying that PP2A may not be acting to down-regulate BCR-ABL1 activity in 
CML. 
 
The results on C-MYC levels corroborated what was seen with SB216763, with phospho 
C-MYC (Thr58) levels decreasing with GSK3β knockdown, while there was no effect 
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seen on the levels of phospho C-MYC (Ser62) and total C-MYC. The fact that both forms 
of GSK3β inhibition have no effect on total C-MYC levels further emphasises that GSK3β 
is not the rate limiting component of C-MYC degradation (Chapter 4 - Results section 
4.4.4).  
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Figure 5.4.7 Inhibition of GSK3β using siRNA 
GSK3β was knocked out in K562 cells using siRNA. Levels of the various PP2A pathway 
components were then measured by FACS analysis (N=4). Results show the trend that 
inhibition of GSK3β by siRNA decreases total PP2A but increases inactive (Tyr307) 
PP2A levels, decreases CIP2A, and SET levels, as well as BCR-ABL1 activity (p-
CrKL/CrKL), and decreases phospho C-MYC (Thr58), while having no effect on total C-
MYC and Ser62 phosphorylation of C-MYC. 
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5.4.3 Does regulation of CIP2A affect GSK3β? 
 
Considering the dynamic relationship between PP2A and GSK3β which could be 
impacted by the regulation of CIP2A on PP2A activity, alongside results in patient 
samples showing high levels of CIP2A correlated with reduced forms of GSK3β, the next 
line of investigation was to manipulate the levels of CIP2A to see if this had an impact on 
GSK3β. 
 
5.4.3.1 Knocking out CIP2A reduces GSK3β 
 
CIP2A siRNA methodology was previously optimised by Dr Lucas. 10μM of both a 
control and CIP2A siRNA was used (Materials and Methods section 2.4) and lysates 
were prepared from the cultures. Levels of GSK3β were measured by western blotting 
(Materials and Methods section 2.9) to determine if knocking out CIP2A has any 
effect of GSK3β levels (N=3). Results show that a reduction in CIP2A gives rise to a 
decrease in all forms of GSK3β (Figure 5.4.8). These results contradict what was seen 
in patients with high CIP2A correlating with low GSK3β, however, the decrease in CIP2A 
via siRNA knockdown would increase active levels of PP2A which would subsequently 
be able to dephosphorylate GSK3β at Ser9, represented by the decrease in phospho-
GSK3β Ser9 seen.  
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Figure 5.4.8 Inhibition of CIP2A by siRNA reduces GSK3β levels 
K562 cells were treated with control siRNA (10μM) and CIP2A siRNA (10μM). GSK3β 
levels were analysed using western blotting and results show that knocking out CIP2A 
results in a reduction of all forms of GSK3β (N=3). 
 
 
 
 
5.4.3.2 Transfecting in CIP2A increases GSK3β 
 
Next, transient CIP2A transfection was used to increase the CIP2A levels, (Materials 
and Methods section 2.5) lysates were prepared from the cultures and western blots 
were carried out (N=3) (Materials and Methods section 2.9). Figure 5.4.9 shows that 
an increase in CIP2A levels results in an increase in both phospho-GSK3β (Ser9), and 
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phospho-GSK3β (Tyr216). This would be as a result of an increase in CIP2A elevating 
the levels of inactive PP2A (Tyr307), which would then increase the levels of Ser9 
phosphorylation of GSK3β as PP2A would not be able to dephosphorylate this residue. 
 
Figure 5.4.9 Transient transfection of CIP2A increases levels of GSK3β 
K562 cells were transiently transfected with GFP-only and CIP2A-GFP to increase levels 
of CIP2A and compared to an untreated control (UNT). Levels of GSK3β were then 
analysed by western blotting (N=3). Results show that both phospho-GSK3β (Ser9) and 
phospho-GSK3β (Tyr216) increase in CIP2A-GFP transfected cells. 
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Neither siRNA knockdown nor transfectional upregulation of CIP2A showed a 
significant effect on the levels of GSK3β, which may indicate that the effect of CIP2A on 
PP2A is reduced in translation to GSK3β levels. 
 
 
5.4.4 Does regulation of CIP2A affect β-catenin? 
 
CIP2A is involved in the regulation of two components which are known to interact with 
β-catenin; PP2A and E2F1. Specifically, the PP2A isoforms B55α and B56γ have been 
reported to regulate the phosphorylation status of β-catenin. The B55α isoform of PP2A 
has been shown to directly interact with β-catenin, as well as Axin, and regulate the 
phosphorylation status of β-catenin by dephosphorylating residues Ser552 and Ser675 
which can also activate β-catenin  [208]. Alternatively B56γ acts as part of the 
destruction complex via association with both APC [170] and Axin [209] and correlates 
with degradation of β-catenin [170, 175, 209]. Additionally, E2F1 has been reported to 
correlate with increased levels of unphosphorylated β-catenin [206, 207]. Since CIP2A is 
known to regulate both of these factors it was of interest to see if regulation of CIP2A 
had an impact on β-catenin levels. 
 
5.4.4.1 Unphosphorylated β-catenin is higher in patients with high CIP2A 
 
Levels of -catenin and CIP2A protein were investigated by FACS analysis (see 
Methods section 2.7) in patient samples that were separated in accordance to their 
CIP2A protein expression levels using a cut off of MFI > or <7 as previously determined 
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by Lucas et al., [176]. Results showed (Figure 5.4.10) that high CIP2A levels correlated 
with increased levels of unphosphorylated -catenin. This could be either a direct effect, 
or an indirect effect via PP2A or E2F1.  
 
Figure 5.4.10 High CIP2A levels correlate with increased levels of active -catenin 
in patient samples 
Levels of -catenin and CIP2A protein were analysed in patient samples and separated 
in high and low CIP2A levels. Results showed a correlation of high CIP2A levels with 
increased levels of unphosphorylated -catenin expression. 
 
  
 
 
 
5.4.4.2 CIP2A transfection increases unphosphorylated β-catenin at the same time 
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-catenin (Figure 5.4.11 B.), which correlated with a decrease in phospho--catenin 
(Ser33/37/Thr41) (Figure 5.4.11 D.) that is targeted for degradation. Additionally 
increasing CIP2A expression increased both phospho--catenin (Ser45/Thr41) (Figure 
5.4.11 C.) and phospho--catenin (Tyr654) (Figure 5.4.11 E.), while it reduced the 
overall expression of total -catenin (Figure 5.4.11 A.). This increase in 
unphosphorylated β-catenin, which correlates with a decrease in phospho-β-catenin 
(Ser33/37/Thr41), shows that with elevation of CIP2A β-catenin is active in the cell and 
hence can activate transcription of its target genes. The differences did not reach 
statistical significance which could either be due to the N number (N=3) or may be due 
to the effect of CIP2A on β-catenin being an indirect effect which may reduce its impact 
on the levels of β-catenin.  
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Figure 5.4.11 Transfection of CIP2A results in an increase in active β-catenin and 
decreases levels targeted for degradation 
K562 cells were transiently transfected with GFP-only and CIP2A-GFP to increase levels 
of CIP2A. Levels of β-catenin were then investigated by FACS analysis (N=3). Results 
show that levels of total-β-catenin (A.) and phospho--catenin (Ser33/37/Thr41) (D.) 
decrease in CIP2A-GFP transfected cells compared to GFP-only transfected. Increasing 
CIP2A expression also increases unphosphorylated β-catenin (B.), phospho--catenin 
(Ser45/Thr41) (C.), and phospho--catenin (Tyr654) (E.).  
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5.4.4.3 CIP2A may be acting through E2F1 to affect levels of β-catenin 
 
CIP2A is known to regulate E2F1 [205], and E2F1 is known to correlate with increased 
levels of unphosphorylated -catenin [206]. Therefore, to determine if the increase in 
unphosphorylated β-catenin is solely due to CIP2A or due to the process of transfection 
also increasing E2F1 levels which then subsequently act on β-catenin, the levels of E2F1 
and phospho-E2F1 (Ser364) were measured by FACS analysis (Methods section 2.7) 
(N=3). Phospho-E2F1 (Ser364) was measured in addition to total E2F1 as this 
phosphorylation is known to stabilise the protein [210]. Results show that the CIP2A-
GFP transfected cells have higher levels of total E2F1 compared to GFP-only transfected 
cells, and significantly higher levels of phospho-E2F1 (Ser364) (P=0.007) (Figure 
5.4.12), which suggests that the increase in unphosphorylated β-catenin could be due 
to E2F1 instead of a direct effect of CIP2A. 
 
Figure 5.4.12 Transfection of CIP2A also increases E2F1 levels 
Levels of total E2F1 and phospho-E2F1 (Ser364) were measured in the transfected 
cells. Results showed that cells transfected with CIP2A had higher levels of total E2F1 
and significantly elevated levels of phospho-E2F1 (Ser364) (P=0.007) compared to GFP-
only transfected cells. 
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5.5 Main Conclusions 
 
In the previous chapter it was discovered that patients in blast crisis had significantly 
less GSK3β activity compared to patients in chronic phase and that PP2A has a role in 
regulating the activity of GSK3β. As a consequence, it was relevant to try to further 
understand the relationship between GSK3β and PP2A.  
 
From this investigation, the main conclusions found were that; 
1. GSK3β shows a relationship with inactive PP2A (phosphorylated on Tyr307) and 
SET levels, with both increasing in patients who have transformed into blast crisis 
compared to chronic phase. This correlates with the decrease in GSK3β activity 
found in the previous chapter, suggesting a mechanism for GSK3β inhibition via SET 
inhibition of PP2A. 
 
2. Levels of both phospho-GSK3β (Tyr216) and phospho-GSK3β (Ser9) are reduced in 
patients who have high levels of CIP2A, opposite to what would be predicted.  
 
3. Inhibition of GSK3β by SB216763 and siRNA has opposite effects on the 
PP2A/CIP2A/SET pathway through different mechanisms of GSK3β inhibition. 
Inhibition with SB216763 causes an increase in Ser9 phosphorylation and 
subsequent decrease in Tyr307 phospho-PP2A levels observed, via 
dephosphorylation of PP2A by PTP1B. In contrast, knockdown of GSK3β by siRNA 
reduces the levels of Ser9 phosphorylation on GSK3β which results in an increase in 
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Tyr307 phosphorylation of PP2A, as GSK3β  is unable to increase levels of PTP1B, 
preventing the dephosphorylation of PP2A at Tyr307. The results for CIP2A, SET 
and BCR-ABL1 activity (p-CrKL/CrKL ratio) are opposite to what would be 
predicted for the levels of PP2A shown, implying that PP2A may not be acting to 
down-regulate BCR-ABL1 activity in CML. 
 
4. Inhibition of GSK3β reduces Thr58 phosphorylation of C-MYC, but does not have a 
significant influence on the expression of total C-MYC, further confirming results 
from the previous chapter that GSK3β is not the rate-limiting component of C-MYC 
degradation in CML. 
 
5. Manipulation of CIP2A levels by siRNA and transient transfection does cause 
changes in the levels of GSK3β. However, these differences are not significant 
suggesting CIP2A is not a vital component in the regulation of GSK3β. 
 
6. Higher levels of unphosphorylated β-catenin correlate with increased CIP2A, both 
in patient samples and manipulation of CIP2A levels by transient transfection in 
K562 cells.  However, it is known that CIP2A regulates E2F1 [205], which in turn is 
known to correlate with increased levels of unphosphorylated -catenin [206]. 
Increasing CIP2A levels by transient transfection consequently increased the levels 
of stabilised E2F1 (Ser365) (P=0.007), therefore CIP2A may not be having a direct 
effect on β-catenin but instead could be acting to increase unphosphorylated β-
catenin levels indirectly through E2F1.   
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Chapter 6 – The role of the Wnt 
Transcription Factors as markers for 
disease progression 
 
6.1 Introduction 
 
Wnt/β-catenin signalling is crucial in maintaining the self-renewal of normal HSCs [143, 
211]  and when the signalling is disrupted, haematological malignancies may develop 
[150, 212, 213]. The first identification of deregulation of the Wnt/β-catenin pathway 
resulting in a haematological malignancy was described in CML, where it was found that 
increased Wnt/β-catenin pathway activation led to β-catenin accumulation. It was 
suggested that this contributed to disease progression [145]. 
 
Regulation of the Wnt/β-catenin signalling pathway is an extremely complex process, 
with multiple members of the pathway either up-regulating or down-regulating signal 
transduction through the cell. This is summarised in section 1.7 of the introduction. In 
addition to the Wnt signal being regulated at the beginning of the pathway through 
secreted proteins, which either prevent the association between WNT ligands and the 
membrane receptors FZD and LRP5/6 (e.g. DKK, WIF, sFRP, CER) or bind to the 
receptors and activate the pathway (e.g. NORRIN, R-SPONDIN), the pathway can also be 
regulated further downstream, some mechanisms of which are described in Table 
6.1.1.  
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Table 6.1.1 Summary of factors involved in the regulation of the Wnt signalling 
pathway 
Antagonists Agonists  
DKK – inhibits signalling by blocking the 
LRP5/6 receptor, preventing Wnt ligand 
binding [85]. 
NORRIN – binds to the receptors (in 
particular Fz4) and activates the Wnt 
pathway [214, 215]. 
WIF - binds to the Wnt ligands to prevent 
the interaction with the Frizzled receptor 
[216]. 
R-SPONDIN - binds to the receptors (in 
particular Fz8 and LRP6) and activates the 
Wnt pathway [217, 218]. 
sFRP – bind to the Wnt ligands to prevent 
the interaction with the Frizzled receptor 
[216]. 
SKL2001 – activates β-catenin activity by 
competing with GSK3β through the 
prevention of β-catenin’s interaction with 
Axin2 [219] 
CER – binds to the Wnt ligands to prevent 
the interaction with the Frizzled receptor 
[85, 216]. 
APC – normally this functions as a tumour 
suppressor by being part of the 
destruction complex – however multiple 
mutations have been discovered which 
switch its role to enhancing the 
accumulation of β-catenin [220, 221]. 
KREMEN – involved with Dkk in the 
internalisation of LRP5/6 preventing 
association with Wnt ligands [85, 216]. 
DSH – prevents the degradation of β-
catenin by recruiting GBP/Frat-1, which 
removes GSK3β from axin. Dsh can itself 
be regulated by PAR1, frodo, β-arrestin1 
and Dapper [85]. 
CtBP – bind to the promoters of target 
genes to prevent transcriptional activation 
[222]. 
PYGO – involved in the activation of 
transcription by mediating the interaction 
of β-catenin or TCF with chromatin [222]. 
GROUCHO  - bind to the promoters of 
target genes to prevent transcriptional 
activation [222]. 
LGS – links Pygopus to β-catenin in the 
nucleus [222]. 
NEMO-like kinase – phosphorylates the 
TCFs to prevent transcription [85]. 
 
ICAT – Interacts with β-catenin to prevent 
binding with the transcription factors [85]. 
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The final stage at which Wnt/β-catenin signalling can be regulated is at the level of the 
transcription factors associated with the pathway. These are the TCF/LEF family of 
transcription factors which include TCF1, TCF3, TCF4, and LEF1. Their structure 
consists of a N-terminal β-catenin binding domain and a C-terminal high mobility group 
DNA binding domain [178] which assists their function by enabling the binding between 
β-catenin and the promoter region of the target genes including  CYCLIN D1 and C-MYC 
[122, 123]. The activity of the transcription factors themselves can be regulated by 
transcriptional co-activators and transcriptional co-repressors (Table 6.1.1). Nuclear 
β-catenin functions by binding to these transcription factors and eliminates any 
inhibition by displacing the co-repressors from TCF/LEF, while the co-activators 
facilitate the association of β-catenin with the transcription factors and enhance 
transcriptional activation [122].  
 
In addition to facilitating the signal transduction of the Wnt/β-catenin pathway, the 
TCF/LEF transcription factors may act independently of the pathway in haematological 
malignancies [178]. Grumolato et al., [178]  showed elevated levels of TCF/LEF 
transcriptional activity in CML cell lines and primary material, which did not correlate 
with an increase in nuclear β-catenin levels. They also showed that both TCF1 and LEF1 
increased the level of TCF/LEF reporter activity in the 293T cell line, which is known to 
not have an active Wnt/β-catenin pathway. Additionally, mutation of TCF1 which 
obstructed β-catenin’s binding ability, or deletion of the binding site of β-catenin on 
TCF1 had little effect on the transcriptional activity of TCF1. These data support the 
theory that TCF1 can act independently of β-catenin and activate transcription [178].  
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To establish which aspects of the Wnt/β-catenin pathway are important in CML, it is of 
interest to see an overall view of the pathway to determine if there are any changes in 
correlation with the different patient responses. Furthermore, since the TCF/LEF 
transcription factors are involved in transcriptional activation, both via the Wnt/β-
catenin pathway and independently, their influence on the disease may be substantial. 
Therefore, an investigation into their relationship with patient outcome is worthwhile. 
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6.2 Aims 
 
The aims of this chapter are to; 
 
1) Screen the components of the Wnt/β-catenin pathway in differing patient 
outcomes to determine if there is any difference in expression levels. 
 
2) Analyse the genes which show the greatest difference between patient outcomes. 
 
3) Investigate the transcription factors involved in the Wnt/β-catenin pathway to 
see if they are differentially expressed in the different patient cohorts. 
 
4) Investigate any relation of the transcription factors with GSK3β or CIP2A. 
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6.3 Optimisation of techniques 
 
All experimentation in this chapter was carried out according to manufacturer’s 
recommendations. The list of primers used can be found in Materials and Methods, 
Table 2.3.   
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6.4 Results 
 
6.4.1 Is there a difference in the Wnt pathway gene expression between differing 
patient responses? 
 
Regulation of Wnt signalling can occur at various stages of the pathway. To establish an 
overall view of the differences in the Wnt pathway gene expression, a RT2 Profiler PCR 
Array for the Human WNT Signalling Pathway (Qiagen) was carried out (see Methods 
section 2.6.3). This permitted the assessment of changes in mRNA expression of the 
pathways components to visualise any upregulation or downregulation of genes. 
Initially, a diagnostic samples from an optimal responder (patient ID #29) was 
compared to a patient at diagnosis who later transformed into blast crisis (patient ID 
#115) to see if any resultant genetic differences could be used as a biomarker for 
disease progression (Figure 6.4.1). Analysis was then undertaken on those genes which 
showed the largest differences to select which genes should be studied further (Figures 
6.4.2 and 6.4.3). 
  
242 |  P a g e
 
Figure 6.4.1 PCR screening of genes involved in the Wnt signalling pathway; 
optimal responder vs blast crisis at diagnosis 
A PCR screening of all Wnt related genes was carried out looking at an optimal 
responder (green) and a patient who later transformed into blast crisis (red), each at 
original diagnosis of chronic phase to see if any genes showed a major difference 
between responses. 
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KEY: 
AES:  Amino-terminal enhancer of split 
APC: Adenomatous polyposis coli 
AXIN1: Axin 1 
BCL9: B-cell CLL/lymphoma 9 
BTRC: Beta-transducin repeat containing 
FZD5: Frizzled homolog 5 (drosophila)  
CCND1: Cyclin D1 
CCND2: Cyclin D2 
CCND3: Cyclin D3 
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CSNK1A1: Casein Kinase 1, alpha 1 
CSNK1D: Casein kinase 1, delta 
CSNK1G1: Casein kinase 1, gamma 1 
CSNK2A1: Casein kinase 2, alpha 1 polypeptide 
CTBP1: C-terminal binding protein 1 
CTBP2: C-terminal binding protein 2 
CTNNB1: Catenin (cadherin-associated protein), beta 1, 88kDa 
CTNNB1P1: Catenin, beta interacting protein 1 
CXXC4: CXXC finger 4 
DAAM1: Dishevelled associated activator of morphogenesis 1 
DIXDC1: DIX domain containing 1  
DKK1: Dickkopf homolog 1 (Xenopus laevis)  
DVL1: Dishevelled, dsh homolog 1 (Drosophila) 
DVL2: Dishevelled, dsh homolog 2 (Drosophila)  
EP300: E1A binding protein p300 
FBXW11: F-box and WD repeat domain containing 11 
FBXW2: F-box and WD repeat domain containing 2 
FGF4: Fibroblast growth factor 4 
FOSL1: FOS-like antigen 1 
FOXN1: Forkhead box N1 
FRAT1: Frequently rearranged in advanced T-cell lymphomas  
FRZB: Frizzled-related protein 
FSHB: Follicle stimulating hormone, beta polypeptide 
FZD1: Frizzled homolog 1 (Drosophila)  
FZD2: Frizzled homolog 2 (Drosophila)  
FZD3: Frizzled homolog 3 (Drosophila)  
FZD4: Frizzled homolog 4 (Drosophila)  
FZD6: Frizzled homolog 6 (Drosophila)  
FZD7: Frizzled homolog 7 (Drosophila)  
FZD8: Frizzled homolog 8 (Drosophila)  
GSK3A: Glycogen synthase kinase 3 alpha 
GSK3B: Glycogen synthase kinase 3 beta  
JUN: Jun oncogene  
KREMEN1: Kringle containing transmembrane protein 1 
LEF1: Lymphoid enhancer-binding factor 1 
LRP5: Low density lipoprotein receptor-related protein 5 
LRP6: Low density lipoprotein receptor -related protein 6 
MYC : V-myc myelocytomatosis viral oncogene homolog (avian) 
NKD1: Naked cuticle homolog 1 (Drosophila)  
NLK: Nemo-like kinase  
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PITX2:Paired-like homeodomain 2 
PORCN : Porcupine homolog (Drosophila)  
PPP2CA: Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform  
PPP2R1A: Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform  
PYGO1: Pygopus homolog 1 (Dosophila)  
RHOU: Ras homolog gene family, member U 
SENP2: SUMO1/sentrin/SMT3 specific peptidase 2 
SFRP1: Secreted frizzled-related protein 1 
SFRP4: Secreted frizzled-related protein 4 
FBXW4: F-box and WD repeat domain containing 4 
SLC9A3R1: Solute carrier family 9(sodium/hydrogen exchanger), member 3 regulator 1 
SOX17: SRY (sex determining region Y)-box 17  
T : T, brachyury homolog (mouse) 
TCF7 : Transcription factor 7 (T-cell specific, HMG-box) 
TCF7L1 : Transcription factor 7-like 1 (T-cell specific, HMG-box) 
TLE1: Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)  
TLE2: Transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila)  
WIF1: WNT inhibitory factor 1 
WISP1: WNT1 inducible signaling pathway protein 
B2M: Beta-2-microglobulin 
HPRT1: Hypoxanthine phosphoribosyltransferase 1 
RPL13A: Ribosomal protein L13a  
WNT1: Wingless-type MMTV integration site family member 1 
WNT10A: Wingless-type MMTV integration site family member 10a 
WNT11: Wingless-type MMTV integration site family member 11 
WNT16: Wingless-type MMTV integration site family member 16 
WNT2: Wingless-type MMTV integration site family member 2 
WNT2B: Wingless-type MMTV integration site family member 2B 
WNT3: Wingless-type MMTV integration site family member 3 
WNT3A: Wingless-type MMTV integration site family member 3A 
WNT4: Wingless-type MMTV integration site family member 4 
WNT5A: Wingless-type MMTV integration site family member 5A 
WNT5B: Wingless-type MMTV integration site family member 5B 
WNT6: Wingless-type MMTV integration site family member 6 
WNT7A: Wingless-type MMTV integration site family member 7A 
WNT7B: Wingless-type MMTV integration site family member 7B 
WNT8A: Wingless-type MMTV integration site family member 8A 
WNT9A: Wingless-type MMTV integration site family member 9A 
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When analysing the results from this screening to determine which of the genes to 
investigate further, initially the WNT specific ligand genes were separated from the rest 
of the screening to establish whether there was an up regulation in any WNT ligands. 
Results from the optimal responder were subtracted from results from the blast crisis 
patient at diagnosis, to distinguish if any could be used as biomarkers of disease 
progression, and plotted with increasing difference (Figure 6.4.2). This showed that 
WNT1, WNT9A and WNT8A had the largest difference between the two patients, and 
therefore these were followed up further in patient cohorts (Section 6.4.1.1). 
 
Figure 6.4.2 The difference in the WNT ligand mRNA expression between an 
optimal responder and a blast crisis patient at diagnosis 
The difference in Wnt ligand mRNA expression in an optimal responder (patient ID 
#29) vs a blast crisis patient (patient ID #115) both at original diagnosis of chronic 
phase showed WNT1, WNT9A and WNT8A have the biggest difference in levels between 
patients. 
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Separate to the WNT ligand genes, the other pathway components were analysed to 
investigate which differed the most between patients. Results from the optimal 
responder were again subtracted from results from the blast crisis patient at diagnosis, 
and the eight components with the largest difference are shown in Figure 6.4.3. Results 
showed FZD7 and NKD1 were both absent from one of the patients. FZD7 was absent in 
the optimal responder at diagnosis, while NKD1 was missing from the blast crisis 
patient at diagnosis; consequently both of these genes were taken on for further 
analysis (Section 6.4.1.2 and 6.4.1.3). 
 
Figure 6.4.3 The difference in Wnt pathway components mRNA expression 
between optimal responder and blast crisis patient at diagnosis 
To determine the difference in the other components of the Wnt pathway, mRNA 
expression of the two patients in Figure 6.4.1 were analysed and the difference between 
patients was determined. Results showed that FZD7 and NKD1 had the largest 
difference between patient responses. 
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6.4.1.1 WNT ligands 1, 8A, and 9A are significantly higher in chronic phase 
compared to blast crisis 
 
To further investigate the previously selected genes, they were examined in a larger 
cohort of patients. Patients again were initially split into the three patient outcomes in 
accordance with the ELN definitions (as described in the introduction section 1.4) 
optimal responders, failure patients and blast crisis patients. These were all analysed at 
original diagnosis of chronic phase, and those patients who had transformed into blast 
crisis were also studied after transformation. 
 
Results for the WNT ligand genes showed that for WNT1, WNT8A and WNT9A there are 
higher mRNA levels in the diagnostic cohorts compared to those patients in blast crisis. 
Comparison between each of the groups however was not statistically significant 
(Figure 6.4.4).  
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Figure 6.4.4. Levels of WNT ligand expression (WNT1, WNT8A and WNT9A) are 
lower in blast crisis compared to diagnostic samples from optimal, failure and 
blast crisis patients 
Analysis of the WNT ligands in patient samples were grouped into optimal responders 
(N=9), failure patients (N=7) and blast crisis patients (N=4) all at original diagnosis of 
chronic phase, and patients who have transformed into blast crisis (N=4). 
Results show levels of the WNT ligands to be higher in the optimal responders, failure 
patients and patients who later progressed to blast crisis at diagnosis compared to 
patients in blast crisis.  
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Alternatively, when data were analysed according to chronic phase vs blast crisis, the 
levels of all the three WNT ligands (WNT1, WNT8A, and WNT9A) were significantly 
higher in chronic phase compared to blast crisis (P=0.011, 0.045, and 0.037 
respectively) (Figure 6.4.5). In combination this could be indicating that activation of 
the Wnt/β-catenin pathway is occurring in chronic phase through the up-regulation of 
WNT ligand expression. This contradicts the literature where an activation of the 
Wnt/β-catenin pathway in progenitor cells is shown through an increase in the 
unphosphorylated form of β-catenin in blast crisis [150, 223]. However since no 
difference was found in the levels of β-catenin in MNCs between patient responses in 
my hands, this may suggest an alternative mechanism in these cells. 
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Figure 6.4.5 Levels of WNT ligand expression (WNT1, WNT8A and WNT9A) are 
significantly lower in blast crisis compared to chronic phase 
Chronic phase samples (N=20) were compared to patients in blast crisis (N=4) for the 
three WNT ligands. Results showed all three have significantly higher mRNA levels in 
chronic phase cohort compared to blast crisis. P=0.011 for WNT1 (A.), P=0.045 for 
WNT8A (B.), and P=0.037 for WNT9A (C.). 
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6.4.1.2 mRNA expression of FZD7 is significantly higher in chronic phase 
compared to blast crisis 
 
The FZD7 gene encodes a member of the Frizzled family that is part of the 7-
transmembrane protein which recognises the WNT ligands to transmit a signal 
intracellularly. It is reported to down regulate APC function while enhancing β-catenin 
mediated signals [224]. The screening showed it to be absent from the optimal 
responder patient (Figure 6.4.3), however when analysed in a bigger cohort of patient 
samples, results revealed there are higher levels in the optimal responders, failure 
patients and patients who later progressed to blast crisis at diagnosis compared to 
patients in blast crisis (Figure 6.4.6 A.). Levels of FZD7  were significantly higher levels 
in the chronic phase cohort compared to blast crisis (P=0.037) (Figure 6.4.6 B.). This 
increase in a member of the FZD receptors in chronic phase could contribute to an up-
regulation of pathway activity correlating with the increase in WNT ligand expression 
seen in Figure 6.4.5. 
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Figure 6.4.6 mRNA levels of FZD7 are significantly higher in chronic phase 
patients vs blast crisis patients 
Patients were grouped as with the WNT ligands, and results showed that FZD7 was 
higher in the diagnostic samples vs patients in blast crisis; however this result was not 
statistically significant  (A.). Levels are significantly higher in chronic phase overall than 
in blast crisis (P=0.037) (B.) 
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6.4.1.3 Levels of NKD1 mRNA expression are significantly higher in chronic phase 
compared to blast crisis 
 
Naked cuticle 1 (NKD1) is a member of the naked cuticle family whose purpose is to 
function as a negative regulator of the Wnt pathway by not only binding to DSH to 
impede the signal transmitting through to the other components of the pathway [225], 
but also by binding directly to β-catenin to inhibit the translocation of β-catenin into the 
nucleus [226].  When comparing an optimal responder patient to a blast crisis patient, 
both at diagnosis, it was absent in the patient’s diagnostic sample who later progressed 
to blast crisis (Figure 6.4.3). When levels of NKD1 were measured in a bigger cohort of 
patient samples, a higher level of NKD1 mRNA expression was seen in the optimal 
responders, failure patients and patients who later progressed to blast crisis at 
diagnosis compared to patients in blast crisis (Figure 6.4.7 A.). This was shown to be 
statistically significant when the patients were grouped into chronic phase vs. blast 
crisis (P=0.013) (Figure 6.4.7 B.). This implies that NKD1 may be being used as a 
negative regulator to compensate for the enhanced expression of the WNT ligands and 
FZD7 shown previously. It has been recently reported that NKD1 is a passive antagonist 
of the pathway that is only activated when there is a surplus of pathway activity [227]. 
This could be the mechanism occurring in chronic phase to stabilise an up-regulation of 
Wnt/β-catenin pathway activity.  
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Figure 6.4.7 mRNA levels of NKD1 are significantly higher in chronic phase 
patients vs blast crisis patients 
Patients were grouped as Figure 6.4.6. Results revealed that NKD1 is higher in the 
optimal responders, failure patients and patients who later progressed to blast crisis at 
diagnosis vs patients in blast crisis (A.). This was statistically significant when  chronic 
phase was compared to  blast crisis (P=0.013) (B.) 
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6.4.1.4 Levels of APC mRNA expression are significantly higher in blast crisis 
compared to chronic phase 
 
Adenomatous polyposis coli (APC) is a component of the Wnt pathway which functions 
as a tumour suppressor by enhancing the phosphorylation and subsequent degradation 
of β-catenin [228] . It acts in the regulation of β-catenin and has been reported to play 
an important role in cancer progression, in particular in colon cancer whereby 
mutations in APC lead to disease progression [220, 221]. While the initial screening 
between two chronic phase diagnostic samples from an optimal responder and a blast 
crisis patient showed no difference in the levels of APC, its importance in malignancies 
[229] led to further investigation in a larger cohort of patients. When grouped according 
to patient outcome at diagnosis and when patients have transformed into blast crisis, 
results showed no significant difference between the cohorts (Figure 6.4.8 A). 
However, when analysed as chronic phase vs blast crisis there are significantly higher 
levels of APC expression in the blast crisis patients compared to chronic phase 
(P=0.026) (Figure 6.4.8 B).   This may be due to the significantly higher levels of FZD7 
found in chronic phase samples which is known to down-regulate APC [224].  
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Figure 6.4.8 mRNA levels of APC are significantly higher in blast crisis compared 
to chronic phase 
Patients were grouped as Figure 6.4.6 and results showed no significant difference in 
APC between patient cohorts. However when stratified by chronic phase vs blast crisis 
there are significantly higher levels of APC in blast crisis (P=0.026) (B.) 
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6.4.1.5 Re-screening of the Wnt/β-catenin pathway genes 
 
To extend our knowledge of what was occurring in CML it was considered appropriate 
to further analyse these genes in a normal control, a failure patient at diagnosis (#9), 
and a patient in blast crisis (#115), alongside the previous optimal responder at 
diagnosis (#29) and the blast crisis patient at diagnosis (#115) (data shown in 
Appendix Figure 8.6). This was intended to give a wider understanding of the 
regulation of the Wnt/β-catenin pathway in all the patient outcomes, however when 
processing the results limitations to this method arose. Firstly screening only one 
patient per cohort reduced the accuracy of this screening significantly. In addition to 
this it proved difficult to determine how much of a change per gene could result in a 
significant effect on the Wnt/β-catenin pathway and its signal transduction, as no 
statistical analysis could be carried out. Therefore, although this screening was a useful 
preliminary overview of what could be occurring to the Wnt/β-catenin pathway 
between different cohorts of patients, it was decided not to base further work on results 
from this screening.  
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6.4.2 Do the transcription factors involved in the Wnt/β-catenin pathway 
correlate with disease progression? 
 
The last stage at which the Wnt/β-catenin pathway can be regulated is through the 
transcription factors which bind β-catenin to the promoter DNA of the targets genes and 
activate transcription [178]. Therefore, the decision was made to further investigate 
these transcription factors and whether they are differentially expressed in the various 
patient cohorts. 
 
6.4.2.1 The transcription factors involved in the Wnt pathway are all higher in 
blast crisis, except TCF3 
 
The transcription factors involved in the Wnt/β-catenin pathway include TCF1, TCF3, 
TCF4, and LEF1 [215]. These all play a significant role in the regulation of 
transcriptional activation, as without them β-catenin is unable to bind to the promoter 
of its target genes and activate their transcription (Introduction section 1.10). 
 
6.4.2.1.1 TCF1 
 
TCF1 has been reported to function as both a tumour suppressor as well as an activator 
of transcription of target genes [215]. Its ability to function as a suppressor is due to a 
large amount of the isoform expressed being spliced leading to the loss of the β-catenin 
binding domain, enabling it to act as a competitor for fully functional isoforms [230]. 
Specifically in lymphomas, TCF1 acts as a repressor of LEF1, shown by both mRNA and 
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protein levels. Without the expression of TCF1, Wnt activity increases causing 
lymphoma progression [231].  
 
TCF1 mRNA levels were analysed by RT-qPCR (Materials and Methods section 2.6.3). 
Results showed levels of TCF1 mRNA are higher in the CML patients who had 
transformed into blast crisis compared to optimal responders, failure patients, and blast 
crisis patients  all at original diagnosis of chronic phase (Figure 6.4.12 A). This was 
shown to be a significant difference when stratified according to chronic phase vs blast 
crisis (P=0.001) (Figure 6.4.12 B). These results indicate that elevated levels of TCF1 
correlate with blast crisis, but do not predict prognosis in chronic phase.  
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Figure 6.4.12 TCF1 mRNA levels are significantly higher in patients who have 
transformed into blast crisis 
Levels of TCF1 were measured according to patient outcome (A.) and according to 
chronic phase vs blast crisis (B.) Results showed higher levels in the patients who have 
transformed into blast crisis compared to diagnostic chronic phase samples from 
optimal responders, failure patients, and patients who later progressed into blast crisis. 
Blast crisis had significantly elevated levels compared to diagnostic samples grouped 
into chronic phase (P=0.001). 
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6.4.2.1.2 TCF3 
 
There have been limited reports of TCF3 and its function in CML. It has been suggested 
that TCF3 functions mainly as a repressor of transcriptional activation [180]. 
Interestingly, TCF3 and TCF1 have been reported to have contrasting roles in the 
regulation of embryonic stem cell self-renewal, with TCF3 suppressing it, while TCF1 
promotes it [232]. However, in breast cancer both mRNA and protein expression of 
TCF3 has been reported to be involved in the regulation of tumour development with 
over-expression correlating with poor differentiation of the disease. In addition, 
reducing TCF3 levels diminished tumour formation [233].   
 
When measuring the mRNA levels of TCF3 in CML patients, results showed higher levels 
in the blast crisis patients compared to the optimal responders, failure patients and 
patients who later progressed to blast crisis at initial diagnosis, however these results 
were not statistically significant (Figure 6.4.13 A). When comparing chronic phase 
overall to blast crisis there was again no statistical difference between the groups 
(Figure 6.4.13 B). This may illustrate that TCF3 is playing less of a role in blast crisis as 
a suppressor of transcription compared to the activational transcription factors. 
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Figure 6.4.13 TCF3 mRNA levels are significantly higher in diagnostic blast crisis 
samples and in blast crisis compared to optimal responders 
TCF3 mRNA levels were also measured according to patient outcome (A.) and according 
to chronic phase vs blast crisis (B.) Results showed higher levels in the patients in blast 
crisis compared to diagnostic cohorts (A.). This was also seen when stratified into 
chronic phase vs blast crisis (B.) however results did not reach a statistical significance.  
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6.4.2.1.3 TCF4 
 
TCF4 is of particular interest as, within CML, TCF4 is known to specifically interact with 
β-catenin which has been directly phosphorylated by BCR-ABL at  tyrosine residues 
Tyr86 and Tyr654, enabling activation of transcription [144]. Additionally it has been 
shown in B-cell CLL that levels of TCF4 were elevated in conjunction with the Wnt target 
gene CCND2, demonstrating the possible importance of the Wnt/β-catenin pathway in 
CLL [234].  
 
Expression levels of TCF4 mRNA are higher in patients who had transformed into blast 
crisis compared to optimal responders, failure patients, and patients who later 
transformed into blast crisis at original diagnosis, however these results did not reach 
statistical significance  (Figure 6.4.14 A). When the results were re-stratified into 
chronic phase compared to blast crisis, TCF4 mRNA levels were significantly higher in 
blast crisis (P=0.016) (Figure 6.4.14 B).  TCF4 has been shown to associate with the 
Tyr654 phosphorylated form of β-catenin to activate transcription [186]. Analysis of 
phospho-β-catenin (Tyr654) showed significantly lower levels in the blast crisis 
patients (Chapter 3 - Figure 3.4.21). To determine if phospho-β-catenin (Tyr654) is 
still associating with TCF4, protein levels of TCF4 would need to be measured and 
immunoprecipitation carried out to ascertain the level of interaction TCF4 is having 
with phospho-β-catenin (Tyr654). It may be the case that, as phospho-β-catenin 
(Tyr654) levels are significantly reduced in patients that have elevated TCF4 levels and 
vice versa, this is not a significant event in CML disease progression.  
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Figure 6.4.14 TCF4 mRNA expression levels are significantly higher in blast crisis 
patients compared to chronic phase 
Levels of TCF4 were measured as before corresponding to patient outcome (A.) and 
according to chronic phase vs blast crisis (B.) Results showed higher levels in the 
patients in blast crisis compared to optimal responders, failure patients, and patients 
who later progressed into blast crisis at diagnosis . When re-stratified, blast crisis  had 
significantly higher levels of TCF4 in comparison to chronic phase (P=0.016). 
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6.4.2.1.4 LEF1 
 
There have been conflicting reports of whether LEF-1 is either an antagonist or agonist 
in the development of different leukaemias. It has been found in cytogenetically normal 
AML that an elevation in LEF1 levels correlated with better cytogenetic response rate, 
overall survival, event-free survival and relapse-free survival. A decrease in LEF1 levels 
conversely correlated with higher blast counts and disease progression [123]. These 
results contradict what has previously been shown with elevated levels of LEF1 
inducing the development of myeloid and lymphoid leukaemia. In B-cell CLL, LEF1 was 
found to be over-expressed and a reduction in the expression of LEF1 reduced the 
survival of CLL cells. This indicates that LEF1 is a pro-survival factor involved in the 
development of CLL [234]. Additionally there have been reports of mutations in LEF1 
taking place in T-cell ALL, and enhanced LEF1 levels correlate with poor prognosis in B-
cell ALL [123]. 
 
Investigation into the mRNA levels of LEF1 in CML patients showed that patients in 
blast crisis have significantly higher levels than the optimal responders (P=0.002), 
failure patients (P=0.008), and blast crisis patients (P=0.008) all at diagnosis (Figure 
6.4.15 A). This result was validated when evaluating according to chronic phase vs blast 
crisis (P=0.003) (Figure 6.4.15 B). This reveals that in CML enhanced LEF1 levels 
correlate with blast crisis.  
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Figure 6.4.15 LEF1 mRNA levels are significantly higher in blast crisis patients in 
comparison to chronic phase 
mRNA levels of LEF1 were measured according to patient outcome (A.) and according to 
chronic phase vs blast crisis (B.) Results for LEF1 showed levels of patients in blast 
crisis being significantly higher than optimal responders, failure patients, and patients 
who progressed into blast crisis at diagnosis (P=0.002, 0.008, and 0.008 respectively). 
Additionally, levels in blast crisis were significantly higher compared to chronic phase 
(P=0.003). 
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6.4.2.2 C-MYC mRNA levels are elevated in blast crisis 
 
The mRNA expression levels of the TCF/LEF transcription factors correlate with poor 
prognosis in CML patients. However, to determine if this is due to enhanced 
transcriptional activation of Wnt target genes, the expression levels of  known target 
genes of the Wnt/β-catenin pathway (CYCLIN D1 and C-MYC) were investigated (see 
Methods section 2.6). Results show that there is no significant difference between 
patient cohorts in CYCLIN-D1 and C-MYC levels (Figure 6.4.11 A. and B.).  However, 
when comparing chronic phase to blast crisis, there are significantly elevated levels of 
C-MYC in blast crisis (P=0.038) (Figure 6.4.11 D.). This activation of transcription of C-
MYC in blast crisis correlates with significantly higher levels of C-MYC protein seen in 
Chapter 4, Figure 4.4.14 C. This implies that the transcription factors are functioning 
as transcriptional activators; however there are other factors which regulate the 
expression of C-MYC which could be contributing to the increase seen.  
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Figure 6.4.11 Blast crisis patients have significantly higher levels of C-MYC but not 
CYCLIN D1 gene expression 
Levels of CYCLIN D1 and C-MYC were measured according to patient outcome (A. and B.) 
and according to chronic phase vs blast crisis (C. and D.) Results showed that there was 
no change in the levels of CYCLIN D1 for either analysis, however for C-MYC there were 
significantly elevated levels in blast crisis compared to chronic phase (P=0.038) (D.). 
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6.4.3 The Wnt transcription factors in relation to GSK3β and CIP2A 
 
In this chapter it has been observed that in chronic phase there is a significant increase 
in Wnt/β-catenin pathway activation, seen through an up-regulation of the WNT 
ligands. This is contradictory to the observation of there being an up-regulation in the 
transcription factors in blast crisis. This, alongside the fact that it has been established 
that the transcription factors TCF1 and LEF1 can also function independently of the 
Wnt/β-catenin signalling pathway[178], instigated the investigation as to whether there 
is a relationship between the transcription factors and either GSK3β which was seen to 
have decreased activity in blast crisis, or CIP2A a predictive biomarker of disease 
progression. 
 
6.4.3.1 GSK3β knockout does not significantly affect the mRNA levels of the Wnt 
transcription factors 
 
To determine whether GSK3β had any effects on the expression of the Wnt transcription 
factors siRNA inhibition of GSK3β (previously optimised in chapter 5, section 5.3.1) 
was carried out in K562 cells and mRNA was extracted from the cultures to perform RT-
qPCR (N=3) (Materials and Methods section 2.6). Results showed that inhibition of 
GSK3β had no effect on the levels of TCF1 expression. Meanwhile, there is a reduction in 
the expression of TCF3, TCF4, and LEF1 when GSK3β has been knocked out (Figure 
6.4.17) however these data did not reach statistical significance, indicating GSK3β does 
not play a significant role in the regulation of the transcription factors expression. 
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Figure 6.4.17 Knock out of GSK3β by siRNA does not significantly affect the mRNA 
expression levels of the Wnt transcription factors 
siRNA was used to knock out GSK3β in K562 cells and then mRNA levels of TCF1 (A.), 
TCF3 (B.), TCF4 (C.), and LEF1 (D.) were measured. GSK3β knockout has no effect on the 
levels of TCF1. It does decrease the levels of TCF3, TCF4, and LEF1 however this 
reduction is not significant. 
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6.4.3.2 The mRNA expression of the transcription factors TCF4 and LEF1 are 
significantly higher in patients with high CIP2A 
 
Next, to see any correlation of the Wnt transcription factors with CIP2A, the patients 
were stratified according to CIP2A protein levels (MFI >7 or < 7). Results showed higher 
TCF4 and LEF1 mRNA levels in high CIP2A patients (P=0.012 and 0.016 respectively) 
(see Figure 6.4.19 C. and D.).  There are no reports of CIP2A being linked with the 
WNT transcription factors, however these results show that patients with high CIP2A 
levels also have elevated levels of the transcription factors. The mechanism by which 
this occurs would need further investigation.  
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Figure 6.4.19 High CIP2A correlates with significantly higher levels of TCF4 and 
LEF1 
Patients were stratified into low CIP2A (MFI<7) (N=8) and high CIP2A (MFI>7) (N=5) 
groups and correlated with the mRNA levels of the WNT transcription factors. Results 
show high CIP2A correlates with increased levels of all the transcription factors. This 
was significant for TCF4 (P=0.012) (C.) and LEF1 (P=0.016) (D.). 
 
 
6.4.3.3 High CIP2A levels also correlate with increased expression of the Wnt 
target genes CYCLIN D1 and C-MYC  
 
The mRNA levels of CYCLIN D1 and C-MYC were also stratified according to their CIP2A 
protein levels (Figure 6.4.20) and results showed that levels of both CYCLIN D1 and C-
MYC were elevated in patients with high CIP2A levels (P=0.06 and 0.28 respectively). 
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This correlates with increased expression of the TCF/LEF transcription factors shown in 
Figure 6.4.19 and their association with poor prognosis.  
 
 
Figure 6.4.20 High CIP2A correlates with elevated levels of both CYCLIN D1 and C-
MYC 
Patients were separated into low CIP2A (MFI<7) and high CIP2A (MFI>7) and CYCLIN 
D1 and C-MYC mRNA levels were measured. Results show high CIP2A protein levels 
correlate with increased (A.) CYCLIN D1 levels (P=0.06) and (B.) C-MYC levels (P=0.28). 
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6.5 Main Conclusions 
 
The Wnt pathway is known to play an important role in the development of several 
malignancies; however its regulation is very complex with numerous factors involved at 
different stages of the pathway, some of which were detailed in Table 6.1.1.  
 
The main conclusions obtained from this chapter include; 
1) The Wnt ligands WNT1, WNT8A, and WNT9A were significantly higher in chronic 
phase compared to blast crisis indicating an up-regulation of Wnt pathway activity 
in chronic phase MNCs.  
 
2) FZD7 is also significantly up-regulated in chronic phase patients, correlating with 
the elevated transcription of the Wnt ligands. 
 
3) This apparent up-regulation in the Wnt/β-catenin pathway could be being 
modulated by NKD1 which acts as a negative regulator of the pathway. Significantly 
higher levels of NKD1 were also found in chronic phase compared to blast crisis 
which could suggest a feedback mechanism of the pathway of intrinsic regulation 
when the pathway is activated. To determine if this is occurring, protein levels 
would need to be investigated to see if they correlate with what is seen in mRNA 
levels. 
 
4) APC showed a significant increase in blast crisis compared to chronic phase. 
Ordinarily, it functions as part of the destruction complex to degrade β-catenin, 
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however mutations of APC have been implicated specifically in colon cancer to 
correlate with poor prognosis [220, 221]. To determine if this is occurring in CML, 
mutational analysis of APC would need to be carried out to determine its 
functionality in the disease. Interestingly, FZD7 has also been reported to down-
regulate APC function whilst enhancing β-catenin mediated signals [224]. This 
could be a reason why APC is low in the chronic phase patients when FZD7 is 
significantly higher, and vice versa in blast crisis patients. 
 
5) All four transcription factors show a significant difference between individual 
patient cohorts and TCF1, TCF4 and LEF1 have significantly higher expression levels 
in blast crisis compared to chronic phase. These results suggest their role as 
transcriptional activators within CML which correlates with blast crisis. TCF3 is 
known to function mainly as a repressor of transcriptional activation [180] which 
could be why it is not significantly up-regulated in  blast crisis similar to the other 
transcription factors.  
 
6) Patients with high CIP2A protein levels have significantly increased mRNA levels of 
TCF4 and LEF1 which correlates with an increase in the target genes CYCLIN D1 and 
C-MYC. This could suggest an alternative method of transcriptional activation 
through up-regulation of TCF4 and LEF1 either directly or indirectly through CIP2A. 
The mechanism by which this occurs needs investigating.  
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Chapter 7 – General Discussion and 
Future Work 
 
The aim of this thesis was to obtain a better understanding of the effects and/or 
contribution of the Wnt/β-catenin signalling pathway in the development and 
progression of CML. Certain aspects of the pathway were prioritised following a review 
of the literature. The main objectives decided were to; 
 
1) Determine if the levels of β-catenin and its phosphorylated forms in MNCs are 
predictive of clinical outcome in imatinib treated patients or differ in relation to 
patient treatment response groups. 
2) Determine if BCR-ABL1 mediated -catenin phosphorylation on Tyr654 
correlates with disease progression. 
3) Investigate phospho-GSK3β Ser9 and phospho-GSK3β Tyr216 to determine if 
GSK3β’s activity differs in relation to patient outcome. 
4) Examine what regulates GSK3β’s activity in CML. 
5) Determine if GSK3β activity correlates with C-MYC degradation. 
6) Screen the Wnt/β-catenin pathway and analyse any of the genes which appear to 
be different between the response groups in a larger patient cohort. 
7) Investigate the transcription factors involved in the Wnt/β-catenin pathway to 
see if they are differentially expressed in the various patient cohorts. 
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7.1 Levels of β-catenin do not correlate with patient outcome 
 
Analysis of β-catenin was initially performed as it has previously been implicated in 
CML disease progression, with unphosphorylated levels having been reported to be up 
regulated in GMPs of blast crisis patients [150]. Investigation into whether this finding 
is also true in MNCs, and whether the phosphorylation status of β-catenin correlates 
with patient outcome, was undertaken to gain a better understanding of the role of β-
catenin in CML. 
 
After initial detection of elevated protein levels of β-catenin in primary CML MNCs at 
diagnosis, the question of whether -catenin mRNA and/or total protein levels can be 
used to distinguish between the different patient cohorts and/or be used to 
differentiate between disease stages was addressed. Results from both mRNA 
expression and total protein levels, show that these levels cannot be used to distinguish 
between different patient response cohorts and do not differentiate between stages of 
disease progression using MNCs. It was considered that β-catenin (CTNNB1) mRNA 
levels may be important in response to treatment as levels reduced after 12 months 
imatinib treatment towards levels found in healthy donors due to the leukaemic cells 
being replaced with normal cells. . This was also shown in patients treated with the 
second generation TKIs (dasatinib and nilotinib), with a significant reduction in β-
catenin mRNA levels seen in the optimal responders after 12 months treatment (P=0.05 
and 0.001 respectively), suggesting that patients who respond well to treatment, 
irrespective of the drug they receive, have a significant reduction in β-catenin mRNA 
levels after 12 months treatment. Results for total β-catenin protein have not previously 
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been found to correlate with disease progression in CML, and considering the activity of 
β-catenin is regulated by its phosphorylation status this would explain why total levels 
are not providing insight into the role of β-catenin in CML. 
 
To determine whether the activity and degradation of β-catenin differs in relation to 
patient outcome in MNCs, the phosphorylation status of β-catenin was investigated in 
the different patient cohorts.  The levels of unphosphorylated β-catenin, used to 
represent the active form of β-catenin, and phospho-β-catenin (Ser45/Thr41), used to 
represent the form of β-catenin targeted for degradation, were measured. Analysis of 
unphosphorylated β-catenin showed no difference when investigating the various 
patient cohorts. When comparing chronic phase to blast crisis, levels were higher in 
blast crisis, correlating with what was seen in GMPs [150], however this difference was 
not statistically significant. Additionally, levels of phospho-β-catenin (Ser45/Thr41) 
were analysed, similarly results showed no variation between patient cohorts, however, 
levels decrease when patients have transformed into blast crisis compared to chronic 
phase. This correlates with the increase in unphosphorylated β-catenin shown. 
However, since neither of these trends reach a statistical significance, this suggests 
while β-catenin is important in achieving the full leukaemic potential of primitive 
leukaemic cells, as the cells progress to become more differentiated they are less 
dependent on β-catenin signalling for their survival, a finding that was also recently 
noted by Heidel et al., [185]. This could explain why the results found for GMPs by 
Jamieson et al.,[150] were not reproducible in MNCs. 
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Subsequent analysis by nuclear and cytoplasmic extraction to investigate subcellular 
localisation of the various forms of β-catenin showed that phospho-β-catenin 
(Ser45/Thr41) is not solely found in the cytoplasm but it is also detected in the nucleus. 
Maher et al., [149] also found this to be the case whereby β-catenin phosphorylated on 
Ser45/Thr41 can localise in the nucleus, unlike β-catenin phosphorylated on 
Ser33/37/Thr41. This suggests that phosphorylation of β-catenin by CK1 may have a 
dual effect on the activity and localisation of β-catenin, not only priming it for 
phosphorylation by GSK3β and subsequent degradation by the proteasome, but also by 
targeting it for nuclear import [149]. An additional question that this finding asks is 
that, if β-catenin phosphorylation on Ser45 by CK1 and Thr41 by GSK3β is occurring, 
what is preventing the phosphorylation on Ser37/33 by GSK3β that allows β-catenin to 
remain in the cytoplasm and degradation to occur instead of translocating to the 
nucleus? This rendered the use of phospho-β-catenin (Ser45/Thr41) unsuitable to 
assess β-catenin degradation and hence the Ser33/37/Thr41 phosphorylated form of β-
catenin should be used as a marker of cytoplasmic β-catenin, and consequently, the 
form targeted for degradation. 
 
Phospho-β-catenin (Ser33/37/Thr41) was therefore added to confocal microscopy 
analysis. From this evaluation a relationship was identified between the various forms 
of β-catenin in individual patients. This was shown by higher levels of 
unphosphorylated β-catenin correlating with low levels of phospho-β-catenin (both 
Ser45/Thr41 and Ser33/37/Thr41). Conversely, when levels of phospho-β-catenin 
(again, both Ser45/Thr41 and Ser33/37/Thr41) were elevated, the levels of 
unphosphorylated β-catenin were low. This shows that regulation of β-catenin by its 
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phosphorylation status is still functioning in CML MNCs, but β-catenin levels in MNCs 
cannot be used to distinguish between patient cohorts. 
 
Due to results not showing a difference in the various forms of β-catenin between 
patient cohorts, CML cell lines were treated with bortezomib, WNT3A and WIF1 to 
address the question of what is happening to β-catenin in CML. Bortezomib (a 
proteasome inhibitor) increased the levels of total and unphosphorylated β-catenin, 
while decreasing phospho-β-catenin (Ser33/37/Thr41). This suggests that in the CML 
cell lines, β-catenin is being actively degraded by the cell and this could be why no 
difference is being detected in the levels of β-catenin. Meanwhile, results seen with 
WIF1 (Wnt pathway inhibitor) and Wnt3A (Wnt pathway activator) did not show the 
expected trend on β-catenin levels, suggesting that the Wnt pathway is not actively 
enhanced in CML MNCs. To substantiate this finding, the effects of bortezomib, Wnt3A, 
and WIF1 should be tested in patient samples to see if the results from cell lines are 
replicable. This would give a better understanding of what is happening to β-catenin in 
patient MNCs. However, as results were suggesting that β-catenin is not effective in 
differentiating between patient groups, it was decided to investigate whether any other 
aspects of the Wnt/β-catenin pathway are important in distinguishing between the 
response cohorts. 
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7.2 Levels of BCR-ABL1 mediated phosphorylation of β-catenin are 
significantly higher in chronic phase compared to blast crisis 
 
BCR-ABL1 is known to be able to phosphorylate β-catenin directly on Tyr86 and Tyr654 
to prevent the association of β-catenin with the destruction complex and target it to the 
nucleus to activate transcription [186], therefore in CML this could have a role in 
disease progression. Coluccia et al., [186] found that there was a correlation between 
BCR-ABL1 expression and nuclear localisation of tyrosine phosphorylated β-catenin in 
blast crisis patients. In this analysis, it was decided to investigate the Tyr654 
phosphorylation of β-catenin as it is known to associate with the basal transcription 
factor TATA-binding protein to enhance transcription [235]. Analysis of this form of β-
catenin showed no difference in the levels of Tyr654 phosphorylation between the 
patient cohorts at diagnosis. This is consistent with the view that BCR-ABL1 activity is 
similar in all patients at initial diagnosis as it will not yet have, in most cases, developed 
mutations or altered activity as a consequence of exposure to imatinib [190]. Levels 
showed a decrease after 12 months of imatinib treatment, which is anticipated as the 
BCR-ABL1 driven phosphorylation of β-catenin would be removed as leukaemic cells 
are replaced with normal cells. When comparing chronic phase to blast crisis there was 
a significant decrease in Tyr654 phosphorylation in patients in blast crisis (p=0.012). 
This could be representative of CML becoming BCR-ABL1 independent at disease 
transformation [191, 236]. Additionally, a further explanation for this could be that the 
evolution of kinase domain mutations in BCR-ABL1 at disease progression [60] could 
alter its ability to phosphorylate β-catenin on Tyr654. To examine if this is the case, 
patients with specific BCR-ABL1 mutations would need to be investigated for their 
levels of phospho-β-catenin (Tyr654), a line of investigation limited by the availability 
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of patient material. Alternatively, the various mutated forms of BCR-ABL1 could be 
transfected into an originally BCR-ABL1 negative cell line and its influence on the levels 
of phospho-β-catenin (Tyr654) measured. When analysing the localisation of phospho-
β-catenin (Tyr654) in cell lines, levels were elevated in the nucleus compared to the 
cytoplasm, confirming the localisation of phospho-β-catenin (Tyr654) as found by 
Coluccia et al., [186].  
 
7.3 GSK3β’s activity is significantly reduced in blast crisis by both 
increased phospho-GSK3β Ser9 and decreased phospho-GSK3β 
Tyr216 
 
Abrahamsson et al., [101] demonstrated a decrease in GSK3β protein expression as 
patients progress through the disease, however GSK3β protein overall does not reveal 
the kinase activity of GSK3β due to its regulation by its phosphorylation status. 
Consequently, it was of interest to examine phospho-GSK3β Ser9, which inhibits GSK3β, 
and phospho-GSK3β Tyr216, which enhances GSK3β activity [152, 155, 156], to 
determine if the activity of GSK3β differs in relation to patient outcome. Results showed 
there was a significant decrease in GSK3β activity in those patients who have 
transformed into blast crisis, which was demonstrated by opposing trends in Ser9 and 
Tyr216 phosphorylation. Elevated levels of phospho-GSK3β Ser9 were found in those 
patients who had transformed into blast crisis compared to those in chronic phase 
(P=0.026), which correlated to reduced levels of phospho-GSK3β Tyr216 in the patients 
who have transformed into blast crisis compared to the chronic phase patients 
(P<0.001). In addition significantly higher MCL-1 protein levels were found in patients 
in blast crisis (P<0.001 for both long and short forms), possibly due to the activity of 
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GSK3β being impaired in blast crisis and therefore it cannot act to phosphorylate and 
degrade MCL-1. The results, however, were not reflected in the levels of β-catenin as 
previously discussed (section 7.1).  A decrease in GSK3β activity would be predicted to 
increase unphosphorylated β-catenin, although as the Wnt/β-catenin pathway is not the 
only signalling pathway affecting GSK3β this may explain why no significant difference 
was seen in the levels of β-catenin between chronic phase and blast crisis. CML cell line 
material was incubated with the GSK3β inhibitor SB216763 and results confirmed that 
GSK3β is acting to degrade β-catenin in CML, with unphosphorylated (active) β-catenin 
increasing with inhibition by SB216763, while phospho-β-catenin (Ser33/37/Thr41) 
decreased with inhibition. This substantiates the question of whether the Wnt/β-
catenin pathway is regulating the activity of GSK3β in CML, or whether it is functioning 
independently of β-catenin, a theory also stipulated by Reddiconto et al., [164]. 
Alternatively, the results could reflect that, while GSK3β is integral in the 
phosphorylation-dependent degradation of β-catenin, it is not the component of the 
destruction complex which is controlling the level at which β-catenin is degraded as it 
has been suggested that a decrease in GSK3β may be compensated by a replacement 
with GSK3α [152]. It is also considered that AXIN acts as a limiting factor in Wnt/β-
catenin signalling due to lower quantities of the molecule being present in the cells 
compared to the other components of the degradation complex. This consequently 
means it could be a key factor in regulating the stability of β-catenin in the cell [88]. It is 
therefore of interest to determine what is impacting the activity of GSK3β, due to the 
significant change seen in disease progression, and whether this decrease in activity is 
in turn affecting other substrates which are central in CML development.  
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When investigating mRNA levels of GSK3β, results showed increased levels in patients 
who subsequently transformed into blast crisis, and patients in blast crisis, compared to 
optimal responders and failure patients at diagnosis. The decrease in GSK3β activity 
shown via protein levels could be a reason why message levels are elevated in those 
patients in blast crisis as a mechanism to compensate for the decrease in GSK3β activity.  
 
7.4 PP2A acts as a regulator of GSK3β 
 
As the activity of GSK3β was shown to correlate with patient outcome, it was of 
importance to determine what was regulating this activity. Initially three TKIs (imatinib, 
dasatinib and nilotinib) were tested in vitro to determine if GSK3β activity was under 
the control of BCR-ABL1. Reddiconto et al., [164] showed that in vitro treatment with 
imatinib in CML chronic phase patients increased the levels of Tyr216 phosphorylation 
of GSK3β while dasatinib reduced it. The effects on Ser9 phosphorylation were not 
tested. My results showed there was no difference in the two forms of phospho-GSK3β 
on treatment with the TKIs. The results for Tyr216 phosphorylation may be 
contradictory due to the difference in material used to examine the effects of TKIs on 
GSK3β levels.  
Next, the Wnt/β-catenin pathway was tested in vitro to see if it played a part in the 
regulation of GSK3β activity using Wnt3A as a pathway activator and WIF-1 as a 
pathway inhibitor. Results showed Wnt3A decreased Tyr216 phosphorylation of GSK3β, 
revealing that activation of the Wnt/β-catenin pathway causes inhibition of GSK3β. 
Results from WIF1 treatment showed no impact of GSK3β activity which implies the 
Wnt/β-catenin pathway may be maximally inhibited in cells. This correlates with the 
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results obtained from bortezomib incubation showing that β-catenin is being degraded 
by the cell. To determine if this is also the case between patient cohorts, samples from 
the different outcomes could be incubated with WIF1 and Wnt3A to determine if 
regulation of the Wnt/β-catenin pathway affects both GSK3β and β-catenin levels. If the 
Wnt/β-catenin pathway is inhibited in MNCs through all stages of the disease, this may 
be why a difference is not seen in the levels of β-catenin between cohorts. 
 
Finally, the effects of PP2A activation and inhibition on the activity of GSK3β were 
investigated by incubation with FTY720 (a PP2A activator) and okadaic acid (a PP2A 
inhibitor). PP2A is a serine/threonine phosphatase which acts as part of the destruction 
complex in the Wnt pathway and is known to de-phosphorylate GSK3β on Ser9 [170]. 
Activation of PP2A via FTY720 reduces levels of phospho-GSK3β Ser9, while inhibition 
of PP2A via okadaic acid increases levels of phospho-GSK3β Ser9. These results show 
that PP2A can regulate the activity of GSK3β in CML via controlling its inhibition. 
Additionally, Lucas et al., [176] showed that PP2A has high importance in CML in 
correspondence with CIP2A [176], therefore the relationship between GSK3β and PP2A 
was examined further.  
GSK3β is also known to influence PP2A indirectly through its phosphorylation status 
[202, 203]. To examine whether this is occurring in CML, GSK3β was inhibited by both 
SB216763 and siRNA and the effects on the PP2A pathway were measured. Results from 
the two forms of inhibition had contradictory outcomes. This is due to SB216763 and 
siRNA having opposite effects on Ser9 phosphorylation of GSK3β. Inhibition with 
SB216763 causes an increase in Ser9 phosphorylation which explains the decrease in 
Tyr307 phospho-PP2A levels observed via PTP1B, as inhibition of GSK3β increases 
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PTP1B and enables dephosphorylation of PP2A on Tyr307 to occur. In contrast, 
knockdown of GSK3β by siRNA reduced the levels of Ser9 phosphorylation on GSK3β 
which resulted in an increase in Tyr307 phosphorylation of PP2A shown, as GSK3β is 
unable to increase levels of PTP1B, preventing the dephosphorylation of PP2A at 
Tyr307. This difference in the effects of GSK3β inhibition by different methods suggests 
careful consideration if using GSK3β as a therapeutic target as considered by 
Reddiconto et al., [164]. The results for CIP2A, SET and BCR-ABL1 activity (p-
CrKL/CrKL ratio) are opposite to what would be predicted for the levels of PP2A shown, 
implying that although GSK3β can act to regulate PP2A, this effect does not translate to 
the inhibitors of PP2A. Additionally, although active PP2A has been reported to 
decrease BCR-ABL1 activity through the tyrosine phosphatase SHP-1 [173, 175], PP2A 
may not be acting to down-regulate BCR-ABL1 activity in CML. 
 
Investigation into the levels of the PP2A pathway in primary CML MNCs showed that 
there was a trend for both phospho-PP2A (Tyr307) and the PP2A inhibitor SET to have 
higher levels in blast crisis compared to chronic phase, consistent with GSK3β activity 
being reduced in blast crisis. Elevation of SET (which correlates with a rise in inactive 
PP2A) suggests that PP2A is unable to dephosphorylate GSK3β on Ser9 in blast crisis, 
resulting in a decrease in GSK3β activity as observed. In relation to the alternative PP2A 
inhibitor CIP2A, patients who had high levels of CIP2A had a reduction in both forms of 
GSK3β. However, manipulation of CIP2A by both siRNA and transient transfection 
produced contradicting results to what was seen in patients. In K562 cells decreasing 
levels of CIP2A results in a decrease in phospho-GSK3β (Ser9), whereas increasing 
CIP2A levels increases phospho-GSK3β (Ser9). This correlates with the hypothesis of 
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PP2A regulating GSK3β activity by showing that increased levels of CIP2A result in an 
increase in GSK3β. This suggests that CIP2A is inhibiting PP2A, preventing its ability to 
de-phosphorylate GSK3β on Ser9. GSK3β may in turn feedback on itself to increase its 
activity by autophosphorylation of Tyr216. However, neither siRNA knockdown, nor 
transfectional upregulation of CIP2A showed a considerable effect on the levels of 
GSK3β, indicating that the inhibitory effect that CIP2A has on PP2A is not being 
translated to the levels of GSK3β. 
  
It is known that CIP2A is able to regulate E2F1 [205], which in turn is known to 
correlate, alongside C-MYC, with increased levels of unphosphorylated -catenin [206]. 
Therefore it was of interest to determine whether -catenin correlates with CIP2A. 
Results from matched patient samples showed that there is an increase in 
unphosphorylated -catenin in patients with high CIP2A levels. However whether this is 
directly due to CIP2A was questionable therefore transient transfection was used to 
increase CIP2A levels and investigate -catenin levels. Results showed that increased 
CIP2A generated an increase in unphosphorylated -catenin, which correlated with a 
decrease in phospho--catenin (Ser33/37/Thr41) to be targeted for degradation. This 
shows that CIP2A increases active β-catenin, enabling it to activate transcription of its 
target genes, at the same time as reducing β-catenin’s degradation. This implies that 
CIP2A can regulate the levels of β-catenin but as results do not show a significant 
difference, it is not a vital component involved in its control. Unfortunately due to the 
transfection also increasing E2F1 levels, no conclusion can be made as to whether 
CIP2A is having a direct effect on β-catenin or whether it is acting indirectly through 
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E2F1. However, as CIP2A does not have a significant effect on β-catenin levels it was not 
deemed important to continue this line of investigation. 
 
7.5 GSK3β is not the rate-limiting step of C-MYC degradation 
 
GSK3β has a multitude of targets including C-MYC [152], a known oncogene which has 
been shown to be important in CML development [198]. Phosphorylation of C-MYC by 
GSK3β is relevant to C-MYC degradation. The protein kinase ERK initiates the sequence 
of events by the phosphorylation of C-MYC on Ser62. This activates C-MYC and if GSK3β 
is available this phosphorylation by ERK acts as a priming phosphorylation to allow C-
MYC phosphorylation on Thr58. Once phosphorylated on Thr58, PP2A removes the 
Ser62 phosphorylation, allowing addition of an ubiquitin tag to C-MYC promoting its 
degradation by the proteasome (Chapter 4, Figure 4.4.13) [237]. Results showed that 
the activity of GSK3β is significantly reduced in blast crisis patients; therefore it was of 
interest to see whether this impacts on the degradation of C-MYC. In patient samples, 
levels of phospho- C-MYC (Thr58) did not change when comparing chronic phase to 
blast crisis, while levels of total C-MYC were significantly higher in blast crisis 
(P=0.024). In addition to this, inhibition of GSK3β by both SB216763 and siRNA reduced 
the levels of Thr58 phosphorylation but had no effect on total levels of C-MYC, 
corroborating with the results in patients, that GSK3β is not the rate limiting component 
in C-MYC degradation. Another stage at which C-MYC degradation could be regulated is 
by the removal of the Ser62 phosphorylation by PP2A. Total PP2A levels were 
significantly higher in blast crisis compared to chronic phase (P=0.013), with no 
significant rise in the levels of inactive PP2A. This contradicts what would be expected 
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as increased levels of active PP2A would correlate to increased removal of Ser62 
phosphorylation, allowing C-MYC to be degraded in blast crisis. Instead there is a 
significantly higher level of total C-MYC seen in blast crisis compared to chronic phase. 
This suggests that neither GSK3β nor PP2A are controlling the rate of C-MYC 
degradation. While this study was being undertaken it was reported that FBXW7, an E3 
ubiquitin ligase responsible for the ubiquitination of C-MYC, is an alternative 
mechanism by which C-MYC degradation can be regulated. FBXW7 has been shown to 
function by controlling the stability of C-MYC in haemopoietic stem cells. This was 
demonstrated by deletion of the FBXW7 gene causing elevated levels of C-MYC protein 
expression [198, 200, 201]. This, alongside the results showing that GSK3β and PP2A 
are not regulating C-MYC degradation, suggests that the ubiquitination of C-MYC by 
FBXW7 is a possible controlling factor of C-MYC degradation. 
 
To develop this line of enquiry further the levels of FBXW7 would need to be 
investigated in the patient samples to determine if there was a difference between blast 
crisis and chronic phase which correlates to the difference in C-MYC levels. Additionally, 
it has been reported in T-cell ALLthat mutations have been found in FBXW7 which 
affect the ubiquitination and the half-life of C-MYC [238]. Consequently, mutational 
analysis of FBXW7 in CML patients could be carried out to determine if there is a 
difference between the patient responses. 
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7.6 Gene analysis of WNT1, WNT8A, WNT9A, FZD7, NKD1 and APC 
showed significant differences between patient cohorts 
 
The overall PCR screening of the Wnt/β-catenin pathway had limitations which 
prevented definitive conclusions being made.  However, it did lead to the selection of a 
few genes to be investigated in a larger patient cohort. These were; WNT1, WNT8A, 
WNT9A, FZD7, and NKD1. In addition, APC was also examined due to it being implicated 
in other malignancies [220, 221]. Results show that the three WNT ligands, along with 
FZD7 had significantly higher levels of mRNA expression in chronic phase compared to 
blast crisis (P=0.011, 0.045, 0.037 and 0.037 respectively), indicating an up-regulation 
of Wnt pathway activity in patients in chronic phase. This finding, however, is not 
consistent with elevated levels of β-catenin indicating that although there may be an 
elevation at the start of the pathway this is not transferred downstream to β-catenin. A 
reason for this could be that along with the WNT ligands and FZD7, NKD1 is also 
significantly elevated in chronic phase (P=0.013). NKD1 acts as a negative regulator of 
the pathway and therefore could imply that there is a feedback mechanism of the 
pathway of intrinsic regulation when the pathway is activated [226]. This could be why 
this increase in pathway activity is not reflected in elevated levels of β-catenin. To 
determine if this is occurring, protein levels would need to be investigated to see if they 
correlate with what is seen in mRNA levels. 
 
 
293 |  P a g e
 
Figure 7.1 Potential mechanism to prevent an increase in unphosphorylated β-
catenin in Chronic phase CML MNCs 
 
 
 
When examining APC mRNA, levels were significantly higher in blast crisis compared to 
chronic phase (P=0.026). APC is part of the destruction complex which acts to degrade 
β-catenin. Jamieson et al., [150] previously showed that β-catenin is up-regulated in 
GMPs of blast crisis; however my analysis of MNCs showed that there was no significant 
difference between patient cohorts (optimal vs. failure vs. blast crisis, and chronic phase 
vs. blast crisis). This could be due to other aspects of the Wnt pathway, such as APC, 
being more active in differentiated cells than in earlier compartments, and down-
regulating the Wnt pathway signal before it reaches β-catenin. An alternative 
explanation as to why APC is low in chronic phase and high in blast crisis could be due 
to FZD7. FZD7 has been reported to down regulate APC function [224] and the results 
for FZD7 show the opposite trend to APC indicating that this could be occurring in CML 
cells. Mutations of APC have been implicated in other malignancies, the most common of 
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which is in colon cancer where they correlate with poor prognosis [220, 221]. To 
determine if this is also occurring in CML, mutational analysis of APC needs to be carried 
out to determine its functionality in the disease.  
 
7.7 The transcription factors TCF1, TCF4, and LEF1 are all significantly 
higher in blast crisis patients compared to chronic phase 
 
The final stage at which regulation of the Wnt/β-catenin pathway can occur is via the 
transcription factors. They act as a binding site for both β-catenin and the promoter 
DNA of target genes to allow activation of transcription, and without them, β-catenin is 
unable to bind to DNA and transcription cannot occur [122, 123, 178]. Levels of mRNA 
were measured according to patient outcome, and comparing chronic phase to blast 
crisis. All four transcription factors show a significant difference between individual 
patient cohorts. TCF1, TCF4 and LEF1 have significantly higher levels of expression in 
blast crisis compared to chronic phase (P=0.001, 0.016, and 0.003 respectively). TCF3 
also has elevated levels but this is not statistically significant. These results suggest their 
role as transcriptional activators within CML which correlates with poor prognosis. 
TCF3 is known to function mainly as a repressor of transcriptional activation [180] 
which could be why it is not significantly up-regulated in blast crisis similar to the other 
transcription factors. In addition, as an upregulation of the Wnt/β-catenin pathway 
activity was not seen in blast crisis patients, this suggests that the reports of the 
transcription factors acting independently of the Wnt/β-catenin pathway in other 
haematological malignancies [178, 239, 240] may also be true for CML. It has been 
reported in haematological malignancies that the ATF2 transcription factors can 
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interact with TCF/LEF, resulting in enhanced transcription of target genes [178].  To 
investigate whether this is occurring in CML, the relationship between the ATF2 and 
TCF/LEF transcription factors would need to be studied further, potentially through 
manipulation of the ATF2 transcription factors by siRNA and transient transfection and 
measuring the effect on target genes, to determine if they are regulating the activity 
Wnt/β-catenin transcription factors. 
 
Regulation of the TCF/LEF transcription factors not only occurs through their 
expression levels, but also through post-translational modifications which impact their 
activity status. These include phosphorylation, sumoylation, ubiquitination and 
acetylation, all of which can regulate the association of the transcription factors with co-
activators, repressors or DNA [87, 95, 179, 180]. With this knowledge, to further 
progress this work it would be of interest to not only investigate whether this difference 
in mRNA levels translates also to protein levels, but also whether post-translational 
modifications are playing a role in the regulation of the transcription factors and 
whether there is a difference between the patient cohorts. Finally, the levels of the co-
activators and co-repressors which act on the transcription factors should be analysed 
to see which, if any, correlate with disease progression. 
 
From observations that there is an up-regulation in the transcription factors in blast 
crisis which does not correlate with other aspects of the Wnt/β-catenin pathway, 
alongside the fact that it has been established that the transcription factors TCF1 and 
LEF1 can also function independently of the Wnt signalling pathway[178], instigated 
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the investigation as to whether there is a relationship between the transcription factors 
and either GSK3β or CIP2A. Results showed that there are significantly higher levels of 
TCF4 and LEF1 in patients who have high CIP2A protein levels which correlated with an 
elevation in the levels of target genes CYCLIN D1 and C-MYC. This could suggest an 
alternative method of transcriptional activation through up-regulation of TCF4 and 
LEF1 either directly or indirectly through CIP2A. CIP2A has not previously been linked 
with the Wnt/β-catenin transcription factors; however, a potential mechanism by which 
CIP2A could be regulating the TCF/LEF transcription factors may be through CYCLIN 
D1. It has been reported in ovarian cancer that a decrease in CIP2A correlated with a 
decrease in CYCLIN D1 levels [241]. This, alongside the increase in CYCLIN D1 found in 
those CML patients with high CIP2A protein levels, suggests that CIP2A may be involved 
in regulating CYCLIN D1. Additionally both CIP2A [205] and CYCLIN D1 [242] are 
modulated by E2F1 further facilitating the mechanism by which CIP2A and CYCLIN D1 
could interact. It has been detailed that CYCLIN D1 can act to regulate the activity of 
various transcription factors as well as transcriptional co-activators and co-repressors 
[243, 244], although the TCF/LEF transcription factors have not been specified. This 
could imply that CIP2A is regulating CYCLIN D1 levels, which is then adjusting the 
activity of the TCF/LEF transcription factors. To test whether this hypothesis is 
accurate, the first aspect which would need to be established is whether CYCLIN D1 is 
acting to regulate the TCF/LEF transcription factors. This could be done using an 
inhibitor of CYCLIN D1 to see its effects on the TCF/LEF levels. If this was confirmed, the 
levels of CIP2A could then be manipulated by siRNA and transient transfection to see 
the effects on CYCLIN D1 and the transcription factors.   
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7.8 Overall Conclusion 
 
In conclusion, although β-catenin was previously shown in GMPs to be implicated in 
blast crisis, it is shown here to be less important in MNCs and therefore cannot be used 
to distinguish between patient response cohorts, or as a factor of disease progression. 
The BCR-ABL1 dependent Tyr654 phosphorylation of β-catenin is significantly 
decreased in blast crisis MNCs, potentially enhancing the theory that the disease can 
become BCR-ABL1 independent. GSK3β activity is significantly down-regulated in blast 
crisis, and appears to be being regulated through PP2A. Inhibition of GSK3β also affects 
the levels of PP2A, however, the mechanism of how GSK3β can be inhibited changes its 
effects on PP2A and its inhibitory Tyr307 phosphorylation. Neither GSK3β nor PP2A are 
the controlling factors of c-Myc degradation in CML. Additionally, up regulation of the 
Wnt pathway in chronic phase represented by the WNT ligands and FZD7 does not 
translate through to β-catenin, possibly due to internal regulation of the pathway by 
NKD1. However, this needs to be tested in protein levels. Finally, the mRNA levels of the 
transcription factors are significantly overexpressed in blast crisis, but may be 
functioning independently from the Wnt/β-catenin pathway.  
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7.9 Future work 
 
The main aspects of this work which would need further investigation, provided there 
were no limitations on patient material and time available, are the following; 
 
1) Examine the effects of bortezomib and SB216763 on the levels of β-catenin, along 
with WNT3A and WIF1 on the levels of both β-catenin and GSK3β, in patient 
samples to distinguish if there is a difference in pathway inhibition between patient 
response cohorts. 
2) Investigate whether inhibition of GSK3β by SB216367 also decreases the inhibited 
form of PP2A (Tyr307) in patient samples, as found in K562 cells, as this would 
enhance the use of the GSK3β inhibitor as a therapeutic drug, previously  
investigated by Reddiconto et al., [164] due to the implications of PP2A levels and 
disease progression [175, 176]. 
3) Determine whether the E3 ligase FBXW7 is controlling the rate of C-MYC 
degradation in CML by investigating the levels in patient samples to reveal if there 
is a difference between blast crisis and chronic phase which correlates with C-MYC 
levels. Additionally, carry out mutational analysis of FBXW7 in CML patients to 
determine if there is a difference between the patient responses which correlates 
with C-MYC levels. 
4) Measure the protein levels of the WNT ligands, FZD7, and NKD1 to determine if the 
significant difference found in mRNA levels which implies a potential negative 
feedback mechanism in response to an elevation in pathway activity in chronic 
phase transcends to protein levels. 
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5) Undertake mutational analysis of APC to investigate whether the significant 
increase in APC mRNA levels found in blast crisis which correlates with poor 
prognosis is due to mutations which affect its function as a tumour suppressor.  
6) Measure the protein levels of the Wnt/β-catenin transcription factors to ascertain 
whether there is still an upregulation of these factors in blast crisis. If this is the 
case, also investigate the ATF2 transcription factors and other co-activators and co-
repressors which regulate the activity of the TCF/LEF transcription factors, 
alongside post translational modifications, to see if they correlate with their 
activity.  
7) Determine whether CYCLIN D1 is acting as the link between CIP2A and the TCF/LEF 
transcription factors by using an inhibitor of CYCLIN D1 to see if it is involved in the 
regulation of TCF/LEF. Then, if this was confirmed, manipulate the levels of CIP2A 
by siRNA and transient transfection to see the effects on CYCLIN D1 and the 
transcription factors. 
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Chapter 8 - Appendix 
 
Figure 8.1 Subcellular localisation of unphosphorylated β-catenin 
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Figure 8.2 Subcellular localisation of phospho-β-catenin(Ser45/Thr41) 
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Figure 8.3 Subcellular localisation of phospho-β-catenin(Ser33/37/Thr41) 
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Figure 8.4 Subcellular localisation of phospho-β-catenin(Tyr654) 
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Figure 8.5 Key for Wnt genes re-screening 
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Figure  8.6 PCR re-screening of genes involved in the Wnt signalling pathway in a 
normal control, optimal responder, failure patient and blast crisis patient at 
diagnosis, and a patient transformed into blast crisis 
Re-screening of all the Wnt related genes in a normal, an optimal responder at 
diagnosis, a failure patient at diagnosis, a diagnosis patient who later transformed into 
blast crisis, and a patient in blast crisis to see if any genes showed a major difference 
between cohorts. 
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